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“For millions of years, mankind lived just like the animals.  
Then something happened which unleashed the power of our 
imagination. We learned to talk and we learned to listen.  
Speech has allowed the communication of ideas, enabling human 
beings to work together to build the impossible.  
 
Mankind's greatest achievements have come about by talking, and 
its greatest failures by not talking. It doesn't have to be like this.  
Our greatest hopes could become reality in the future.  
With the technology at our disposal, the possibilities are unbounded.  
All we need to do is make sure we keep talking.” 
-Stephen Hawking 
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1.1 Introduction 
One of the key challenges in medicine is the creation of therapeutic 
agents that act only where needed. By specifically targeting diseased tissue, 
adverse effects in normal tissue can be limited while the drugs themselves could 
have improved efficacy.1 An interesting new class of therapeutics are biological 
molecules (biologicals) that can target proteins either through direct binding, as 
has been reported for peptides, antibodies and alternative protein scaffolds, or 
through modifying their splicing or expression levels, which is the goal for most 
nucleotide-based strategies. A major challenge for the successful development of 
therapeutic strategies, based on for example biologicals, is sufficient 
accumulation at the intracellular target in vivo, where these molecules can 
perform their therapeutic task.2 For intracellular delivery, some (potential) 
therapeutics depend on synthetic carriers, such as polyplexes and liposomes for 
gene or siRNA delivery, whereas designs inspired by nature, such as viral vectors 
or bioengineered bacteria are also used.3 Several other interesting strategies for 
the development of next-generation intracellular therapeutics have been reported 
and include, but are not limited to the use of polymer-drug conjugates for 
improved small-molecule delivery4, monoclonal antibodies for targeting of 
overexpressed receptors on cancer cells that lead to endocytotic internalization5 
and gold nanoparticles for delivery of small molecules, genetic materials and/or 
proteins.6 A special class of molecules that have the potential to cross the plasma 
membrane in a receptor-independent pathway and without inducing toxicity are 
the so-called cell-penetrating peptides (CPPs). 
CPPs have the capacity to efficiently induce the cellular uptake of various 
cargoes into cells. One of the first CPPs that was reported to display cellular 
uptake activity was Tat, a peptide derived from the HIV-1 Tat protein. The ability 
of the HIV transactivator protein to be taken up by cells was found in 1988 by HIV-
researchers.7 It was quickly discovered that only a highly basic stretch of nine 
amino acids comprised in the full-sized protein, was responsible for this 
remarkable behavior. More importantly, the nonapeptide could be coupled to 
other compounds while maintaining its ability to be taken up by cells. Since then, 
more CPPs were identified from naturally occurring protein domains with cell-
penetrating ability, and artificial CPPs were developed later on. CPPs are the 
main subject of research in this thesis and will be further introduced in this 
chapter. 
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1.2 Classification of cell-penetrating peptides 
CPPs can be divided into several categories and the most useful classification 
places CPPs in three different ones: primary amphipathic, secondary amphipathic 
and non-amphipathic CPPs.8 This classification is based on how CPPs bind to the 
cell membrane and penetrate into cells, which is closely linked to their amino acid 
sequence. The classification is shown schematically in figure 1. 
Primary amphipathic CPPs (paCCPs) consist of a distinct hydrophobic 
and a hydrophilic domain, and are commonly longer than 20 amino acids. They 
strongly bind to both neutral and anionic membranes, which suggests that the 
membrane interaction is dominated by hydrophobic interactions. paCCPs 
penetrate deeper into the cell membrane than other classes of CPPs, which 
indicates that these CPPs enter the cells by a direct permeation mechanism. 
Notably, this deep penetration may cause leakage in the cell membrane.9 
Secondary amphipathic CPPs (saCCPs) are usually shorter than 20 
amino acids and, in contrast to paCCPs, their primary structure does not contain a 
distinct hydrophobic and hydrophilic domain at first sight. However, upon 
interaction with lipids or glycosaminoglycans (GAGs) they may adopt secondary 
structures (α-helices and β-sheets) in which a distinct hydrophobic and hydrophilic 
region becomes apparent (more on the interaction with GAGs and CPPs is 
described in section 1.4 below). saCCPs do not rapidly insert into the bilayer of 
the cell membrane, and need sufficient electrostatic interactions for their 
penetration. In a study by Ziegler et al. it was found that if the anionic lipid content 
is less than 50%, no membrane perturbation is observed.9 Above this level direct 
permeation may be possible. 
The peptides found in the class of non-amphipathic CPPs (naCCPs) are 
generally short and highly enriched in cationic amino acids. Because of their 
distinct positive charge, these CPPs may bind strongly to anionic membranes by 
electrostatic interactions. The uptake mechanism of these CPPs is strongly 
concentration dependent, with several endocytotic pathways involved at low 
concentrations, but at higher concentrations they may be taken up by direct 
translocation or via nucleation zones as will be discussed in the next paragraph 
(section 1.3) 9,10 
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Parallel to this classification based on structure and thus on physico-
chemical properties, CPPs can also be categorized based on their origin. CPPs 
can be derived from natural proteins or peptides, such as heparin-binding 
peptides, DNA and/or RNA binding peptides, homeoproteins, signal peptides, 
antimicrobial peptides and viral proteins. In contrast to the discovery of naturally 
occurring CPPs, artificial ones can be designed or derived from large peptide 
libraries, for which common features of natural CPPs are taken into account. All of 
the naturally occurring cell-penetrating proteins and peptides have a biological 
function that either requires interactions with plasma membranes (heparin-binding 
peptides and signal peptides) or the presence of positive charges (DNA and/or 
RNA binding peptides and homeoproteins) or requires cell-penetration for 
biological function (viral proteins), making these excellent natural CPPs.11 Table 1 
gives an overview of some frequently used CPPs. 
 
Figure 1 - Schematic representation of the lipid binding of CPPs as function of their amphipathic 
property and lipid head group charge. Symbols refer to (+) cationic and (●) hydrophobic amino acid 
residues of the CPP, and to (−) anionic and (○) neutral head group of the lipid. Primary amphipathic 
CPPs (paCPPs) penetrate into membranes of high and low anionic lipid content and induce membrane 
leakage already at low micromolar concentration. In contrast, membrane binding of secondary 
amphipathic (saCPPs) and non-amphipathic (naCPPs) at low micromolar concentrations requires a 
higher fraction of anionic lipids (N 10%) than typically found in eukaryotic cells.. Figure reproduced 
from ref.9 
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Table 1 - Overview of some well-known CPPs.9 Pa = primary amphipathic, sa = secondary 
amphipathic, na = non-amphipathic.  
 
1.3 Cellular uptake mechanisms for cell-penetrating peptides 
CPPs can deliver a wide range of hydrophilic and macromolecular cargos inside 
eukaryotic cells, without causing significant damage to the cell membrane, 
allowing the transport of therapeutic or imaging agents into cells.20 The cellular 
internalization of these peptides has been extensively studied and it has been 
demonstrated that CPPs are active for a large panel of cells. Thanks to the 
research effort to elucidate the exact mechanism of cellular uptake for CPPs, it 
has become known that there are many different processes that can play a role at 
the same time (figure 2). These different uptake mechanisms can be roughly 
divided into two categories, one comprising all energy-dependent vesicular 
mechanisms, better known as endocytosis, and the other containing all 
mechanisms that depend on direct translocation of the plasma membrane, which 
is an energy-independent process.21 It has been established that the mechanism 
of uptake of a CPP is not only dependent on the (structure of the) CPP itself, but 
also on various conditions such as concentration, temperature, cargo and 
incubation time.21-26 
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Figure 2 - Schematic representation of the various cellular uptake mechanisms that are known for 
CPPs. Endocytosis is possible via macropinocytosis, clathrin-mediated endocytosis, caveolin-
mediated endocytosis or clathrin- and caveolin-independent endocytosis. Direct translocation is 
possible via a carpet model, a barrel-stave model or via an inverted micelle (not shown). Reproduced 
from Stewart et al.21 
Endocytosis comprises phagocytosis and pinocytosis, which are both 
important processes that cells use to take up extracellular fluids and solutes within 
these fluids. While phagocytosis can only be performed by specialized cells, such 
as macrophages, to internalize solid particles, pinocytosis is employed by all 
cells.21 All forms of endocytosis are energy-dependent processes in which 
glycosaminoglycans and other membrane glycans are of importance. It is 
suspected that the positive charges of CPPs recruit and cluster plasma 
membrane glycans, thereby inducing endocytotic uptake mechanisms.27 The 
interaction between the positive charges that most CPPs possess and the 
negative charge of proteoglycans is further discussed in section 1.4. 
Four distinct endocytotic pathways that result in cellular uptake can be 
distinguished for CPPs (figure 2). These are all pinocytotic mechanisms and 
uptake of CPPs as a consequence of these mechanisms is non-specific. The first 
pinocytotic pathway is called macropinocytosis (top left in figure 2) and it involves 
ruffling of the membrane which triggers the formation of membrane protrusions. 
Via subsequent collapse and fusion with the membrane it eventually results in the 
formation of large endocytotic vesicles. Another pinocytotic mechanism is clathrin-
mediated endocytosis (figure 2). This is initiated by the formation of "coated pits" 
on the plasma membrane, which capture transmembrane-receptors and their 
bound ligands. These pits are coated with clathrin and they form endocytotic 
vesicles via encapsulation and pinching off of the plasma membrane, resulting in 
internalization of receptors and ligands. The third mechanism is caveolae-
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dependent (figure 2) and comprises uptake of extracellular fluids via flask-shaped 
invaginations of the plasma membrane, which are organized by caveolin. The last 
pinocytotic mechanism is clathrin- and caveolin-independent (top right in figure 2) 
and relies on other cholesterol-rich microdomains of the plasma membrane. 
These so-called lipid rafts can capture extracellular fluids and are internalized 
within the endocytotic vesicle.21,28 
One major drawback of cellular uptake of CPPs via endocytosis, is that 
the CPP and attached cargo are initially trapped inside endosomes. Due to this, 
they are hampered to enter the cytosol or any organelle in which the cargo might 
have its function.11,21 In order to use CPPs for therapeutic purposes, methods 
must be established to induce endosomal escape.29,30 Although different 
mechanisms have already been found to facilitate release of CPPs and/or cargo 
from the endosomes 29, it would still be preferable to have CPPs and their 
cargoes taken up via non-endocytotic processes, as this would prevent 
endosomal entrapment in the first place. 
Direct translocation results in cytosolic delivery of the CPP and attached 
cargo, thus circumventing the need for endosomal escape strategies. Direct 
translocation of CPPs through the plasma membrane is believed to occur as a 
result of interactions between the CPP and phospholipids in the membrane, and 
thus demands the CPP either to favorably interact with the membrane or to 
possess the ability to perturb the integrity of this barrier in such a way that it 
allows the peptide to pass through. As direct translocation is dependent on these 
CPP-membrane interactions, this process is affected by changes in membrane 
properties such as the membrane potential and its efficiency therefore varies 
between cell types. 
Direct translocation is, in contrast to endocytosis, an energy-independent 
cellular uptake process, which can, similar to endocytosis, proceed via several 
pathways, as depicted in (figure 2). One of the mechanisms of direct translocation 
depends on positively charged peptides that interact with negatively charged 
phospholipids to form an inverted micelle structure. When this structure opens 
intracellularly, the CPP is delivered to the cytosol.21,23 Other mechanisms of 
cellular uptake via direct translocation depend on the formation of membrane 
pores. These can be formed in a carpet-like fashion (bottom left in figure 2), when 
CPPs are interacting alongside the plasma membrane, or in a barrel-stave way 
(bottom right in figure 2), when CPPs are protruding through the membrane 
aligning a pore.21 Both of these translocation pathways directly lead to cytosolic 
delivery.  
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Although endocytosis and direct translocation are the main mechanisms 
of cellular uptake for almost all CPPs, the relative contribution of both processes 
varies greatly between different CPPs, as was also reported in the work by Sagan 
and co-workers.31 They investigated the import pathways for a series of arginine-
rich CPPs and penetratin (RQIKIWFQNRRMKWKK) at concentrations lower than 
2 µM.31 The authors observed direct translocation across the plasma membrane 
when low micromolar concentrations were used, however at concentrations 
higher than 2 µM, glycosaminoglycan-dependent endocytosis was induced. In 
addition, various CPPs induce cellular uptake mechanisms under distinct 
conditions.10,11,21 For example, striking differences in cellular uptake mechanisms 
were observed, when the cellular uptake efficiencies of nona-arginine (R9), the 
Antennapedia-homeodomain-derived penetratin (RQIKIWFQNRRMKWKK), and 
the HIV-1 Tat protein-derived Tat peptide (RKKRRQRRR) were compared.10 R9 
and the Tat peptide were taken up via macropinocytosis and caveolae-mediated 
endocytosis at concentrations below 10 µM. The penetratin was taken up via both 
of these mechanisms, but in addition clathrin-mediated endocytosis contributed to 
cellular uptake. For oligo-arginines and Tat (conjugated to a small cargo), rapid 
cytoplasmic uptake from restricted membrane areas at a concentration of 20 µM 
was reported by the group of Cardoso.32,33 They named this uptake route 
transduction. Around the same time, the group of Brock studied the concentration-
dependent uptake mechanisms of arginine-rich peptides in close detail. They 
found that at concentrations of 10 – 20 µM a transition from endocytosis to rapid 
cytosolic uptake occurs, and that the cytosolic uptake originates from areas of 
local enrichment at the plasma membrane that were named nucleation zones.10 A 
schematic representation of concentration-dependent uptake by arginine-rich 
CPPs is shown in figure 3. Importantly, in the paper by Duchardt et al. it was 
shown that upon inhibition of endocytosis, uptake via nucleation zones is 
promoted, suggesting that the uptake mechanism of CPPs is dependent on 
available internalization pathways. Later, it was found that this cytosolic delivery is 
dependent on the activation of acid sphingomyelinase and ceramide formation.34  
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Figure 3 – Schematic representation of various concentration-dependent uptake mechanisms for 
arginine-rich CPPs.35 Intracellular red arrows indicate the requirement for the activation of molecular 
processes inside the cell, a characteristic that distinguishes transduction from translocation. For 
induction of endocytosis, cross-linking of glycosaminoglycan-bearing transmembrane proteins such as 
syndecans is shown (described in more detail in section 1.4). For transduction, the formation of a 
membrane microdomain is indicated, with concurrent import along the domain boundary. Microdomain 
formation is a consequence of ceramide formation. The various uptake mechanisms may occur at the 
same time. Reproduced from35 
 
1.4 Interactions with cell surface heparan sulfate proteoglycans 
It has often been suggested that interactions with cell surface heparan sulfate 
proteoglycans are involved in CPP uptake. Proteoglycans (PGs) encompass a 
heterogeneous group of proteins that carry one or more, highly negatively 
charged glycosaminoglycan (GAG) polysaccharides (such as heparan sulfate 
(HS)) that vary in size and shape. Because of their abundant carboxyl and sulfate 
groups, GAGs constitute a major source of macromolecular polyanions that 
surround almost all cell types.36 Heparan sulfate proteoglycans (HSPGs) bind a 
wide variety of extracellular ligands. The interaction of a molecule with HSPGs in 
the extracellular matrix or on the cell surface is largely dependent on it having a 
positive net charge and, in the case of a polypeptide, the spatial arrangement of 
basic amino acid stretches. The predominant HSPGs on the cell surface are 
glypicans and syndecans. Proteoglycans have been reported to be involved in 
different pathways controlling cell motility, shape or cell proliferation, which are 
directly associated with the dynamics of the cytoskeleton and actin network.37 In 
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addition, syndecans and glycans have been reported to interact with the actin 
network via their cytoplasmic tail actin-binding protein and are both involved in the 
regulation of membrane receptors and the cellular uptake of macromolecules.38  
The literature often discusses the possibility that HSPGs may play an 
important role in the uptake of some cell-penetrating molecules. The initial step for 
the uptake of several CPPs is being regarded the association with HSPGs due to 
strong electrostatic interactions with negatively charged GAGs. In addition, it has 
been suggested that GAGs trigger the internalization of these CPPS via different 
endocytosis pathways depending on the presence and the nature of the cargo 
and the ability of the CPP to interact with lipids.39 For example, Futaki and co-
workers showed that macropinocytosis is the main pathway of entry of the 
arginine-rich peptides Tat, polyarginines and branched arginines and that this 
pathway is accompanied by the organization of F-actin.40 Both structure and 
charge density determined their cellular uptake dependency on the membrane-
associated proteoglycans.41 In addition, the group reported that the Tat peptide is 
highly dependent on heparan sulfate proteoglycans (HSPGs), whereas the 
internalization of octa-arginine is less dependent on HSPGs. This led to the 
conclusion that the structure of the peptides may determine the specificity for 
HSPGs, and that HSPG is not the sole receptor for macropinocytosis.42 In various 
reports it has been noted that a deficiency in HSPG often results in a decrease in 
arginine-rich peptide uptake by the cells, and thus HSPG has been suggested as 
a primary receptor for the cellular uptake of the arginine-rich peptides.39 
Furthermore, it was shown that both Tat and octa-arginine were taken up more 
efficiently by cells overexpressing syndecans than by wild type cells. In the 
following experiments it was found that F-actin and lamellipodia organization were 
dependent on HSPGs. The report concluded that membrane-associated 
proteoglycans play a significant role in the induction of the F-actin organization 
and subsequent macropinocytosis. This indicates that the membrane-associated 
proteoglycans function as potential receptors for the induction of 
macropinocytosis by the arginine-rich peptides. 
Ziegler and Seelig investigated GAG binding and clustering of various 
mono- and multivalent cell-penetrating molecules, such as DNA transfection 
vectors, oligo-arginines and classical CPPs, using isothermal titration calorimetry 
and dynamic light scattering.27 The authors found that in spite of structural 
differences among the tested cell-penetrating molecules, they all shared the 
property of GAG binding and clustering. The observed binding was rather strong, 
with dissociation constants ranging from 0.34 to 1.34 µM, indicating the biological 
relevance of these interactions. For highly cationic CPPs it was found that the 
binding to GAG was mainly due to electrostatic interactions, whereas for 
amphipathic CPPs the GAG binding was dominated by the decrease in the water- 
accessible surface area, highlighting the importance of hydrophobic interactions. 
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Because it was suggested in literature that GAG-mediated CPP uptake involved 
the clustering of GAGs, the authors next investigated whether the CPPs could 
induce GAG clustering with potential consequences for endocytotic signals. It was 
found that all tested cell-penetrating molecules upon GAG binding, produced 
particles of considerable size (70 nm or larger). This suggested that these clusters 
consisted of several GAG chains cross-linked by cell-penetrating molecules. For 
Tat it was estimated that each cluster contained up to 2.1 x 105 heparin molecules 
(each complexed with six or seven Tat molecules) depending on the actual state 
of hydration. This study showed that despite their structural differences, most cell-
penetrating molecules interact with GAGs in a similar fashion.  
Dowdy and co-workers reported controversial findings about the influence 
of heparan sulfates and sialic acids (SAs) on the Tat-mediated induction of 
macropinocytosis.43 In their report, the authors make a clear difference between 
Tat peptides localized in the endosomes and Tat that was able to escape from the 
endosomes and translocate into the cytosol. The authors highlight the importance 
of this distinction, because the inside of the endosome is essentially the outside of 
the cell, and as a consequence, no biological response will be evoked simply by 
uptake into these vesicles. Surprisingly, the authors found that in cells lacking all 
GAGs, including HS, and in cells lacking SAs, transduction into the cytosol 
occurred more efficiently than in wild type cells. These results enforce the 
hypothesis that acidic glycans create a large charge area to which Tat binds on 
the cell surface, but that this binding is independent of the internalization 
mechanism and the induction of macropinocytotic uptake by Tat. In conclusion 
they showed that Tat-induced macropinocytotic fluid-phase uptake is intact in 
glycan-deficient cells, thus indicating that these glycans are not needed to 
stimulate endocytosis. However, depletion of cell-surface proteins with protease 
resulted in drastically reduced endocytosis efficiency. 
Interestingly, it was reported that CPPs that strongly bind GAGs also 
induced efficient uptake in cells that are poor in GAGs such as Jurkat cells that 
have only about 10% of the GAG expression level present on HeLa cells.44,45 
Even more surprising, D-peptides show only about half the uptake efficiency of 
their L-amino acid counterparts in spite of the same binding affinity for heparan 
sulfate proteoglycans.46 The previous examples show that the exact role of GAGs 
in the uptake of CPPs is yet to be elucidated. A detailed review on the contribution 
of GAGs in cellular uptake was reported by Favretto et al.47 All in all, the possible 
involvement of HSPGs in the uptake of arginine-rich peptides is an interesting 
research subject.  
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1.5. Arginine-rich CPPs 
Although all CPPs have interesting properties, in this thesis the research is 
focused on two different arginine-rich CPPs: the Tat peptide and oligo-arginines. 
These are our CPPs of choice, since both Tat and oligo-arginine peptides have 
been shown to exhibit excellent cell-penetrating properties48 and because they, in 
contrast to other CPPs, have characteristics that are beneficial for the activation 
strategies employed in our work.  
1.5.1 Tat 
Tat is the nuclear transcriptor activator protein encoded by the 101 amino acids 
HIV-1 protein, which is required for viral replication.7 HIV-1 Tat efficiently crosses 
the plasma membranes of cells in a clear energy dependent way and localizes to 
the nucleus. The structure responsible for the cellular uptake of HIV-1 Tat was 
found to reside in a highly basic region constituted by amino acid residues 49–57 
(RKKRRQRRR). The detailed uptake mechanism for Tat49–57 (further being 
referred to as ‘Tat’) is not yet fully understood. A structural analogy can be drawn 
between Tat and homopolymers of cationic residues, such as arginine and 
ornithine, which are also known to be able to cross the plasma membrane 
efficiently.  
Rotbard and co-workers investigated the structural elements required for 
the uptake of Tat.49 To do so, the authors synthesized a series of truncated 
analogues of Tat, which were fluorescently labeled. The ability of these peptides 
to enter Jurkat cells was evaluated by flow cytometry. When an arginine residue 
was deleted from the amine terminus (Tat50-57) a significant decrease (80%) of 
intracellular fluorescence relative to the original sequence (Tat49-57) was observed. 
Deletion of one arginine from the carboxyl terminus (Tat49-56) yielded similar 
results. Further deletion of R56 from the carboxyl terminus (Tat49–55) resulted in an 
additional 60% loss of intracellular fluorescence, whereas deletion of K50 from the 
amine terminus (Tat51–57) did not further reduce the amount of internalization. This 
result suggests that arginine residues contribute more to the efficient cellular 
uptake of Tat by Jurkat cells than the lysine residues. In a subsequent 
experiment, the individual contribution of the nine amino acids in Tat was 
analyzed by performing a so-called alanine scan. In this scan, nine different 
analogues were synthesized in which for each position a variant was obtained 
that had an alanine substituted at that position. Substitution of the glutamine (54) 
in Tat by alanine only resulted in a slight decrease in cellular uptake while all 
other mutations resulted in a 70-90% decrease in internalization efficiency. 
Replacements of lysine or arginine by alanine thus had similar effects on the 
uptake of the proteins in this case. Next, it was determined whether the chirality of 
the transporter peptide was important. The D-isomer of Tat entered the cells 
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equally efficient as L-Tat, showing that the chirality of the backbone is not 
important for cellular uptake. The uptake efficiency of also the retro-inversed 
isomer of Tat was tested on Jurkat cells, and surprisingly this peptide showed to 
enter cells more rapidly than the original Tat49-57 peptide. Because it is inverted, 
the retro-inversed peptide has three arginine residues located at the N-terminus 
instead of at the C-terminus, and consequently does not have an N-terminus 
featuring one arginine and two lysines as in the parent Tat peptide. Its enhanced 
uptake thus shows that residues at the amine-terminus are more important and 
that arginines are more efficient than lysines for internalization.  
Although much effort has been made in understanding the uptake 
mechanism of Tat, an agreed mechanism has yet to emerge. Involvement of a 
classical endocytotic pathway has been shown by the co-localization of Tat with 
early/recycling endosomes markers Transferrin or FM4-64.50,51 Fischer et al. 
furthermore showed that internalized Tat peptides co-localize with the Golgi 
marker BODIPY-ceramide.52. No peptide was observed in late endosomes and 
lysosomes which were labeled with lysotracker. These observations suggested 
that Tat peptides were able to utilize the retrograde secretory pathway via the 
Golgi complex and could enter the cytosol from the endoplasmic reticulum. 
Conflicting results are reported for the involvement of caveolae for the uptake of 
Tat. First, it was reported that Tat fusion proteins could be taken up via membrane 
caveolae53, leading to the internalization in neutral caveosomes, but more recent 
reports suggest that caveolae are not required for the uptake of Tat.54 
Contradictory, in a report by Fretz et al. Tat-coated liposomes were shown to be 
taken up by endocytosis, entering acidic lysotracker positive compartments25 and 
Nørgaard et al. showed that the full-length Tat protein entered late endocytotic 
compartments containing the mannose-6-phosphate receptor.55 In an attempt to 
better understand the trafficking of Tat, the intracellular traffic of fluorescent 
conjugates of Tat was studied by Al-Taei et al. in human leukemia KG1a-CD34+ 
and K562-CD34- cells, which serve as models for primary hematopoietic stem 
cells and myeloid leukemia.40 To do so, the cells were incubated with 3 µM 
Alexa488-Tat for 120 min at 37 °C, and afterwards analyzed by fluorescence 
microscopy using live cells. The authors labeled distinct endocytotic structures of 
both cell lines with fluorescent probes whose intracellular fate following 
endocytotic capture is well defined. In their study, early endosomes were defined 
as organelles containing internalized probe after 0-10 minutes of uptake, late 
endosomes after 10-30 minutes, and lysosomes after more than 30 minutes. 
Because Tat uptake was relatively insensitive to the drug amiloride, which is an 
inhibitor of macropinocytosis, it could be concluded that this pathway was not the 
only uptake mechanism involved. Because the K562 cells do not express 
caveolin-1 and are phenotypically devoid of plasma membrane caveolae, the 
results in using these cells suggest that the uptake of Tat is caveolae-
independent. The Tat-peptides were observed in vesicular structures containing 
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internalized transferrin, which could either be early and/or recycling endosomes. 
The authors found that the Tat peptide traffics to lysosomes in the tested cell 
lines, and suggested that cytosolic localization is due to the peptide escaping from 
the endosomes.  
Recently, the group of Cardoso reported an analogue of Tat that induces 
cytosolic delivery more efficiently than Tat.48 The peptide reported is a cyclic 
variant of Tat, as the authors argued that an increase in structural rigidity leads to 
higher transduction efficiency. Indeed, it was found that cyclization of Tat induced 
increased cytosolic delivery which may due to the guanidinium groups being 
forced into maximally distant positions by cyclization. This orientation could 
increase membrane contacts that may lead to enhanced cell penetration. In a 
follow-up study, Nischan et al. showed the cytosolic uptake of whole proteins 
induced by cyclic Tat.56 
1.5.2 Oligo-arginines 
Oligo-arginines, homo-oligomers of arginine residues, are able to cross cell 
membranes efficiently when composed of six or more amino acids. For these 
CPPs, too, an exact mechanism of entry has still to be defined. It is reported to be 
temperature sensitive, although uptake has been observed at 4ºC.19 However, 
pretreatment of cells with sodium azide (an agent that blocks endocytosis 
pathways by ATP depletion) inhibited their uptake completely.26 The guanidinium 
head groups of the arginine residues seem to be crucial to induce cellular uptake, 
while the chirality of the amino acids, the length of the side-chains and the 
spacing and composition in the backbone may be varied.19,49 The uptake 
efficiency of oligo-arginines is dependent on the peptide concentration, but also 
on the guanidinium content. An improved rate of uptake was observed when the 
chain length was increased up to 15 residues. When the chain length was further 
increased, the peptides were still taken up efficiently but became cytotoxic. 
It has been shown that nonamers of arginine enter cells more rapidly than 
the nonapeptide Tat49-57 (RKKRRQRRR) or the 16-amino acid penetratin.49 
Interestingly, Tat, which contains 6 arginine residues, was found to be equally 
efficient as hexa-arginine. This prompted the group of Rothbard to study the 
importance of the guanidinium head group for cellular uptake. The authors 
showed that short homopolymers of arginine were able to cross the cell 
membrane more efficiently than homopolymers of lysine, histidine or citrulline of 
the same length.19 Citrulline is an isostere of arginine, the difference being the 
replacement of a nitrogen of the guanidine by an oxygen, creating a urea-like 
moiety. This small structural difference however blocked the cellular uptake 
completely. There is a strong difference between the basicity of guanidine (pKa = 
12) and urea (pKa = 0.1). As a consequence, there are significant differences in 
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the ability of both groups to from ionic interactions. The charged amine of the 
guanidine is a hydrogen bond donor, whereas the oxygen in urea is a hydrogen 
bond acceptor. This points out the uniqueness of guanidine to form very stable 
bidentate hydrogen bonds with anionic groups on the cell surface such as 
phosphates or sulphates. Neither lysine nor histidine is able to form these 
hydrogen bonds.  
To further investigate the significance of the guanidinium head groups, 
Rothbard and co-workers synthesized a library of polyguanidine peptoids.49 In 
these peptoid derivatives the 1,4-backbone spacing of side chains of arginine 
oligomers was preserved, but the backbone consisted of oligoglycine and was 
devoid of stereogenic centers. The uptake of the N-Arg5,7,9 peptoids by Jurkat 
cells was compared to the uptake of D-arginine peptides, Arg5,7,9 using flow 
cytometry. The D-arginine peptides were used in this comparison because these 
have the same proteolytic resistance as the peptoid structures. The amount of 
fluorescence measured inside the cells was proportional to the amount of 
guanidinium groups N-Arg9 >N-Arg7 > N-Arg5, analogous to the trend found for 
Arg5,7,9. Because the peptoid derivatives only showed a slightly lower uptake 
efficiency than the homopolymers of D-arginine, it could be concluded that the 
hydrogen bonding along the backbone of oligomers of arginine was not a required 
structural element for cellular internalization. Next, the authors investigated the 
effect of side chain length (number of methylenes) on the rate of cellular uptake 
(figure 4). They found that the internalization efficiency for a given number of 
guanidine residues (5, 7, or 9) was proportional to side-chain length. Peptoids 
with longer side chains were shown to be able to cross the cell membrane more 
efficiently, with N-hxg9 > N-btg9 > R9 > N-Arg9 > N-etg9.  
 
Figure 4 - Structure of polyguanidine peptoids with varying side chain length. N-etg, X = (CH2)2; N-Arg, 
X = (CH2)3; N-btg, X = (CH2)4; N-hxg, X = (CH2)6; N-ocg, X = (CH2)8; N-chg, X = trans-1,4-cyclohexyl.  
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Importantly, the longer side chains embodied in the N-hxg peptoids 
appeared to improve the cellular uptake significantly, demonstrating even greater 
uptake efficiency than the corresponding D-arginine oligomers. A similar trend 
was found in the corresponding hexamers and pentamers. The N-hxg peptoids 
increased the internalization efficiency to such an extent that the amount of 
uptake was comparable to the corresponding D-arginine oligomer containing one 
more guanidine residue. 
In a final experiment, the authors investigated whether the increase in cellular 
uptake was due to the increased hydrophobic nature or the flexibility of the side 
chains. To do so, they synthesized a new series of peptoids, containing 
cyclohexyl side chains: N-chg5,7,9 peptoids. The cyclohexyl spacer contains the 
same number of carbons as the hexyl spacer, but has less degrees of freedom. 
Interestingly, the N-chg5,7,9 peptoids showed to have much lower cellular uptake 
activity than all other peptoids. This suggested that the high degree of freedom 
and sterically unencumbered nature of a straight chain alkyl spacing group are 
important elements for efficient cellular uptake of these peptoids. 
Because of the above described results Rothbard et al. further 
investigated the role of backbone spacing for the efficient uptake of oligo-arginine 
carriers.57 The authors first determined the spatial preferences of the guanidinium 
head groups of a decamer of L-arginine, by modeling the peptide to identify 
families of low energy conformers. It was found that in one family of conformers 
with low energy, seven of the ten guanidinium groups were displayed opposite to 
the other three side chains (at the 2nd, 5th, and 8th residues). Because the set of 
seven residues shared the same directionality, they also shared the potential to 
contact a common surface such as a membrane or receptor, whereas the 
residues 2, 5 and 8 would not be able contribute to the formation of a complex 
with this surface. A similar pattern in which only a part of the arginine residues 
share the same directionality was found among other families of the decamer. 
These results suggest that at any given time point, only a subset of the arginine 
residues will simultaneously contribute to the cellular uptake owing to the 
apparent property of only subsets of residues to sterically point in a given 
direction at the same time. To study which of the arginine residues could be 
removed without diminishing the cellular uptake, a set of 17 decamers possessing 
arginines at positions 1, 3, 4, 6, 7, 9, and 10, and at positions 2, 5, and 8 each of 
the naturally occurring α-amino acids, except arginine, cysteine, and tryptophan 
were synthesized and conjugated to fluorescein. The design was such that all 
analyzed decamers contained seven equally spaced arginine residues. The 
peptides displaying glutamic or aspartic acid at the mutated positions entered 
cells poorly, which is probably due to the ability of guanidine to internally form salt 
bridges with carboxylate functionalities, and in doing so, reducing the ability of 
guanidine to cross the cell membrane. There was no decrease in uptake 
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observed when positions 2, 5, and 8 were substituted with valine, alanine, glycine, 
methionine, or threonine, although these analogues each contained only seven 
guanidinium groups. When the uptake efficiency of the peptides containing seven 
arginine residues (at the above described positions) and three variable amino acid 
residues was compared to hepta-arginine, it was found that the decapeptides 
entered cells more efficiently than R7, underlining the relevance of spacing 
between the arginine residues to enhance cellular uptake. To further investigate 
these results the authors synthesized two additional decamers of arginine: one 
with in which positions 2, 5 and 8 were substituted with 4-aminobutyric acid (abu) 
and the other with 6-aminohexanoic acid (Ahx). The ability of these peptides to 
enter cells was compared with a decamer in which the three positions were 
substituted by glycine, and by R7 and R10. Because glycine has a single 
methylene between the amino and the carboxyl groups, but 4-aminobutyric acid 
has three, and 6-aminocaproic acid has five, the influence of spacing on uptake 
could be analyzed further by studying the uptake of these peptoids. When the 
number of methylenes increased from one to three to five, a large increase in 
uptake compared to R7 was observed (by a factor of 4, 5 and 16 respectively). 
The peptide with 6-aminocaproic acid entered cells even more effectively than 
R10.  
 In a deeper analysis, all possible permutations of seven arginines and 0 
to 6 Ahx spacers were investigated. A positive correlation between uptake 
efficiency and Ahx content was revealed, with the fully Ahx-spaced peptoid being 
the most efficient. The location of Ahx within the peptoid was found to be 
irrelevant. Two possible explanations present themselves: First, Ahx-spaced 
peptoids could be more resistant to protease activity, leading to a higher effective 
molarity and thus uptake. Second, the increased flexibility of the Arg residues 
could result in enhanced interaction with relevant uptake receptors. To determine 
which explanation was the real cause of this effect, additional variants were 
produced. These variants had spacers other than Ahx, of different length, and the 
peptoid was a D-peptoid. Under these less protease-susceptible conditions, the 
peptoids with the longer spacers exhibited the greatest uptake levels, implying 
that flexibility is paramount for this system. 
In a next study, Rothbard et al., discussed how these results can be 
related to the uptake mechanism of guanidinium-rich peptides.58 It was 
considered unlikely that receptors would be involved in the uptake of these 
peptides, because of the broad varieties in structural modifications that could lead 
to an increased internalization efficiency. The authors argued that the polarity of 
the guanidinium head groups could be diminished by interactions with negatively 
charged cell surface groups such as phospholipid, fatty acid salts or sulphates, 
resulting in a less polar ion pair that might be able to diffuse through the plasma 
membrane. To test this hypothesis, a fluorescein-linked octamer of D-arginine 
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was added to a bilayer of octanol and water to determine its logP value. In this 
system, the highly cationic polar molecule almost completely partitioned into the 
water layer. But when sodium laurate (a surrogate for a fatty acid salt in the 
plasma membrane) was added to the system, octa-arginine significantly 
partitioned into the octanol layer. In contrast, an octamer of ornithine remained in 
the water layer under both conditions. The difference between the arginine and 
ornithine peptides could be explained by the ability of guanidinium to form stable 
bidentate hydrogen bonds, which is not possible for ornithine. To explain the 
energy dependent uptake that is often observed and reported for oligo-arginines, 
the authors reasoned that the uptake of guanidinium-rich peptides might be driven 
by the voltage potential present across most cell membranes. A potential 
dependent uptake was described previously for penetratin.59 To test the voltage 
dependency of lymphocytes, the membrane potential was brought close to zero 
by incubating the cells with an isotonic buffer having potassium concentrations 
equivalent to intracellular concentrations. It was found that the uptake of both 
octa-arginine and Tat decreased with more than 90% for all tested concentrations. 
When the experiment was repeated with a series of buffers having potassium 
concentrations between 0 and 140mM (the intracellular K+ concentration in 
lymphocytes), it was observed that the uptake decreased with an increasing 
extracellular concentration of K+. These experiments showed that the efficiency of 
uptake of arginine-rich peptides is proportional to the membrane potential. 
In a recent study, the internalization efficiency of nona-arginine was 
compared for the frequently used cell lines HeLa and HEK.60 It was shown that 
these cell lines have fundamentally different uptake mechanisms. In their report, 
Wallbrecher et al. investigate the basis for these differences. As they describe, 
the most striking contrast is that HeLa cells show a concentration-dependent 
uptake mechanism for nona-arginine, with the peptide only entering the cytosol at 
high concentrations. However, in HEK cells, cytosolic delivery was observed at 
low concentrations. First, it was tested whether the membrane potential was 
initializing the cellular uptake but this was refuted by membrane potential 
measurements using whole cell patch clamp after using gramicidin A-induced 
depolarization. The authors found that the differences in the lipid composition 
between HEK and HeLa cells is the foundation for discrepancies in their uptake 
mechanisms as lipid analysis of the plasma membranes showed that HEK cells 
have a low sphingomyelin content, which indicates a permissive membrane. In 
contrast, HeLa cells, which have a high sphingomyelin content, have a resistant 
membrane that may become permissive if the sphingomyelin content is reduced 
upon conversion into ceramide. This work underlines the complexity of CPP 
uptake, and shows that their uptake mechanism may be cell-type dependent.  
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1.6 Introducing selectivity in CPPs 
It has been shown that most CPPs are able to penetrate almost every type of cell. 
In other words, CPPs are hardly cell-type specific, which may be advantageous if 
it is desired to target all cell types present in a mixture of cultured cells or in 
tissue. But in general, for most pharmaceutical applications the lack of cell-type 
specificity of CPPs is hampering their clinical use. Therefore, efforts are made to 
introduce cell-type specificity in CPPs. 
Recently, several different approaches to achieve this have been 
reported.61 Such strategies can be roughly divided into two categories, a first one 
consisting of CPPs that are modified to contain an inactivating domain that can be 
removed or activated by a (enzymatic) trigger present in a specific tissue or cell 
type,21,62-64 and a second one in which a targeting ligand is added to the CPP or 
CPP system61,65,66. 
1.6.1 Activatable CPPs 
One method to introduce selectivity to CPPs is to activate them from a dormant to 
an active state. There are many options to force a CPP into a dormant state, but 
they have all one important thing in common: it has to prevent the CPP from 
penetrating into cells, until a specific external trigger activates the CPP (e.g. a 
change in pH or temperature, exposure to UV-light, or an enzymatic reaction). In 
this section several methods for inactivation and reactivation will be discussed, 
classified by the stimulus required to activate the CPPs. 
1.6.1.1. CPP activation by pH 
One external stimulus that is often employed for the activation of CPPs is a 
change in pH. A tumor environment is generally more acidic than the environment 
of healthy cells. Many CPPs contain a significant amount of basic amino acids 
(such as lysine and arginine, see earlier herein) that are protonated at 
physiological pH-values (pH ≈ 7.4) and their polycationic nature allows them to 
interact with and ultimately penetrate cell membranes. At basic pH-values (i.e. 
above the pKa-values of lysine and arginine side chains) the CPPs are not 
protonated and as a consequence unable to penetrate into cells. This offers 
potential to introduce selectivity, as these CPPs can be kept unprotonated and 
thus inactive until they come in close proximity of the targeted cells.61  
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Figure 5 - Schematic representation of pH sensitive targeting. Micelle-(PSD-b-PEG) complex at pH 
7.4 (left) in which the Tat peptide is shielded, inhibiting uptake of the micelles. At a decreasing pH 
polysulfonamides dissociate, exposing Tat on the outside of the micelles, obtaining a complex that can 
be internalized in cells. Figure adapted from ref.67  
An elegant example in which such an approach is employed was reported 
by Sethuraman and Bae (shown in figure 5).67 In their work, a system was used 
based on poly(L-lactic acid)-b-poly(ethylene glycol) (PLLA-b-PEG) block 
copolymers that form micelles with drugs encapsulated in the hydrophobic core. 
The PEG tails were conjugated to Tat peptides and a second, polyanionic block 
copolymer, poly(methacryloyl sulfadimethoxine)-b-poly(ethylene glycol) (PSD-b-
PEG) was complexed with the Tat-conjugated micelles at physiological pH (figure 
5). However, at the lower pH that is present around tumor tissue, the PSD block 
became protonated, and therefore lost its negative charge, releasing the PLLA-b-
(PEG-Tat) micelle. Consequently, the micelles were able to enter human breast 
adenocarcinoma (MCF-7) cells.  
Jin et al. also showed an interesting strategy for a pH-triggered activation 
of Tat. In their approach, the lysine and glutamine residues in the Tat sequence 
were modified to succinyl amides, which resulted in a modified peptide that was 
unable to enter cells.62 Upon exposure to acidic pH, the succinyl amides were 
hydrolyzed, triggering internalization of the peptide. When poly(ethylene glycol)-
block -poly(ε -caprolactone) micelles were functionalized with these modified 
peptides, the micelles accumulated in tumor tissue and successfully delivered 
doxorubicin to this tissue. 
Another example of using a pH-change for selective targeting was 
provided by Wang and co-workers.68 They used a TP10-inspired CPP, named TH, 
in which all lysine residues were replaced by histidine residues, and to which 
camptothecin (an anti-cancer drug) was coupled via a disulfide linkage. Histidine 
has a pKa of 6.5 and is thus not protonated at pH 7.4. When located near acidic 
solid tumors the histidine residues were protonated allowing the CPP to only enter 
tumorous cells (HeLa cells). Once the construct was taken up, the high 
glutathione concentration inside the cell cleaved the disulfide linkage, which 
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released camptothecin, causing apoptosis in cancer cells. Importantly, this 
method showed low cytotoxicity towards healthy cells.  
1.6.1.2. Activation by UV-light 
Another stimulus that can be applied to activate CPPs is UV-light. Generally, UV-
activatable systems bear a light-responsive group that can either be cleaved off or 
that may undergo a conformational change upon UV-light irradiation, which then 
leads to a change in the CPP activity. 
In 2011 Shamay et al. reported a cancer cell-targeting system that could 
be activated upon UV-irradiation (λ = 365 nm).69 An analogue of the CPP 
penetratin was used, which had the following amino acid sequence 
KRRMK(Nvoc)WK(Nvoc)K(Nvoc), where Nvoc is 6-nitroveratrylcarbonyl (figure 6). 
The Nvoc groups on the lysine side chains shielded the activity of the CPP, but 
could be removed using UV-light. In their work, a  
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer scaffold was used, to 
which a number of these so-called caged CPPs were coupled (figure 6).  
 
Figure 6 - A CPP-construct with a caged CPP that upon UV-light illumination is activated for cellular 
uptake, which is coupled to a pro-apoptopic peptide, that is liberated when the pH sensitive linker is 
broken upon cellular internalization. Figure adapted from ref.69 
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The authors observed that unshielding of up to 80% of the CPP moieties 
could be achieved after eight minutes of illumination. To induce cellular uptake a 
prolonged incubation time of two hours was needed. Next, the polymer-CPP 
construct was modified such that the FITC moieties were replaced with the pro-
apoptotic KLAK peptide (KLAKLAKKLAKLAK), coupled via a pH-sensitive 
hydrazone linker, which is stable towards UV-illumination, and cleaved after 
cellular uptake (figure 6). The authors showed cell viability depends on both the 
duration of illumination (3.5 – 8 minutes) and the concentration of the drug (20 - 
80 µM) and that apoptosis was only induced when the KLAK peptides were used. 
Hansen et al. developed a UV-triggered system for the selective delivery 
of liposomes.64 In this approach, Tat was coupled on both termini to a 
poly(ethylene glycol) tail, which enabled the peptide to be anchored into a 
liposome membrane. In this way, the Tat peptide was shielded and unable to 
induce cellular uptake of the liposomes. One of the linkers was however made UV 
cleavable, and upon UV irradiation, the Tat peptide was exposed on the surface 
of the liposomes, allowing it to induce cellular uptake of the liposomes. 
1.6.1.3. Enzymatic activation 
An elegant method to activate dormant CPPs is by the use of enzymes. Because 
these biocatalysts are upregulated in diseased tissue, their use offers a promising 
tool for the development of specific CPPs. 
Tsien and co-workers designed an activatable CPP based on matrix 
metalloproteinases (MMPs). MMP-2 and MMP-9 are well-characterized proteases 
that are overexpressed by tumors and are able to hydrolyze peptide bonds. In 
their initial study in 2004, the authors tested several cleavable systems.70 These 
systems consisted of a nona-arginine polycation that on the C-terminus was 
coupled to a cargo and on the N-terminus to a MMP sensitive linker (PLGLAG). 
The linker was also coupled to a polyanionic sequence, usually containing a 
stretch of glutamate residues. In this way the intermolecular electrostatic 
interactions prevented cellular uptake. Addition of MMPs resulted in cleavage 
between the neighboring glycine and leucine amino acid residues of the linker, 
release of the polyanionic peptide and subsequent cellular uptake, both in vitro 
and in vivo in mice. 
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Figure 7 – Enzyme-selective targeting by using activatable CPP dendrimers. The system consists of a 
poly(amido amine) fifth generation dendrimer (grey), containing a cargo (yellow dots). The dendrimer 
is linked to six CPPs (blue). The CPPs are coupled to MMP cleavable linkers (green) that are again 
coupled to polyanionic peptides (red). The covalently linked polyanionic peptides prevent cellular 
uptake until the linkers are cleaved by matrix metalloproteinases. Figure reproduced from ref.71 
After further exploring the properties of these activatable CPPs,63,71 Tsien 
and co-workers applied them for fluorescence and MRI guided tumor surgery, 
using the system as depicted in figure 7.72 In earlier studies they found that 
coupling the CPPs to poly(amido amine) fifth generation dendrimers resulted in 
improved imaging results. In addition, the dendrimer contains reactive sites that 
can be used to couple cargos, such as a Cy5 dye for fluorescence imaging or 
gadolinium-DOTA for MRI visualization. This system was used to more effectively 
label tumor tissue, and it thus allowed subsequent removal of more tumor tissue 
than compared to standard surgery without similar labeling. After such a 
procedure, there was an average of 90% fewer residual cancer cells. This system 
is not only selective, but also results in more effective surgical tumor treatment.  
Another approach that is also based on activation of CPPs by an enzyme 
uses the endoprotease legumain, which was reported by Liu et al.73 Legumain is 
upregulated in various solid tumors, and recognizes the tripeptide Ala-Ala-Asn. 
This tripeptide was attached to a lysine in the CPP Tat, to create a blocking 
branched moiety which led to a substantial decrease in cellular uptake. The 
branched peptide was used for the delivery of doxorubicin-loaded liposomes to 
legumain-expressing cells (4T1 cells). This led to tumor regression a 4T1-
orthotopic model.  
1.6.2 Cell-targeting peptides (CTPs) 
Cell-targeting peptides (CTPs, sometimes referred to as cell-targeting domains, or 
CTDs) and homing peptides (HPs) provide another tool to induce cell-specificity in 
drug delivery systems. These peptides are able to target specific classes of cells, 
which may take place when two requirements are met. The diseased cells have to 
differentiate themselves from the general population by the expression of 
enzymes or receptors or through exhibiting an alternative uptake pathway to 
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identify themselves. Furthermore, the CTDs or HPs have to recognize these cells 
without having too much affinity for other cell types, in other words they have to 
be selective. 
Diseased cells often overexpress certain enzymes or molecules, as for 
example the matrix metalloproteinases in tumor cells that were discussed above. 
These overexpressed enzymes or molecules can act as a ‘zip-code’ system, 
attracting HPs and CTPs.74 Some peptides that could serve at CTPs were 
accidently discovered, whereas others were identified via phage display.75 Using 
in vivo phage display, Laakkonen et al. were able to identify several CTPs for 
different tumors and sometimes also for different states of the tumors (i.e. 
premalignant lesion vs full-blown tumor).76 Most literature reports focus on 
targeting diseased cells; however, it is also possible to target healthy cells. There 
are CTPs known for a range of different organs and tissues, including but not 
limited to: lungs, skin, white fat, prostate and brain.66  
To use CTDs for the introduction of selectivity in CPPs, chimeric peptides 
that contain a CPP-part and a CTD-part have to be obtained. An example of such 
system was reported by Mäe et al.77 in which a chimeric peptide consisting of the 
CPP pVEC (table 1) and the short homing peptide CREKA (CREKA-pVEC) was 
studied. Cellular uptake in human breast cancer cells was shown for fluorescently 
labeled CREKA-pVEC. Furthermore, the CREKA-pVEC construct was coupled to 
the anti-cancer drug chlorambucil (Cbl-CREKA-pVEC). Proliferation essays on the 
cultured cells showed that the Cbl-CREKA-pVEC construct resulted in up to 80% 
cell death at concentrations varying from 1 to 25 µM of peptide. Without the 
CREKA homing peptide (Cbl-pVEC), proliferation was less affected, with a 
maximum of 60% of the cells that were affected by the drug.  
In more recent studies, this CPP-CTP approach has been used for the 
intracellular delivery of small interfering ribonucleic acids (siRNA). Fang et al. 
showed selective cellular uptake of siRNA in vascular endothelial growth factor 
receptor 1 (VEGFR1) overexpressing cells by the use of a CPP-CTP chimeric 
peptide.78 VEGFR1 is highly overexpressed on almost all tumor cells, but not on 
healthy cells, which makes it a suitable target. Studies on a CTP that can be used 
to target VEGFR1 provided a six amino acid peptide named A1 (sequence: 
WFLLTM). The authors conjugated the Tat peptide to A1. Furthermore, GAPDH-
targeting siRNA (GAPDH = glyceraldehyde-3-phosphate dehydrogenase) was 
coupled to the Tat-A1 construct to evaluate the gene silencing activity. GAPDH is 
an enzyme required for glycolysis. The Tat-A1-siRNA construct was studied in 
human hepatocarcinoma (HepG2) liver cancer cells, and compared to 
Lipofectamine 2000, a common, commercially available transfection agent that 
enhances the transfection efficiency of RNA into in vitro cell cultures. After 48 
hours, the Tat-A1-siRNA construct was more effective compared to the 
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Lipofectamine, suggesting to be an efficient targeting method for VEGFR1 
overexpressing cells.  
Xiang et al. developed a system that combines the properties of 
activatable CPPs as discussed above and the selective targeting properties that 
can be introduced with a targeting motif.79 In their research, they focused on 
selectively targeting prostate cancer, thereby exploiting the high expression levels 
of prostate specific antigen (PSA) and prostate-specific membrane antigen 
(PSMA) that are observed in this form of cancer. A schematic overview of the 
system is shown in figure 8. The membrane of liposomes containing siRNA was 
functionalized with various DSPE-PEG-tails. These tails were either functionalized 
with folate or with an activatable CPP. Folate (also known as folic acid or vitamin 
B9) functions as a targeting motif for PSMA. Although folate itself is not a peptide, 
it does provide a targeting function for the CPPs. As activatable CPP, 
(DGG)4HSSKYQGr8GC was used, consisting of the CPP D-octa-arginine (r8), the 
anionic shielding peptide (DGG)4 and a linker (HSSKYQG) that can be cleaved by 
PSA. In an enzymatic hydrolysis test the authors showed that PSA indeed 
cleaved this linker. 
 
 
Figure 8 - Prostate cancer targeting by PSA-sensitive and PSMA-mediated functional liposomes. The 
liposomes are loaded with siRNA and functionalized on the outside with folate moieties (that target 
prostate specific membrane antigen (PSMA)) and an activatable CPP (D-octa-arginine) that can be 
activated by prostate specific antigen (PSA), when PSA cleaves the linker between the CPP and the 
shielding peptide domain. Figure reproduced from ref.79  
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Polo-like kinase 1 (PLK-1) is overexpressed in many human solid tumors 
and was used to test the system in vitro. The liposomes were encapsulated with 
PLK-1 specific siRNA and their gene silencing activity was evaluated for various 
liposomes (non-functionalized, folate-functionalized, CPP-functionalized, 
activatable CPP-functionalized and both folate and activatable CPP 
functionalized). It was found that the combination of folate and activatable CPPs 
was the most effective system if PSA was present to activate the CPP. In addition 
to their gene silencing activities, all liposomes induced a higher rate of apoptosis. 
Thus, the system not only inhibits further cell growth, but also eliminates diseased 
cells. In vivo tests with Cy5-siRNA in mice bearing tumor xenografts showed that 
dual-functionalized liposomes yielded the most selective targeting, although 
liposomes that were only functionalized with folate also showed significant 
selectivity. Altogether, Xiang et al. showed that their folate- and activatable CPP-
functionalized liposomes are effective and selective targeting systems for prostate 
cancer.79  
The combination of homing peptides and CTPs with CPPs is an 
interesting development that may increase cell type specificity of CPPs. However, 
the specificity and affinity of homing devices may be improved, because with 
current strategies, some tumor antigens are also present in healthy tissue, which 
may induce adverse side-effects. Furthermore, some non-specific uptake of the 
chimeric peptides is to be expected, because the CPP-part remains active in all 
tissue. To prevent this, the CPP-part is sometimes altered to reduce its activity. 
For example this was demonstrated in an elegant study reported by Tan et al.80 In 
their case, a modified and less potent CPP was conjugated to a 12-mer targeting 
peptide and was shown to specifically target ErbB2-overexpressing breast cancer 
cells. 
1.6.3 Targeting by cell-specific cargoes 
Apart from CTPs and HPs, cell specific targeting may be introduced by the use of 
a cargo that is selective. Such cargo may then be coupled to a traditional, non-
specific CPP such as Tat or nona-arginine. 
Dowdy and co-workers developed a system, in which Tat was employed 
against HIV-infected cells.81 In their study, named the Trojan horse strategy, a 
modified caspase 3 protein was used. Caspase 3 is known to induce apoptosis in 
cells after the inhibitor is endogenously cleaved off. In the modified caspase 3 
protein (Casp3), they replaced the endogenous cleavage site with the HIV p17-
p24 gag cleavage site A (sequence: SQVSQNYPIVQNLQ), so that it will only be 
cleaved by HIV protease. They showed that Tat-A-Casp3WT was able to 
internalize into Jurkat cells, as was Tat-A-Casp3MUT, a mutation in which a 
cysteine was replaced with methionine. This Tat-A-Casp3MUT is catalytically 
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inactive, whereas Tat-A-Casp3WT can catalyze the activation of inactivated Tat-A-
Casp3WT, thereby amplifying the apoptotic effects. In addition, Tat-HIVpr was 
synthesized, which consists of Tat coupled to the HIV protease that can activate 
Casp3. It was shown that both Tat-A-Casp3WT and Tat-A-Casp3MUT were cleaved 
by Tat-HIVpr. Next, the apoptotic properties were tested by assessing the cell 
viability. Tat-A-Casp3WT and Tat-A-Casp3MUT were studied with or without addition 
of Tat-HIVpr and with or without Ritonovar (an HIV protease inhibitor). Only the 
combination of Tat-A-Casp3WT with Tat-HIVpr showed a significant effect on cell 
proliferation (cell viability ≈ 25%), whereas for all other combinations, cell viability 
exceeded 75%. Similar results were obtained when tested in Jurkat cells that 
were infected with HIV. Although the Tat-A-Casp3WT also internalizes in healthy 
tissue, it was shown that Casp3 was not activated in these cells, thereby showing 
the selective targeting properties of this system.  
Next to a decreased pH in and around tumor tissue, a lower partial 
pressure of oxygen (pO2) may also be present. As a consequence, this tissue 
cannot be affected by radiotherapy or chemotherapy. Harada et al. developed a 
system to target these so-called hypoxic tumor cells.82 Hypoxia-inducible factor-1α 
(HIF-1α) is an important mediator of the hypoxic response of tumor cells by up-
regulation of several factors that are vital for tumor growth, and it is up-regulated 
itself by decreased O2 concentrations. This makes the inhibition of HIF-1α an 
important target to prevent tumor growth in hypoxic tumors. HIF-1α contains an 
oxygen-dependent degradation (ODD) domain that is responsible for the 
degradation of HIF-1α. First, the authors determined the essential amino acid 
sequence of the ODD domain. Next, a model fusion protein Tat-ODD-(β-
galactose) was designed and tested in vivo in mice bearing human pancreatic 
tumor xenografts. This protein was able to internalize into both hypoxic and 
normoxic cells, but was only stable in hypoxic cells. When β-galactose was 
replaced by Casp3, which can also be activated in hypoxic conditions, the 
stabilization effect remained the same (only in hypoxic cells), but the Casp3 also 
reduced the tumor sizes without noticeable side effects.  
Introducing cell selectivity by the use of targeting cargoes may provide a 
useful strategy for selective targeting. An advantage is that any CPP may be 
used, however only a small amount of cell-selective cargos is known at this 
moment. Furthermore, because the CPP is intrinsically active, collateral 
internalization in healthy tissue is to be expected. The non-specific uptake is not 
addressed as a potential problem in the examples described above because the 
desired pharmaceutical effect can only take place in diseased cells. However, 
undesired side-effects may occur when healthy cells take up large protein 
complexes. 
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1.6.4 Cell-penetrating homing peptides 
As described above, CPPs may be conjugated to CTPs or other cell-targeting 
motifs to selectively target cells using the overexpression of molecules or proteins 
on the outside of the cells. However, some peptides are reported that combine the 
properties of CPPs and CTPs, and are called cell-penetrating homing peptides 
(CPHPs).1 A schematic representation of the cellular interactions of homing 
peptides (HPs), chimeric CPPs-HPs (CTPs) and CPHPs can be found in figure 9. 
 
 
Figure 9 - Principle of cell-selective peptide targeting and delivery. (a) A homing peptide (HP) has no 
inherent internalization properties and only delivers its cargo to specific cell-surface receptors. (b) A 
HP conjugated to a cell-penetrating peptide (HP-CPP) undergoes receptor binding and then typically 
undergoes cargo internalization via endocytosis or pore formation. (c) A cell-penetrating homing 
peptide (CPHP) has the ability to internalize without the aid of external agents. Reproduced from ref.1 
Using phage display screening against cell suspensions prepared from 
MDA-MD-435 breast cancer xenografts, Laakkonen et al. identified a nine amino 
acid cyclic peptide LyP-1 (sequence: CGNKRTRGC) that could bind over 100 
times stronger to cultured MDA-MD-435 cells than non-recombinant phage.8,76,83 
They showed selective homing properties of LyP-1 to tumor lymphatic vessels 
and some tumor cells, as well as cellular uptake of the peptide. In addition to 
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MDA-MD-435 (melanoma), it also homes to MMTV-PyMT (breast cancer), 
TRAMP (prostate cancer), K14-HPV16 (skin cancer) and, to a lesser extent, KRIB 
(osteosarcoma), but it did not home to C8161 (melanoma), HL-60 (leukemia) or 
K14-HPV16/E2 (cervix). Hence, some form of selectivity is present. LyP-1 
preferentially accumulates in hypoxic areas in the tumors, shown by co-
localization with hypoxic markers. In vivo experiments in mice bearing breast 
cancer tumor xenografts showed tumor cell apoptosis, an inhibition in tumor 
growth and a reduction in the number of tumor lymphatics. Importantly, other cells 
remain unaffected, suggesting that LyP-1 could be used for cancer therapy, 
especially as lymphatic vessels are highly relevant in tumor metastasis. Another 
series of CPHPs identified by mRNA phage display was reported by Kondo et 
al.84 In general, the peptide sequences comprised both hydrophobic and positively 
charged amino acids, a general property of many CPPs (as explained earlier 
herein). The authors observed that each amino acid is crucial for induction of 
cellular uptake. Importantly, the reported peptides were shown to be taken up 
selectively by tumor cells. 
Two CPHPs were identified using a phage display screen with synovial 
cell lines.85 Peptides dubbed HAP-1 (SFHQFARATLAS) and HAP-2 
(HIQLSPFQSWR) were able to transduce only primary human synovial fibroblasts 
but were not able to do so for non-synovial cell types. When conjugated to the 
apoptotic peptide D(KLAKLAK)2, both peptide conjugates were able to reduce the 
viability of human rheumatoid arthritis (RA) synovial cells in a dose-dependent 
manner.  
Gao et al. reported a cell-penetrating homing peptide derived from 
interleukin-13.86 The interleukin-13 peptide (IL-13p) specifically targets to 
IL13Rα2, a tumor-restricted receptor and interestingly, the peptide also possesses 
cell-penetrating properties. To study the potential of the peptide, the authors 
anchored IL-13p onto nanoparticles (ILNPs) for glioma-targeting and delivery, and 
compared the uptake of INLPs with that of unmodified nanoparticles (NPs) in a 
cell line derived from malignant gliomas. In vivo, the fluorescence intensity of 
ILNPs in tumors was almost 3-fold higher when compared to NPs. The 
modification with IL-13p also significantly improved the speed and rate of 
penetration from vessels to tumor cells. The enhanced tumor localization of ILNPs 
was mostly attributable to the elevated tumor cell internalization of ILNPs, 
whereas most NPs co-localized with micro-vessels or macrophages. Svensen et 
al. recently reported four CPHPs, namely PYEE, LKKP, EPKK* (K* = N-alkyl 
glycine lysine-like peptoid) and ELK*K*.1 These peptides were found to home to 
and internalize in amelanotic melanoma cells, myeloid leukemia cells, embryonic 
stem cells and human primary monocytes, respectively. Furthermore, the 
peptides could be used for the delivery of peptide nucleic acids (PNA), with 
endocytosis demonstrated as the uptake mechanism. The incorporation of a 
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peptide mimetic (K*) makes EPKK* and ELK*K* more resistant to protease 
degradation, thereby enhancing the circulatory half lives in vivo.  
Interestingly, several RGD-based peptides have been identified as 
CPHPs. RGD recognizes the αv class of integrins, which are upregulated during 
tumor progression, and various forms of RGD (e.g. RGD-4C, iRGD and cRGD) 
have been coupled to apoptotic peptides and anticancer drugs to target both 
arthritis and various tumor tissue.22,87,88 The first compound with CPHP 
characteristics to enter clinical trials is cilengitide (EMD 121974, Merck), the salt 
of a cyclized RGD-based pentapeptide cyclo[Arg-Gly-Asp-D-Phe-(NMeVal)]. This 
peptide targets αvβ3 and αvβ5 integrins. In phase II clinical trials, treatment with 
cilengitide in patients with glioblastoma showed an important increase in survival 
after 1 year of treatment.89 In phase III studies it was however found that patients 
with newly diagnosed glioblastoma did not live significantly longer when treated 
with cilengitide plus chemoradiotherapy, underlining the complexity of the disease 
and the search for efficient treatment.90 
1.7 Outline of this thesis 
The promising characteristics of CPPs for the field of drug delivery make them an 
interesting scientific topic, however, many unanswered questions about their 
mechanism of action remain and even more importantly, there are still large 
challenges hampering their use in the pharmaceutical industry. The research in 
this thesis is focused on activatable CPPs, to gain control over the moment of 
uptake of CPPs and to increase their cell-type specificity. In the first three 
chapters of this thesis, the general idea is to link two inert peptides together to 
obtain an extended active CPP. If the linkage between the two short peptides is 
initiated by a specific trigger, such approach may be used to obtain activatable 
CPPs and based on the nature of the trigger that induces activity, a degree of 
selectivity may be obtained. In chapter 2, we describe an initial approach to 
obtain activatable oligo-arginine CPPs. To this aim, it was evaluated whether 
fluorescently labeled oligo-arginines (shorter than 5 arginine residues) bearing a 
C-terminal cysteine could internalize into cells. As these peptides (called 
truncated peptides) were shown to be inactive, the next step was to link these 
short oligo-arginines to complementary short peptides (≤ 5 arginine residues) 
through disulfide bridge formation. This was possible because the second series 
of short inert oligo-arginines were N-terminally functionalized with a cysteine 
residue that was modified with 3-Nitro-2-pyridinesulfenyl (Npys). This group 
activates the thiol for rapid heterodimerization at neutral pH. Through the disulfide 
linkage, extended peptides (containing 8 or 9 arginine residues) were obtained 
that can efficiently enter HeLa cells. Although the various extended peptides differ 
in uptake efficacy, some of them were equally efficient as octa-arginine. 
Interestingly, concentration dependent uptake mechanisms were observed for 
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several of the extended peptides. In chapter 3 we investigate the possibility for in 
situ activation of CPPs. For this application, a system based on disulfide bridge 
formation may be disadvantageous, because many membrane proteins contain 
thiol groups that may react with the activatable peptides. The research in this 
chapter is therefore focused on linking the two truncated oligo-arginines by 
mutually reactive bio-orthogonal groups. Therefore two series of tetra-arginines 
were used, with the first series containing an N-terminal fluorescent label and a C-
terminal tetrazine functionality, and the second series consisted of tetra-arginines 
with a norbornene or bicyclo[6.1.0]nonyne (BCN) functionality. These truncated 
peptides were joined to make up active oligo-arginine CPPs via tetrazine-
norbornene and tetrazine-BCN cycloadditions. We observed no significant cellular 
uptake for the truncated peptides, and clear uptake of pre-ligated CPPs. 
Importantly, it was demonstrated that in situ activation of the peptides was 
possible via tetrazine-BCN cycloaddition.  
In chapter 4, the activation approach described in chapter 2 is taken 
further by decorating hetero-dimerizing leucine zippers with the truncated 
peptides, rendering cellular uptake only possible after coiled-coil formation. 
Importantly, by changing the amino acid composition and stability of the coiled-
coil, the uptake mechanism can be influenced, making it possible to deliver the 
complexes directly to the cytosol. It was found that when a very stable coiled-coil 
was used, there was no need to link the two truncated arginine sequences via a 
disulfide bridge. We furthermore showed that this leucine-zipper induced 
activation strategy may be used to deliver an intact protein, GFP, to HeLa cells.  
After focusing on the activation of olio-arginine CPPs by reconstitution of 
two inert peptides upon a specific trigger, in the next part of the thesis an 
activation approach is investigated that relies on blocking the positive charges in 
the Tat peptide, temporarily hampering the activity of Tat. In chapter 5, we 
introduce this strategy, which is based on enzymatic reactions to cleave off the 
blocking groups on Tat, and subsequently inducing activity of the peptide. The 
use of a specific enzymatic reaction to trigger uptake of an inert peptide offers a 
relevant targeting strategy because the activation process takes place in a short 
time and only in areas where the specific cell surface enzyme is present. To this 
purpose, the lysine side chain of Tat peptides was modified with an enzyme-
cleavable domain of minimal size. This yielded blocked Tat-peptides which were 
inactive in HEK cells but that could be activated by co-incubation with the selected 
enzymes. 
In chapter 6, the modified Tat-peptides studied in chapter 5 are studied 
with regard to their intrinsic cell-type specificity. We found that without the addition 
of enzyme, the modified peptides could be taken up by HeLa cells, whereas they 
are inactive in HEK cells. This prompted us to study the peptides further in these 
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two cell lines and in more detail in leukemic cell lines and white blood cells 
derived from a healthy donor. Importantly, we observed efficient uptake in various 
leukemic cell lines derived from acute myeloid leukemia and B-cell lymphoid 
leukemia, whereas no cell-penetrating activity was observed for healthy white 
blood cells. Our results suggest that both the type of side-chain modification and 
the position of the modification (first or second lysine residue of Tat, or both of 
them) greatly influences the degree of selectivity of the peptide. 
In the last chapter of the thesis the subject of interest is changed from 
CPPs to cell adhesion materials, and to this aim the RGD peptide is used. In 
chapter 7, polydiacetylene-containing peptide amphiphiles fibers are described 
that may be used to sense cell adhesion by means of a color change. The 
diacetylene-containing peptide amphiphiles were functionalized with the cell-
binding motif RGDS, and subsequently mixed with non-functionalized diacetylene-
containing spacer amphiphiles. The diacetylenes in the backbone of these fibers 
were polymerized using UV-light to give dark blue fiber solutions. Subsequent cell 
adhesion induced a color change from blue to pink. The propensity of the RGDS 
fibers to change color upon cell adhesion could be tuned by varying the C-
terminal amino acid of the spacer amphiphile. In addition to this, by varying the 
RGDS density we found that the optimum colorimetric response was obtained for 
fibers with a 6:1 ratio of non-RGDS to RGDS amphiphiles. 
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2.1 Introduction 
Cell-penetrating peptides (CPPs) are peptides that can induce the cellular uptake 
of (bio)molecules that otherwise only poorly enter cells.1 Because of this, they are 
being regarded as promising tools for drug delivery.2 However, there are still 
major challenges that hamper the pharmaceutical use of CPPs.3 Despite being 
extensively studied, the exact mechanism of cellular uptake has yet to be 
elucidated and varies among different classes of CPPs.4 Nevertheless, it is 
generally agreed that after connecting a large cargo to a CPP, these complexes 
are almost exclusively taken up by endocytosis.5 Therefore, circumventing 
endocytotic entrapment of the CPP payload will make CPPs more suitable for 
pharmaceutical use.6 But perhaps most importantly, the clinical use of CPPs is 
limited because of the lack of cell-type specificity of most CPPs and because 
temporal control over their uptake is still unavailable.3 Recently, we and others 
reported delivery systems in which an inactivated CPP can be activated by an 
external trigger, such as UV-light, a change in pH or enzymatic cleavage.8 
However, these triggers may be phototoxic or require tumor-induced pH shifts or 
specific enzymatic activity. Here we present a redox-sensitive activatable system 
based on disulfide bridge formation. This physiologically benign coupling 
chemistry between two cysteines allows the combination of two truncated and 
inactivated CPPs into a functional system and has the potential to become a 
useful complementary strategy for the modular activation of cellular uptake. 
 One of the most promising classes of CPPs are the oligo-arginines.9 
Interestingly, these CPPs only show cell uptake ability if a minimum amount of six 
arginines are present in a single sequence.10,11 This inspired us to investigate if by 
conjugation of two smaller inactive oligo-arginine fragments an active conjugate 
could be obtained. Here we show this to be a feasible strategy. 
2.2 Results and discussion 
2.2.1 Synthesis of truncated and extended oligo-arginine peptides 
A truncated and thus inert CPP was synthesized that could be selectively linked to 
a complementary short oligo-arginine to obtain an active CPP. The first peptide, 
the “truncated peptide” (R4) (figure 1, truncated peptide R4), consisted of four 
arginine residues and contained a C-terminal cysteine residue to provide a handle 
for linkage to the second (activating) peptide. This activating peptide (*R4) 
consisted of a tetra-arginine stretch and a cysteine residue at the N-terminus. Its 
thiol was functionalized with 3-nitro-2-pyridinesulfenyl (Npys), which both protects 
the thiol and activates it for rapid disulfide bridge formation at neutral pH.11 Using 
this protecting group, homodimerization of the peptides was circumvented.  
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To allow fluorescence-based techniques for evaluation of uptake 
efficiency, the truncated peptide was N-terminally labeled with fluorescein 
isothiocyanate (FITC) using an ε-aminohexanoic acid spacer (Ahx). By mixing the 
truncated and activating peptide at pH 7.5, a disulfide-linked peptide was 
obtained, consisting of 8 arginines and an N-terminal FITC-label (figure 1 - 
extended peptide R4-R4). 
2.2.2 Uptake experiments using the truncated peptide and extended peptide  
Cellular uptake into HeLa cells of both truncated peptide (R4) and the extended 
peptide (R4-R4) was visualized using confocal fluorescence microscopy. Cells 
were incubated with 5 µM peptide in serum-containing medium for 30 minutes at 
37 ºC. This experiment showed that the truncated peptide was indeed not able to 
enter cells, whereas, much to our satisfaction, the extended peptide clearly 
showed cellular uptake by endocytosis (figure 1). This suggested that that the 
conversion of two short inert oligo-arginines into a CPP was possible through 
disulfide linkage.  
 
Figure 1 – schematic representation of truncated peptide R4 and extended peptide R4-R4 where the 
truncated peptide and activating peptide (blue) are linked together via a disulfide bridge (highlighted in 
red). On the right the confocal fluorescence micrographs of HeLa cells treated with 5 µM peptide for 30 
minutes in serum-containing medium at 37ºC.  
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2.2.3 Synthesis of a small library of truncated, activating and extended peptides 
Encouraged by the above described results on cellular uptake of the extended 
peptide, a small library of peptides (figure 2) was synthesized to further 
investigate this induced activity. The additional truncated and activating peptides 
that were prepared, consisted of three or five arginines. By combining these 
peptides, five extended peptides were obtained, composed of 8 or 9 arginine 
residues in total, and one peptide with 10 arginine residues (R5-R5) (figure 2).  
 Even though disulfide bridges are stable in the extracellular environment, 
they are prone to reduction in intracellular compartments.12 To investigate the 
influence of the reducibility of the linkage, a triazole-linked variant (R4-t-R4) to the 
disulfide-linked R4-R4 peptide was synthesized (figure 2). This peptide was 
obtained after a copper catalyzed cycloaddition reaction13 between a tetra-
arginine peptide functionalized with azido-homoalananine at its N-terminus (Azh-
R4), and another tetra-arginine sequence containing propargylglycine at its C-
terminus (R4-Ppg, both peptide structures in appendix). Furthermore, linear octa- 
(R8) and nona-arginine (R9) were used as positive controls to compare the 
uptake behavior of the disulfide-linked peptides to native linear oligo-arginines. 
These control peptides were also N-terminally labeled with FITC. 
 
Figure 2 - Structures of truncated peptides (R3, R4, R5), activating peptides (*R3, *R4, *R5), extended 
peptides (R3-R5, R4-R4, R4-R5, R5-R3, R5-R4, R5-R5) and non-reducible peptide (R4-t-R4). 
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2.2.4 Cellular uptake studies at low concentration (5 µM) 
This small peptide library allowed us to study the relation between uptake 
behavior and subtle structural differences, e.g. by varying the position of the 
disulfide bridge. Prior to the uptake experiments, possible cytotoxic effects of the 
peptides were studied. HeLa cells were incubated with 5 or 20 µM peptide for 30 
minutes, after which the cells were washed thoroughly and allowed to rest for 3 
hours. The mitochondrial activity of the cells was analyzed as a measure of their 
viability. The results of this experiment are summarized in figure 3. As none of the 
peptides induced cytotoxicity, we could proceed with the uptake experiments. 
 
Figure 3 – Summary of cell viability assays in which the amount of viable cells was calculated by the 
mitochondrial activity of the cells. Untreated cells were set to 100% viability to allow for comparison of 
cytotoxicity of the peptides.  
The uptake efficiency of the peptides at a concentration of 5 µM in HeLa 
cells was quantified using flow cytometry (figure 4A) and visualized by confocal 
fluorescence microscopy (figure 6). Prior to the experiments it was demonstrated 
using an Ellman’s test14 that the disulfide bridge of the extended peptides was 
intact, and a free thiol was present in case of the truncated peptides. For 
reference, R8, R9 and the triazole-linked peptide (R4-t-R4) were also studied. The 
main observation of these experiments was that the truncated peptides were 
indeed inactive, whereas the extended peptides showed clear uptake. 
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Interestingly, the extended peptides consisting of eight arginine residues were all 
internalized with efficiencies comparable to one of control peptides, R8. 
Furthermore, the reducibility of the disulfide bridge did not influence the uptake 
properties, as the extended peptide R4-R4 was taken up to the same extent as its 
triazole-linked analogue R4-t-R4. However, for the peptides containing nine 
arginine residues, a striking difference in uptake was found between extended 
peptide R4-R5 and extended peptide R5-R4. While R4-R5 was taken up nearly as 
efficient as R9, R5-R4 was taken up even less than R4-R4. The position of the 
disulfide bridge is the only distinction between the two peptides, suggesting that 
this significantly influences the uptake efficiency of these extended peptides. To 
explain this difference, three additional peptides were synthesized: the R5-R5 
peptide and analogues to R4-R5 and R5-R4, for which the two arginine parts 
were linked together via an amino-octanoic acid spacer (Aoc) instead of the 
disulfide bridge, FITC-Ahx-Arg4-Aoc-Arg5-NH2 (R4-Aoc-R5) and FITC-Ahx-Arg5-
Aoc-Arg4-NH2 (R5-Aoc-R4) (structures in appendix). Using amino-octanoic acid 
as a spacer, the atomic distance between the two peptide parts remained the 
same, however flexibility and hydrophobicity were introduced.  
Uptake of these additional peptides was tested by flow cytometry using 
the same conditions as in the experiment before. Interestingly, for R5-R5 the 
same diminished uptake was observed as for R5-R4. Furthermore, the amino-
octanoic acid linked peptides showed a similar difference in uptake efficiency as 
between R4-R5 and R5-R4, albeit less pronounced (figure 4B).  
 
Figure 4 – A) Summary of flow cytometry results of the truncated and extended peptides, and the 
control peptides R8, R9 and R4-t-R4 at 5 µM. The uptake of R9 is set to 100%. B) Summary of flow 
cytometry results performed to explain the difference in uptake behavior between R4-R5 and R5-R4. 
The uptake of R9 is set to 100%. 
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Arginine-rich peptides are substrates as well as inhibitors of furin 
proteases and either role depends on the length of the peptide.15 As our 
experiments were performed in the presence of serum, differences in uptake 
efficiency may relate to differences in sensitivity to proteolytic breakdown. 
Fluorescence correlation spectroscopy (FCS) was carried out to study the stability 
of the peptides in serum over time. This showed that the extended peptides were 
equally or more stable in serum than control peptide R9 (figure 5).  
 
Figure 5 – Results for the FCS experiment to test the stability of peptides R4-R4, R4-t-R4, R4-R5, R5-
R4 and R9 in serum. This data indicates that the length of the two arginine modules may have an 
impact on proteolytic stability. However, it cannot explain the observed differences in uptake among 
the extended peptides, as all of these peptides are equally or more stable in serum than control 
peptide R9. 
To study the uptake behavior of the extended peptides more carefully, 
cellular localization studies using confocal fluorescence microscopy were 
performed (figure 6). Again, HeLa cells were treated with 5 µM peptide for 30 min 
at 37ºC. We observed no fluorescence for the truncated peptides, meaning that 
they were indeed not taken up. The positive controls, R8 and R9 showed clear 
punctate spots indicating endocytosis. Similar patterns were observed for the 
corresponding extended peptides R4-R4, R3-R5, R4-R5 and R5-R3. Again, the 
uptake of R5-R4 and R5-R5 was diminished. These results corroborate the flow 
cytometry experiments.  
 
Figure 6 – Confocal fluorescence images for uptake experiment at 5 µM. Scale bar represents 40 µm. 
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2.2.5 Cellular uptake studies at high concentration (20 µM) 
Because it was previously described that the mechanism in which arginine-rich 
CPPs can enter cells is strongly concentration dependent16, both flow cytometry 
and confocal fluorescence studies were repeated at the higher concentration of 
20 µM (figure 7 and 8). The flow cytometry experiment showed an interesting 
difference in internalization efficiency among the peptides containing eight 
arginines (figure 7). Extended peptide R4-R4 showed to be taken up equally well 
as the positive control R8, however the uptake of peptides R3-R5 and R5-R3, as 
well as that of the triazole-linked analogue R4-t-R4 was slightly diminished. In the 
same experiment, the uptake of the extended peptides, R4-R5 and R5-R4, was 
compared to the positive control R9. Now, both extended peptides were taken up 
much less efficiently than R9. This is a remarkable observation compared to the 
results at 5 µM, where R4-R5 was taken up to the same amount as R9. 
Interestingly, uptake or R5-R5 was increased compared to R4-R5 and R5-R4, but 
this peptide was still taken up less efficiently than R4-R4. Also, the Aoc-linked 
peptides R4-Aoc-R5 and R4-Aoc-R5 were taken up more efficiently than the 
disulfide linked R4-R5 and R5-R4. These results suggest that at a high 
concentration (20 µM) other CPP sequence characteristics influence the uptake 
than those that govern this process at a lower concentration (5 µM).  
 
Figure 7 – A) Summary of flow cytometry results of the truncated and extended peptides, and the 
control peptides R8, R9 and R4-t-R4 at 20 µM. The uptake of R9 is set to 100%. B) Summary of flow 
cytometry results performed to explain the difference in uptake behavior between R4-R5 and R5-R4. 
The uptake of R9 is set to 100%. 
Confocal fluorescence studies allowed us to investigate this observation 
in more detail (figure 8). This experiment showed that at high concentration 
several different uptake mechanisms may play a role, depending on the position 
of the disulfide bridge, the amount of arginines present in the peptide sequence 
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and the hydrophobicity of the peptide. For the positive control R8, three distinctive 
localizations of fluorescence can be observed: punctate spots that originate from 
endocytosis, diffuse signals in the cytosol indicating either endosomal escape or 
direct translocation, but also bright fluorescent cells. The latter might have been 
caused by uptake through nucleation zones.17 Similar results were obtained for 
R4-R4, while its triazole-linked analogue R4-t-R4 showed mainly cytosolic 
staining but no uptake via nucleation zones. Interestingly, for peptides R3-R5 and 
R5-R3 only punctate spots were observed. For R9, uptake via nucleation zones 
seemed to be the main mechanism of entry. Remarkably, for peptides R4-R5 and 
R5-R4 only punctate signals were observed, however for R4-Aoc-R5, R5-Aoc-R4 
and R5-R5 all three fluorescence patterns (described above) were observed 
(figure 8). For R5-R5 we also observed some aggregation of the peptide on the 
cell membrane, which might have caused a slight overestimation of the 
fluorescence signal in the flow cytometry experiment. 
 
Figure 8 – Confocal fluorescence images for uptake experiment at 20 µM. Scale bar 40 µm. 
2.2.6 Discussion on the cellular uptake mechanism of the extended peptides 
Previous reports describe that uptake via nucleation zones is concentration-
dependent but is also highly influenced by the peptide sequence.17,18 This uptake 
process is considered to be much faster than endocytosis, causing a large 
difference in uptake efficacy among the extended peptides, depending on whether 
or not uptake via nucleation zones is achieved. Our results suggest that the 
position of the disulfide bridge, and hence the structural arrangement of the 
arginine residues thus strongly influences the mechanism of uptake. This 
corroborates earlier work from Wender et al., in which oligo-arginines were 
interrupted by various flexible spacers, inducing changes in uptake efficacy and 
mechanisms.19 Our findings furthermore indicate that a symmetric distribution of 
the guanidinium groups in the peptide (R4-R4 and R5-R5) yields more active 
CPPs. A final indication that the spatial arrangement of oligo-arginines appears to 
be crucial for inducing specific pathways was obtained from the uptake 
experiment of the amino-octanoic acid linked peptides R4-Aoc-R5 and R5-Aoc-R4 
(figure 8). In contrast to the disulfide bridge extended peptides R4-R5 and         
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R5-R4, R4-Aoc-R5 and R5-Aoc-R4 are taken up by several mechanisms, with 
great similarity to R9. This indicates that next to structural arrangement of the 
arginine residues, the hydrophobicity and flexibility of the peptide also plays a role 
in uptake.  
2.3 Conclusion 
In brief, we have shown the possibility of activating a set of truncated oligo-
arginines into cell-penetrating peptides by extending their sequence through 
disulfide linkage to complementary oligo-arginines. The uptake efficiency of the 
resulting extended peptides heavily depended on the arrangement of arginine 
residues. This system offers a new, physiologically relevant strategy to control the 
moment of uptake of CPPs. 
2.4 Experimental Section 
Reagents 
NovaPEG Rink amide resin and polystyrene Rink amide resin were purchased from 
Novabiochem and Fmoc-L-amino acids from Bachem (Bubendorf, Switzerland) or 
Novabiochem (EMD Chemicals, Gibbstown, USA). Boc-Cys(Npys) was obtained from 
Bachem (Bubendorf, Switzerland). Fmoc-L-γ-azidohomoalanine was purchased from 
Chiralix (Nijmegen, The Netherlands). Fmoc-ε-aminohexanoic acid was purchased from 
Novabiochem and Fmoc-8-aminooctanoic acid from Sigma Aldrich. Dulbecco’s modified 
Eagle medium, fetal bovine serum, and RPMI were obtained from Invitrogen, Eugene, 
U.S.A.). The cell counting kit (CCK-8) was obtained from Dojindo Molecular Technologies 
(Rockville, U.S.A.). Carboxyfluorescein-labelled nona-arginine was purchased from EMC 
microcollections (Tübingen, Germany). All other chemicals were purchased from Baker, 
Fluka or Sigma Aldrich and used as received. 
Peptide synthesis 
General peptide Synthesis 
Peptides were synthesized on NovaPEG Rink amide or polystyrene Rink amide resins 
using a Labortec640 peptide synthesizer (Labortec, Bubendorf, Switzerland), employing a 
standard Fmoc solid-phase peptide synthesis (SPPS) protocol. In brief, the resin was 
swollen in DMF for 30 minutes prior to use. The Fmoc protecting groups were removed by 
washing the resin with piperidine in DMF (20%, v/v) and then shaking it 3 times for 6 
minutes with another portion of piperidine in DMF. The desired sequence of amino acids 
was coupled to the resin using Fmoc-L-amino acids (3.0 equiv), diisopropylcarbodiimide 
(DIPCDI, 3.3 equiv) and N-hydroxy benzotriazole (HOBt, 3.6 equiv). Peptide couplings 
were monitored using the Kaiser test. After the final Fmoc removal the resin was washed 
with DMF, DCM, i-PrOH, DCM, i-PrOH and air-dried for at least 2 h.  
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Synthesis of fluorescein-labeled peptides 
The following peptides were synthesized using standard SPPS as described above: R3 
(FITC-AhxArgArgArgCys-NH2), R4 (FITC-AhxArgArgArgArgCys-NH2), R5 (FITC-
AhxArgArgArgArgArgCys-NH2), R8 (FITC-AhxArgArgArgArgArgArgArgArg-NH2), R4-Aoc-
R5 (FITC-AhxArgArgArgArgAocArgArgArgArgArg-NH2) and R5-Aoc-R4 (FITC-
AhxArgArgArgAocArgArgArgArgArgArg-NH2) For these peptides, the last coupling step 
was performed using fluorescein isothiocyanate (FITC, 2 equiv.) and N,N-
diisopropylethylamine (DIEA, (3 equiv.) in DMF/DCM (1:1 v/v). The reaction was monitored 
by using the Kaiser test.20 The peptides were cleaved from the resin by suspension in a 
mixture of trifluoroacetic acid/water/triisopropyl-silane/thioanisole (90:5:2.5:2.5 v/v/v/v) for 
6 h. The free peptides were precipitated in Et2O, redissolved in water and lyophilized 
yielding the crude peptides. The crude peptides were purified by reversed phase HPLC 
and subsequently lyophilized yielding a yellow powder. Purity was evaluated by analytical 
reversed-phase HPLC and identity confirmed by mass spectrometry.  
Synthesis of activating peptides 
The following peptides were synthesized using standard SPPS as described above:  
*CR3 (C(Npys)ArgArgArg-NH2); *CR4 (C(Npys)ArgArgArg-NH2) and *CR5 
(C(Npys)ArgArgArg-NH2). The last coupling was performed using 3 equiv. Boc-Cys(Npys), 
3.3 equiv. DIPCDI and 3.6 equiv. HOBt in DMF. The peptides were cleaved from the resin 
by suspension in a mixture of trifluoroacetic acid/water/triisopropyl-silane(92.5:5:2.5 v/v/v) 
for 6 h. The free peptides were precipitated in Et2O, redissolved in water and lyophilized 
yielding the crude peptides. The crude peptides were purified by reversed phase HPLC 
yielding a yellow powder after lyophilization. Purity was evaluated by analytical reversed 
phase HPLC and identity confirmed by mass spectrometry. 
Preparation of extended peptides 
Disulfide linkage between the activating and truncated peptides was achieved by dissolving 
the truncated peptide in a 0.1 M degassed sodium phosphate buffer (pH 7.4) and 
subsequently mixing it with 1.1 equiv. activating peptide. During this reaction, the final 
peptide concentration was 1 to 5 mM. The reaction was monitored by reversed-phase 
HPLC. At the end of the reaction, the resulting peptides were purified by reversed-phase 
HPLC on a C18 column, using a linear gradient of acetonitrile in an aqueous solution 
containing 0.1% (v/v) TFA. After lyophilization, the peptides were obtained as yellow 
powders. All peptides were obtained with a purity > 95%, as assessed by analytical 
reversed phase HPLC. 
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Synthesis of triazole-linked peptide R4-t-R4 
R4-Ppg and Azh-R4 were synthesized using standard SPPS as described above. The 
copper-medicated click-reaction between the two peptides was performed by dissolving 
0.99 µmol of both peptides together with 24 µmol CuSO4• 5H2O in water (1 mL). Lutidine 
(49.4 µmol) was suspended in the reaction mixture and stirred under Ar overnight. Sodium 
ascorbate (20.0 µmol) was added and the reaction was stirred for another night. The crude 
peptide was purified by reversed-phase HPLC on a C18 column, using a linear gradient of 
acetonitrile in an aqueous solution containing 0.1% (v/v) TFA. After lyophilization, the 
peptide was obtained as a yellow powder with a purity of > 95% as assessed by analytical 
reversed phase HPLC.  
Peptide Characterization  
Peptides were characterized using mass spectrometry and purity was analyzed using 
analytical reversed phase HPLC. 
Mass spectra were acquired on a Thermo Finnigan LCQ-Advantage MAX ESI-ion trap. 
Analytical HPLC was performed on a Shimadzu LC-20A Prominence system (Shimadzu,‘s- 
Hertogenbosch, The Netherlands) equipped with a C18 ReproSil column, 150x3 mm, 
particle size 3 µm (Screening Devices, Amersfoort, The Netherlands). Elution of the 
peptides was achieved with acetonitrile/water gradient containing 0.1% trifluoroacetic acid 
(5-100%, 1-40 min, flow 0.4 mL/min). 
Peptide ESI-ion trap m/z HPLC RT (min) 
R3 [M+H]+1105.2 (calcd. 1104.7) 12.1 
R4 [M+H]+1260.3 (calcd. 1260.8) 14.5 
R5 [M+H]+1417.4 (calcd. 1416.9) 15.2 
R8 [M+H]+1782.3 (calcd.1781.9) 
[M+2H]2+ 891.6 (calcd. 891.5) 
17.9 
R4-Aoc-R5 [M+2H]2+969.7(calcd. 969.5); 
[M+3H]3+ 646.7 (calcd. 646.4) 
22.3 
R5-Aoc-R4 [M+2H]2+969.8(calcd.969.5) 
[M+3H]3+ 646.7 (calcd. 646.4) 
23.3 
R4-t-R4 [M+H]+1504.3(calcd.1503.9)  
[M+2H]2+ 752.8 (calcd. 752.5) 
22.7 
*R3 [M+H]+ 741.8 (calcd. 742.3) 2.6 
*R4 [M+H]+ 897.9 (calcd. 898.4) 2.9 
*R5 [M+H]+1417.4 (calcd. 1416.9) 3.1 
R3-R5 [M+2H]2+1002.8 (calcd. 1002.5) 
[M+3H]3+ 668.5 (calcd. 668.7) 
14.8 
R4-R4 [M+2H]2+ 1002.7 (calcd. 1002.5)  
[M+3H]3+ 668.5 (calcd. 668.7) 
15.9 
R4-R5 [M+2H]2+ 1080.4 (calcd. 1080.6)  
[M+3H]3+ 720.5 (calcd. 720.7) 
18.1 
R5-R3 [M+2H]2+ 1002.6 (calcd. 1002.5)  
[M+3H]3+ 668.6 (calcd. 668.7) 
14.5 
R5-R4 M+2H]2+ 1080.4 (calcd. 1080.6)  
[M+3H]3+ 720.6 (calcd. 720.7) 
17.3 
R5-R5 [M+2H]2+ 1158.3 (calcd. 1158.7)  
[M+3H]3+ 772.6 (calcd. 772.7) 
17.8 
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Cell culture and cell viability assays  
Cell culture 
HeLa cells were maintained in sterile conditions in DMEM or RPMI (Gibco, Invitrogen, 
Eugene, U.S.A.) supplemented with 10 % heat-inactivated fetal bovine serum (FBS; PAN 
Biotech). All cells were incubated at 37 ºC in a humidified atmosphere of 5 % CO2. Cells 
were passaged every 2 to 3 days. 
Cell viability assay 
Cell viability was evaluated using Cell Counting Kit-8 (CCK-8, Dojindo Molecular 
Technologies, U.S.A). HeLa cells were seeded in 96-well plates to obtain 40,000 cells/well 
the day of the experiment. On the day of the experiment, cells were incubated with 100 µL 
peptide solution in DMEM for 30 minutes at 37°C. Cells were washed 3 times with DMEM + 
10% FBS and maintained in this solution after the last washing step. After 4 hours of 
incubation, the supernatant was removed and a solution of CCK-8 (10 % in DMEM + 10% 
FBS) was added. After 3 hours of incubation at 37 °C, the absorbance was measured at 
450 nm using a microplate reader (Wallac Victor 1420 multilabel counter, Perkin Elmer). 
The experiments were performed in triplicates and repeated twice independently. A value 
of 100% survival was obtained by measuring cells that were not incubated with peptides 
and viability of cells treated with the peptides was calculated from this.  
Cellular uptake experiments 
Flow cytometry 
HeLa cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) one (80,000 
cells/well) or two (40,000 cells/well) days prior to the experiment. On the day of the 
experiment, cells were incubated with the peptide solutions (5 µM or 20 µM) for 30 min at 
37°C in RPMI + 10% FBS. After washing the cells with HBS buffer pH 7.4 (10 mM HEPES, 
135 mM NaCl, 5 mM KCl, 5 mM MgCl2, 1.8 mM CaCl2), cells were detached by 
trypsinization for 5 minutes, spun down and resuspended in 200 µL RPMI + 10% FCS. The 
fluorescence was measured using a FACSCalibur flow cytometer (BD Biosciences, 
Erembodegem, Belgium) and subsequently data was analyzed with the Summit software 
(Fort Collins, USA). Results were based on 10,000 gated cells.  
Confocal laser scanning microscopy 
HeLa cells were seeded in chambered coverslips (Nunc, Wiesbaden, Germany) at a 
density of 40,000 cells (one day) or 20,000 cells per well (two days prior) to the experiment. 
Cells were incubated with the indicated peptide concentrations for 30 min at 37 ºC. Cells 
were washed twice after incubation with RPMI + 10 % FBS and living cells were analyzed 
immediately by confocal microscopy using a TCS SP5 confocal microscope (Leica 
Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63 x N.A. 1.2 water 
immersion lens. Cells were maintained at 37 ºC on a temperature-controlled microscope 
stage. Fluorescein was excited by an argon laser at 488 nm and emission was collected 
between 500 and 550 nm.  
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Stability of the peptides 
Fluorescence correlation spectroscopy 
Peptide samples (5 µM) were prepared in HBS supplemented with 10% FBS and heated to 
37ºC using a heat block. Aliquots (5 µL) were collected at the indicated time points, diluted 
20 times with protease inhibitor cocktail and were directly frozen (Roche, Mannheim, 
Germany). After 8h proteinase K (2 mg/mL) (Roche, Mannheim, Germany) was added to 
the remaining peptide solution and incubated for 5 h at 37ºC. After this incubation, the 
sample was treated as the previous samples. For FCS measurements, 384 well plates 
were coated with 0.1% BSA (Roche, Mannheim, Germany) for 30 min and washed twice 
with PBS. Samples were thawed on ice and diluted 200 times with Tris buffer pH 8.8. 20 µL 
of this diluted solution was taken for FCS measurement. Measurements (per samples 5 
measurements of 20 s) were performed on a TCS SP5 confocal microscope (Leica 
Microsystems) equipped with a dual channel FCS unit using an Argon laser for the 
excitation of fluorescein at 488 nm. Data was analyzed with a two component fit using the 
ISS VISTA software. 
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Appendix 
Additional peptide structures 
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3.1 Introduction 
Cell-penetrating peptides (CPPs) are a class of peptides that have the ability 
to penetrate the otherwise impermeable plasma membrane. In addition to this 
extraordinary characteristic, CPPs can also transport large cargoes with them for 
cellular delivery. As a result these peptides are very promising tools for delivery 
of bioactive molecules, into cells.1 There are large varieties in the sequence and 
structure of CPPs, suggesting that several factors may contribute to the induction 
of cellular uptake.2 Indeed, a variety of mechanisms of uptake are available for 
CPPs. 3 Among these, mechanisms that lead to cytosolic delivery of cargo are 
most desirable for a drug delivery strategy, although unfortunately endocytotic 
mechanisms are more common and do not facilitate this directly.2 For this reason, 
it is interesting to identify the key structural elements in CPPs that contribute to 
uptake in the cytosol. Although the predominant endocytotic uptake of many 
CPP-cargo constructs is hampering their pharmaceutical use, there is another, 
possibly even more important challenge to overcome. CPPs are in fact hardly 
cell-type specific, and there is no temporal control over their uptake. 
Consequently, strategies should be developed to introduce cell-type selectivity in 
CPPs and make them activatable, in order for them to be applicable in 
therapeutic systems.4-7 
Activation based on several triggers has been reported, such as a pH-
change4, exposure to UV-light8, or by enzymatic reactions.6 pH-triggered 
activation is biologically relevant, as the environment of tumor tissue is 
characterized by a decreased pH. This phenomenon may be used to protonate a 
peptide after which it becomes positively charged and hence a CPP, for example 
when histidine-rich peptides are employed.9 Alternatively, the drop in pH may 
deshield CPPs that were immobilized on a delivery vehicle.10 Most activation 
strategies are promising to induce specific cellular uptake, but they generally 
depend on the properties of the targeted tissue or cell type, making them very 
sensitive for any changes in the targeted environment. Therefore it would be 
beneficial to develop an activation strategy that is more generally applicable and 
less sensitive to biological changes. 
We have demonstrated earlier (chapter 2) that oligo-arginines can be 
used for such an activation strategy.11 For these peptides it is known that a 
minimum amount of six arginine residues is needed to induce cellular uptake.12 
Making use of this characteristic, an activation approach was designed that 
involved truncated oligo-arginines consisting of three to five arginine residues and 
a C-terminal cysteine. These peptides were elongated through disulfide bridge 
formation with complementary oligo-arginines containing an N-terminal cysteine 
residue. Whereas the truncated peptides did not induce uptake in HeLa cells, the 
elongated octa- and nona-arginines were efficient CPPs.13 
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 Although this approach demonstrated that activation of short oligo-
arginine peptides is possible by extension of their sequence, its dependency on 
the formation of disulfide bridges for activation, is disadvantageous for in vivo 
activation, because many membrane-bound proteins contain thiol groups that 
could thus interact with activatable oligo-arginines. To overcome this limitation, 
an alternative activation strategy should be employed. Several fast chemical 
ligation reactions are known, and among these bio-orthogonal reactions are of 
particular interest because the reaction partners are not likely to interact with 
membrane proteins. 
 The reaction partners in bio-orthogonal ligations ideally react fast, and 
selectively form one specific product in high yields; in addition, the reaction is 
inert to biological systems.14 The groups of Sharpless and Meldal reported the 
so-called "click"-reaction between an azide and an alkyne (scheme 1, upper 
row).15,16 This reaction is catalyzed by copper and is therefore referred to as 
copper-catalyzed azide-alkyne cycloaddition (CuAAC). This CuAAC reaction is 
very fast, high yielding and selective for the formation of the 1,4 triazole 
product. However, due to the dependency on copper, this reaction is regarded as 
not fully biocompatible. Therefore,  much research has been carried out to 
develop “click reactions” that meet this additional condition.14 Generally, the use 
of a copper catalyst can be circumvented by using ring-strained alkynes, such 
as bicyclo[6.1.0]nonyne (BCN), to induce cycloaddition with an azide (scheme 
1, middle row).14,17. These types of bio-orthogonal ligations are known as 
strain-promoted azide-alkyne cycloadditions (SPAAC). Although the SPAAC 
reaction has the advantage of being a spontaneous reaction, the rate of the 
reaction however is still a limiting factor for in vivo applications. 
  More recently, another bio-orthogonal ligation has been developed 
between 1,2,4,5-tetrazines and alkenes or alkynes (scheme 1, lower row).18 This 
ligation was demonstrated to be very fast.19 Several different applications have 
been reported that make use of this inverse electron demand Diels-Alder 
(iEDDA) ligation such as in vivo imaging 20, live cell labeling19,21-24 or cross-linking 
of cell-laden hydrogels. 25  
 In addition to these applications, the iEDDA between a tetrazine and an 
olefin might be very suitable for an activation strategy of CPPs. This reaction 
will therefore be further explained in the next part of this chapter. 
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Scheme 1 – schematic overview of ligation reactions. Upper row; CuAAC between an azide and 
alkyne, middle row; SPAAC between an azide and BCN, lower row; iEDDA between a tetrazine and 
olefin. 
3.1.1 Tetrazine ligations 
The ligation of tetrazines and alkenes or alkynes is based on an iEDDA reaction 
in which the tetrazine acts as a diene and the alkene or alkyne functions as the 
dienophile. This eventually results in formation of a product that is ligated through 
a pyridazine or dihydropyridazine. The iEDDA, depicted in figure 1A, starts with a 
[4+2] cycloaddition between the 1,2,4,5-tetrazine and an alkene to give a bicyclic 
structure via a transition state. The bicyclic compound is highly strained and will 
rapidly release nitrogen in a retro-Diels-Alder reaction to give the less strained 
4,5-dihydropyridazine, which isomerizes to the more stable 1,4-dihydropyridazine. 
In contrast, when an alkyne is used as dienophile, a pyridazine is formed directly 
from the bicyclic structure.18 
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Figure 1 – A) Schematic overview of the iEDDA between a tetrazine and an olefin. B) chemical 
structure of tetrazine I that will be used for the experiments described in this chapter.  
A large variety of tetrazines has been demonstrated to react with 
olefins.18 All of these have their own specific characteristics determining their 
general stability and their reactivity towards dienophiles. From the library of 
tetrazines known, we have selected tetrazine I (figure 1B) for the in situ 
activation strategy described in this chapter. This tetrazine was selected because 
of its stability and solubility in aqueous environments. Due to the stabilizing 
methyl and benzyl substituents, the reactivity of this tetrazine is moderate 
compared to other tetrazine derivatives, however reaction rates that can be 
reached with this tetrazine may be fast enough for biological applications.26 
Therefore, this tetrazine is a good compromise between stability and reactivity 
and thus a suitable candidate to use in an in situ activation strategy of CPPs. 
 Tetrazines can undergo iEDDA reactions with many different reaction 
partners that contain an alkene or alkyne functionality. Generally, the reaction rate 
of the iEDDA ligation is increased by the alkene or alkyne being strained or 
having electron-donating substituents. Suitable olefins that meet these conditions 
and that have been shown to react with tetrazines in iEDDA reactions are 
depicted in figure 2. The importance of ring strain can be acknowledged when 
comparing the relative reactivities of for example styrene, which has almost no 
ring strain, to BCN and TCO that are highly strained.18 When applying the iEDDA 
ligation with tetrazine in an in situ activation strategy of oligo-arginines, a fast 
reaction rate is desirable. Therefore, TCOs and BCNs are suitable reaction 
partners for tetrazines in such a system, as they are known to react at very high 
rates.  
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Figure 2: Overview of relative reactivities of dienophiles in iEDDA with tetrazines. 
Tetrazines are known to react with increasing rate with styrene (A), cyclopentene (B), norbornene C), 
cyclooctyne (D), BCN (E), methylcyclopropene (F), trans-bicyclo[6.1.0]nonene (G) and trans-
cyclooctyne (TCO) (H).  
Herein, we report an activation strategy for CPPs based on short oligo-
arginine peptides that were functionalized with mutually reactive bio-orthogonal 
reaction groups. The peptides consisted of tetra-arginines with an N-terminal 
fluorescent label and a C-terminal tetrazine functionality and of tetra-arginines 
with an N-terminal norbornene or bicyclo[6.1.0]nonyne (BCN) functionality. 
Norbornene and BCN were selected as candidates to show the concept of in situ 
activation of olio-arginines through tetrazine ligations because they have been 
widely used in our laboratory and were readily available. The truncated peptides 
could be joined together to form active oligo-arginine CPPs via tetrazine-
norbornene and tetrazine-BCN cycloadditions. The cellular uptake behavior of the 
truncated and pre-ligated CPPs was visualized using confocal laser scanning 
microscopy and quantified by flow cytometry.  
 
3.2 Results and discussion 
3.2.1 Synthesis of truncated peptides 
In order to develop a system in which truncated and thus inert oligo-arginines can 
be activated by extension of their sequence through in situ bio-orthogonal ligation 
reactions, tetra-arginine peptides were synthesized that were functionalized with a 
tetrazine group (R4-Tz). The tetrazine of choice is asymmetrically substituted with 
a methyl and a benzyl functionality (tetrazine I in figure 1B) and is expected to be 
suitable for this system as it has been shown to be stable in aqueous media and 
serum and furthermore it has sufficient reactivity.26 The truncated peptide was N-
terminally functionalized with fluorescein isothiocyanate (FITC) (green in scheme 
2) to enable the visualization of cellular uptake with confocal fluorescence 
microscopy (CLSM) and quantification using flow cytometry. R4-Tz was 
synthesized by first preparing FITC-Ahx-Arg-Arg-Arg-Arg-OH in a standard Fmoc 
solid phase peptide synthesis (SPPS) on a 2-chlorotrityl resin. This resin was 
chosen because it produces a C-terminal carboxylic acid after cleavage, which is 
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necessary for C-terminal functionalization of the peptide with an amine-bearing 
tetrazine. FITC was N-terminally connected via a 6-aminohexanoic acid spacer 
(Ahx). After the initial peptide synthesis and cleavage from the resin, the amine-
functionalized tetrazine was coupled to the peptide in solution, yielding R4-Tz 
(scheme 2). The tetrazine needed for this reaction was kindly donated by 
Suzanne Timmermans. After some optimization it was found that an overnight 
reaction using DiPEA and BOP as a coupling agent gave the best yield, as was 
assessed by HPLC. Although epimerization at the C-terminus might be induced 
using this coupling strategy, this was not investigated because we first aimed to 
show the concept of the in situ activation strategy. However it might be interesting 
to look into the epimerization effect on cellular uptake behavior, as it was 
previously reported for other CPPs that this subtle structural change might 
influence cellular uptake pathways.27  
 
Scheme 2 – Synthesis of R4-Tz from FITC-labeled R4 which was synthesized using SPPS on 2-
chlorotrityl resin. To obtain R4-Tz, this peptide was reacted in solution coupling with the amine-
functionalized tetrazine.  
To induce click reactions between the truncated peptide (R4-Tz) and 
other tetra-arginines, additional truncated peptides were synthesized (figure 3). 
R4-Tz may react via an iEDDA mechanism with both norbornene-functionalized 
tetra-arginine (norb-R4) and BCN-functionalized tetra-arginine (BCN-R4). The 
synthesis of these peptides started with the preparation of tetra-arginine using 
standard Fmoc SPPS on a Rink amide resin, to obtain peptide amides after 
cleavage. These C-terminal amides on the peptide were preferred because of 
their neutral charge; moreover, peptides with terminal amides are more stable 
towards proteolytic degradation. After cleavage from the resin, the resulting tetra-
arginine was N-terminally functionalized by reacting it in solution with either an 
NHS-ester norbornene derivative or an analogous BCN compound (scheme 3). 
The NHS- norbornene derivative was kindly donated by Suzanne Timmermans, 
and the BCN NHS-ester is commercially available.  
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Scheme 3 – Schematic overview of the synthesis of norb-R4. The synthesis of BCN-R4 proceeded via 
a similar approach, using BCN-NHS for the in solution functionalization of tetra-arginine. 
The functionalization reactions proceeded well in an aqueous phosphate 
buffer (pH 7.5) at room temperature overnight in solution, after which the products 
(figure 3) could be purified by preparative HPLC. 
 
Figure 3 –Molecular structures of R4-Tz, norb-R4 and BCN-R4. 
 
3.2.2 Synthesis of pre-ligated peptides 
To study the potential of the proposed in situ activation strategy, pre-ligated 
extended peptides were prepared for evaluation of their cell-penetrating activity. 
Furthermore, FITC-labeled octa-arginine (R8) was synthesized as a positive 
control for the cellular uptake experiments. This peptide was obtained after 
standard SPPS on a rink amide resin. Additionally, a peptide was synthesized in 
which two tetra-arginine parts were linked via a triazole group (R4-t-R4). It might 
be interesting to study the uptake behavior of this peptide parallel to the pre-
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ligated peptides, because we previously observed (chapter 2) that the nature of 
the linker may greatly influence cellular uptake behavior. This allowed us to 
compare the influence of three hydrophobic linkers (one resulting from a tetrazine-
norbornene ligation, one from a tetrazine-BCN ligation and from a triazole-linked 
peptide, figure 4) on cellular uptake behavior.  
 
Figure 4 – Schematic structures of pre-ligated peptides: ligated through tetrazine and norbornene (R4-
n-R4), through tetrazine and BCN (R4-b-R4) and through a triazolo linkage (R4-t-R4) 
R4-n-R4 was prepared by stirring R4-Tz and norb-R4 overnight in MilliQ. 
To examine the speed of this reaction, it was monitored by analytical HPLC. This 
showed that only after 4 hours a new compound had formed, the ligation product. 
Overnight incubation only resulted in approximately 50% conversion, as 
assessed by analytical HPLC. These findings suggested that this ligation was not 
fast enough for in situ activation of CPPs under these conditions. 
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R4-b-R4 was prepared by reacting R4-Tz with BCN-R4 in MilliQ 
overnight. This reaction was also monitored by analytical HPLC and it was found 
that already after a mere 20 minutes the reaction had proceeded to almost full 
conversion. Another indication that the reaction had taken place was through the 
color of the reaction mixture, which turned from orange to yellow as a result from 
the conversion of the pink tetrazine to a colorless product while the FITC-group 
maintained its yellow color. Since this reaction was demonstrated to be very fast, 
it was expected to be suitable for in situ activation of CPPs.  
 Initially, the R4-t-R4 peptide was attempted to be synthesized by the 
CuAAC reaction between R4-Az and pent-R4 (scheme 4). Possibly due to the 
low reactivity of the aryl azide, we did not observe any product formation, 
although several different reaction conditions were tested.  
 
Scheme 4 - Chemical structures of R4-Az and Pent-R4 that were used in unsuccessful CuAAC to 
obtain R4-t-R4.  
To be able to study the effect of a triazole linkage on cellular uptake 
behavior, we proceeded with the synthesis of R4-t-R4 via an alternative 
procedure in which CuAAC was performed between Fmoc-(4-
azidophenyl)methanamine and 4-pentynoic acid to yield a non-natural amino acid 
that was used in SPPS to obtain R4-t-R4 (scheme 5).  
 
Scheme 5 – Synthesis of Fmoc-3-(1-(4-aminomethyl)phenyl)-1H-1,2,3-triazolo-4-yl)propanoic acid for 
use in SPPS to obtain R4-t-R4. 
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3.2.3 Cellular uptake studies on truncated and pre-ligated peptides 
Since it is known that the mechanism of uptake of arginine-rich CPPs is 
dependent on their concentration13, cellular uptake studies were performed at 
various concentrations. The cellular uptake of the truncated peptide R4-Tz, pre-
ligated peptides, R4-b-R4 and R4-n-R4 and control peptides R4-t-R4 and R8 was 
studied at 5 µM, 10 µM, 15 µM and 20 µM using confocal fluorescence 
microscopy. These experiments showed that the truncated peptide R4-Tz was 
not taken up at low concentrations (5 µM and 10 µM), which was in accordance 
with earlier findings that demonstrated that at least 6 arginines within one 
sequence are required for efficient cellular uptake. However, at higher 
concentrations (15 µM and 20 µM) some minor cellular internalization was 
observed. This might have been caused by the presence of the aromatic rings in 
the tetrazine structures, since hydrophobic groups also have been shown to 
contribute to cellular uptake efficiency.2 Since R4-Tz was slightly taken up by 
HeLa cells from concentrations above 15µM, in situ activation studies could not 
be conducted at higher concentrations, as then no actual activation of cellular 
uptake could be investigated. 
 All pre-ligated peptides were taken up both at low and high 
concentrations, although the mechanisms of uptake varied between peptide 
concentrations (figure 5). R8, R4-t-R4 and R4-b-R4 were taken up via 
endocytosis at low concentrations (5 and 10 µM), and were in addition taken up 
via nucleation zones and possibly other direct translocation mechanisms at the 
higher concentrations 15 and 20 µM; for R4-b-R4 uptake via nucleation zones 
was even observed at 10 µM. R4-n-R4 was taken up via endocytosis at each 
concentration tested. The concentration dependent uptake of arginine-rich CPPs 
has been described in the literature before13 and we have also observed it in the 
research described in chapter 2.11 However, it was surprising that the 
concentration at which HeLa cells switched to different uptake mechanisms 
differed between the four tested peptides, although they were structurally quite 
similar.  
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Figure 5 - CLSM micrographs corresponding to cellular uptake studies in HeLa cells. Upper row: CPP 
concentration of 5 µM, second row concentration of 10 µM, third row concentration of 15 µM and 
bottom row concentration of 20 µM. The experiments were performed at 37 ºC, with an incubation 
time of 30 minutes in serum-containing medium.  
In an attempt to better understand the differences that were observed in 
the cellular localization of the internalized peptides, the cellular uptake behavior 
of the CPPs at 5 µM and 15 µM was studied more extensively using flow 
cytometry.As was established above, at 5 µM the sole mechanism of entry for all 
pre-ligated peptides and R8 was endocytosis. Using flow cytometry, it was 
confirmed that at this concentration the pre-ligated CPPs were efficiently taken 
up by HeLa cells, whereas the truncated peptide R4-Tz was not taken up. 
Interestingly, the flow cytometry results furthermore showed that R4-t-R4 was 
taken up more efficiently than the positive control R8 and that both R4-b-R4 and 
R4-n-R4 were both taken up to a lesser extent at this concentration (figure 6). 
This suggests that the structure of R4-t-R4 was more suitable to induce 
endocytosis than R8, R4-b-R4 and R4-n-R4 at 5 µM.  
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Figure 6 – Flow cytometry results for HeLa cell uptake studies of CPPs at 5 µM concentration in 
serum-containing medium after 30 minutes of incubation. This experiment was only performed once. 
The evaluation of uptake efficiency by flow cytometry was also performed 
at peptide concentrations of 15 µM. Corroborating the CLSM experiment, large 
differences in uptake behavior were observed between the tested peptides. R4-n-
R4 was taken up least efficiently at this concentration, which is probably due to 
the peptide only inducing endocytosis. R8 and R4-b-R4 were shown to be taken 
up with similar efficiency, which is in accordance with the CLSM experiment 
where both endocytosis and uptake via nucleation zones was observed for these 
peptides (figure 7). R4-t-R4 was taken up most efficiently, which is in line with the 
observation that this peptide can induce efficient uptake via nucleation zones.  
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Figure 7 – Flow cytometry results for HeLa cell uptake studies of CPPs at 15 µM concentration in 
serum-containing medium after 30 minutes of incubation. This experiment was only performed once. 
The large differences in uptake efficiency and internalization pathways of 
pre-ligated peptides may be explained by the structural differences of the linkages 
between the tetra-arginine parts of these peptides. Properties that might play a 
role are the relative orientation of both tetra-arginine stretches, the hydrophobicity 
of the linker and its length and flexibility, and stability of the peptide in serum. 
Structural differences might affect the efficiency of glycan recruitment and 
clustering by CPPs, (as discussed in chapter 1), possibly affecting cellular uptake. 
 The relative orientation of the guanidinium head groups varies 
considerably for the different peptides. For R4-t-R4 the linkage is quite flat, 
probably keeping the tetra-arginine parts in a conformation that is quite similar to 
the orientation in R8. The linker resulting from the tetrazine-norbornene ligation in 
R4-n-R4 is more twisted, resulting in an altered orientation of the arginine 
stretches. The orientation of the R4-b-R4 linkage is U-shaped, possibly bringing 
the tetra-arginine parts closer together in space. It is difficult to predict how these 
differences influence the cellular uptake behavior, since only little is known about 
its relationship with peptide conformation. In fact, some studies indicate that there 
are no specific 3D-structural requirements for cellular uptake for the highly 
cationic oligo-arginine CPPs,2 although it has also been demonstrated that some 
cyclic poly-arginines are taken up more efficiently than their linear analogues.28 
This suggests that conformational effects cannot be ruled out.  
In chapter 2, an influence of hydrophobicity and flexibility of the linker on 
CPP efficacy was observed. These factors might also contribute to the differences 
in cellular uptake behavior that have been observed for the investigated pre-
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ligated CPPs. Although all linkages are quite similar, the triazolo linkage of R4-t-
R4 is shorter and less hydrophobic than the linkages in R4-b-R4 and R4-n-R4. 
This might contribute to its efficient cellular uptake, since both tetra-arginine parts 
are closer together. On the other hand, hydrophobic groups are known to 
contribute to cellular uptake efficiency in some cases. 2 To substantiate the 
influence of the linkage between two tetra-arginine parts on cellular uptake 
behavior, a larger library of peptides should be prepared and tested.  
3.2.4 In situ activation of oligo-arginines 
With the promising results on the fast ligation rate between R4-Tz and BCN-R4 
and the efficient cellular uptake of the subsequent R4-b-R4 peptide, we 
proceeded to study the potential of in situ activation of oligo-arginines using this 
ligation strategy.  
HeLa cells were co-incubated with R4-Tz and BCN-R4 in serum-containing 
culture medium, to allow in situ ligation and formation of R4-b-R4. The cellular 
uptake was studied using CLSM (figure 8). The experiment was performed using 
both 5 and 15 µM R4-Tz in presence of 5 eq. BCN-R4. As a positive control, R8 
was studied, while R4-Tz was used as a negative control. Furthermore, pre-
ligated R4-b-R4 was added as a reference for comparison of the uptake of in situ 
formed R4-b-R4 with the pre-ligated peptide.  
 
Figure 8 – CLSM micrographs for HeLa cell uptake studies to test in situ activation. Confocal FITC 
fluorescence images are depicted for positive control R8, negative control R4-Tz, pre-ligated R4-b-R4 
and in situ activated R4-b-R4. For the in situ activation HeLa cells were incubated with 5 µM or 15 µM 
R4-Tz and 5 eq. of BCN-R4 for 90 minutes. 
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 The results indicate that in situ activation of R4-b-R4 was possible within 
90 minutes of co-incubation of R4-Tz and 5 eq. of BCN-R4 at both concentrations 
tested, since the uptake of the in situ activated R4-b-R4 was similar to the uptake 
of the pre-ligated CPP after an incubation time of 30 minutes. After showing that 
the basic concept of in situ activation was successful, it was evaluated whether 
uptake could be improved by adding more equivalents of BCN-R4 or by 
prolonging the incubation time with the truncated peptide. Using CLSM it was 
demonstrated that addition of 10 eq. of BCN-R4 instead of 5 eq. did not improve 
uptake (figure 9), nor did increasing the incubation time to 120 minutes. A striking 
difference that was found between the samples that were incubated for 120 
minutes and the ones that were incubated for 90 minutes, was in the cell density. 
The samples that were incubated for 120 minutes displayed a diminished cell 
count, suggesting that during the incubation, cells had died and detached from the 
culture surface. This could have been caused by toxicity of the peptides or by 
extensive uptake of CPPs during the long incubation time.  
 
Figure 9 - HeLa cell uptake studies to test in situ activation at 5 µM and 15 µM R4-Tz with 5 or 10 
equivalents of BCN-R4 in serum-containing medium, incubation time of 90 or 120 minutes. 
Now that it was shown that prolonging the incubation time or increasing 
the amount of BCN-R4 did not increase the uptake efficiency of the in situ 
activation, it was evaluated using CLSM whether shorter incubation times (30 or 
60 minutes) and addition of 2.5 eq. of BCN-R4 instead of 5 eq. would be sufficient 
for in situ activation of R4-b-R4. This is interesting, because to decrease possible 
cytotoxic effects, a minimal amount of BCN-R4 should be used, whereas 
decreasing the incubation time allows for some analysis of the ligation rate in 
presence of cells. After 30 minutes of incubation with R4-Tz at 5 µM and 5 eq. of 
BCN-R4 cellular uptake in HeLa cells was observed, although to a lower extent 
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than after 90 minutes (figure 10). However, after 60 minutes of incubation, cellular 
uptake had reached levels that were similar to the uptake after 90 minutes. In 
contrast, incubation with R4-Tz at 15 µM and 5 eq. of BCN-R4 for 30 minutes, led 
to cellular uptake that reached similar levels compared to 90 minutes of 
incubation. Incubation with 2.5 eq. of BCN-R4 instead of 5 eq. resulted in a 
decrease in cellular uptake for both R4-Tz concentrations tested (5 µM and 15 
µM). These results indicate that the minimal incubation time for this system is 
concentration dependent, and that at least 5 eq. of BCN-R4 are needed to reach 
cellular uptake levels that are similar to the uptake efficiency of pre-ligated R4-b-
R4.  
 
Figure 10 - HeLa cell uptake studies to test in situ activation at 5 µM and 15 µM R4-Tz with 2.5 or 5 
equivalents of BCN-R4 in serum-containing medium, incubation time of 30, 60 or 90 minutes. 
 
3.2.5 Cell viability 
As it is known that oligo-arginines may be toxic to cells 12,13, the effects of all 
truncated and pre-ligated peptides on the viability of HeLa cells were tested. 
Furthermore, the conditions for in situ activation were examined for their influence 
on cell viability. HeLa cells were incubated with peptide solutions at 5 µM, 15 µM, 
20 µM or 150 µM in culture medium during 30 min in a humidified atmosphere 
with 7.5% CO2 at 37 ºC. After the cells were thoroughly washed, they were 
incubated for 3.5 hours with WST-8 in culture medium, to allow this colorless 
compound to be converted to the WST-8 formazan dye by mitochondrial activity 
of viable cells. 
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With the use of a plate reader, the absorption of this dye at 450 nm was 
determined, which is directly proportional to the number of living cells. The 
absorption of the culture medium at this wavelength was subtracted and a control 
of untreated HeLa cells was used to set a value for 100% viability. For all 
samples, the absorption at 450 nm was used to calculate the percentage of living 
cells. The results of this experiment are summarized in figure 11.  
 
Figure 11 – The percentage of viable cells after incubation for 30 minutes with truncated, pre-ligated 
and in situ activated peptides, followed by 3.5 hours of incubation with WST-8. Cells were incubated 
with truncated (R4-Tz, BCN-R4 and norb-R4) and pre-ligated (R8, R4-t-R4, R4-b-R4 and R4-n-R4) 
peptides at 5 µM and 20 µM. BCN-R4 was also added to HeLa cells at a concentration of 150 µM. The 
conditions for in situ activation were tested at 5 µM and 15 µM of R4-Tz and 5 (in situ 5 eq.) or 10 (in 
situ 10 eq.) eq. of BCN-R4. Untreated cells were used as a reference for 100% viability. 
The results of this viability assay (figure 11) clearly showed that all 
peptides evaluated were not toxic to HeLa cells under the tested conditions. In 
addition, the conditions for in situ activation (in situ 5 eq. and in situ 10 eq.) were 
shown to be not toxic to cells. As for the activation it is desirable to use excess 
BCN-R4 to speed up the in situ ligation, the influence of BCN-R4 at 150 µM was 
also tested. Reassuringly, no cytotoxic effects were observed at this 
concentration. Although these results are very promising, it should still be 
considered what the effects of these peptides are when cells are exposed to them 
for prolonged time.  
3.3 Conclusion  
We have successfully developed an in situ activation strategy for oligo-arginine 
CPPs based on tetrazine-dependent bio-orthogonal ligations. To this purpose, a 
FITC-labeled tetra-arginine peptide was synthesized with a C-terminal tetrazine 
functionality (R4-Tz) that could react with tetra-arginines functionalized with BCN 
or norbornene on their N-terminus (BCN-R4 and norb-R4). These tetra-arginines 
were used to prepare pre-ligated CPPs via tetrazine-BCN (R4-b-4) and tetrazine-
norbornene cycloadditions (R4-n-R4). As a control an octa-arginine was prepared 
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in which the two tetra- peptides were conjugated via a triazole linker (R4-t-R4). 
The relative reaction rates of the ligations were determined, indicating that the 
ligation of R4-Tz with norb-R4 was too slow for in situ activation. However, the 
ligation of R4-Tz with BCN-R4 was fast, proceeding to almost full conversion 
within 20 minutes, and was therefore expected to be feasible for in situ activation. 
 The R4-Tz peptide was not able to induce cellular uptake at 
concentrations varying from 5 µM to 20 µM, whereas at these concentrations all 
pre-ligated peptides were taken up, highlighting the feasibility of this activation 
strategy. Interestingly, the cellular uptake behavior of the pre-ligated peptides was 
strongly concentration dependent and varied greatly among the peptides. This 
indicates that the nature of the linkage between the two tetra-arginine parts can 
greatly influence the ability of the peptide to induce specific internalization 
pathways. 
  Finally, it was demonstrated that efficient in situ activation of R4-Tz with 
BCN-R4 was already possible with an incubation period of 60 minutes, which 
resulted in similar cellular uptake behavior observed for the pre-ligated R4-b-R4 
peptide (incubation time 30 minutes). Therefore, we have shown that bio-
orthognal ligation strategies offer a new, biologically-inert approach to induce in 
situ cell-penetrating activity in oligo-arginines.  
3.4 Outlook 
The work that is described in this chapter strongly suggests that in situ activation 
of oligo-arginine CPPs is possible, employing an iEDDA between a tetrazine and 
BCN. However, there are a number of issues that have to be addressed to 
evaluate the actual feasibility of the approach. First of all, flow cytometry may be 
used to quantify the cellular uptake efficiency of in situ activated R4-b-R4. This 
might lead to a better understanding of the incubation time and amount of BCN-
R4 needed for in situ activation of R4-Tz. In addition, time-lapse microscopy, 
which allows for continuous visualization of cells from the addition of R4-Tz and 
BCN-R4 onward, may be used to further study and understand the dynamics of 
this activation. In addition, more truncated peptides should be synthesized that 
can react with R4-Tz in a fast ligation reaction. TCO has been shown to react with 
3-(benzylamino)tetrazine at a rate of 35000 M-1 s-1.19, which is even faster than 
the reaction rate of BCN with the same tetrazine (29000 M-1 s-1).24 As comparison, 
the reactivity of norbornene with the same tetrazine has been shown to be much 
slower, 1.9 M-1 s-1. 23 
  
  
Chapter 3 
 
70 
	  
Because of its fast reaction rate with tetrazines, TCO-R4 will be an 
interesting peptide to study in situ activation of oligo-arginines. The commercially 
available TCO-N-hydroxysuccinimidyl carbonate may be used to prepare a 
truncated TCO-R4 peptide, similarly to the synthesis of BCN-R4 and norb-R4. 
This TCO-R4 can then be ligated to R4-Tz via an iEDDA reaction.  
It was demonstrated that differently ligated oligo-arginine CPPs show 
distinctive cellular uptake behavior, varying both in mechanisms of uptake and in 
the efficiency of cellular uptake. Although these preliminary results suggest that 
structural differences in the linkages between both tetra-arginine stretches of 
these CPPs may cause the differences that are observed in cellular uptake 
behavior, these effects should be further investigated in order to make a reliable 
prediction on the influence of the linkage structure on the observed differences. 
One suggestion to do this, is to create a larger library of pre-ligated CPPs (such 
as R4-tetrazine-TCO-R4) that are ligated through additional linkages and to 
evaluate the cellular uptake behavior of all the peptides in this library. 
Furthermore, the structure of the tetrazine may be varied to generate even more 
differently ligated R4-R4 peptides. Cellular uptake studies of these additional 
CPPs might give more insight into the importance of relative orientation of both 
tetra-arginine stretches, hydrophobicity of the linkage, length and flexibility of the 
linkage and stability of the linkage in serum. 
 Finally, the position of these different linkages between the arginine parts 
can be varied to address the role of the relative position of the arginine parts on 
cellular uptake behavior. Since it has been demonstrated before that the position 
of a disulfide bridge between two oligo-arginine parts can have a major impact on 
the cellular uptake behavior (chapter 2)11, it would be very interesting to 
investigate whether this effect would also be observed for the bio-orthogonal 
ligations that were described in this chapter. A more detailed perspective about 
the application of in situ activatable CPPs can be found in chapter 8.  
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3.5 Experimental section 
General 
Unless stated otherwise, all chemicals were purchased from commercial sources and all 
reactions were carried out under ambient atmosphere. Breipohl (Rink amide) resin and 2-
chlorotrityl chloride resin were obtained from Bachem (Bubendorf, Switzerland). Fmoc-
Arg(Pbf)-OH was purchased from Novabiochem (EMD Chemicals, Gibbstown, U.S.A.), 
Fmoc-6-Ahx-OH was acquired from Iris biotech GMBH (Marktredwitz, Germany) and 4-
pentynoic acid was bought from Acros Organics (Thermo Fisher Scientific, New Jersey, 
U.S.A.). Fluorescein isothiocyanate was obtained from Santa Cruz biotechnologies (Dallas, 
Texas, U.S.A.) and BCN-NHS was purchased from SynAffix (Oss, The Netherlands). MilliQ 
was double deionized using a Labconco Water Pro PS purification system (18.1 MW). 
HeLa culture medium comprised Dulbecco’s modified eagle medium (DMEM) (Gibco High 
Glucose) supplemented with 44 mM NaHCO3, 44 mM pyruvate and 10% amino acid 
supplement (consisting of cysteine, alanine, asparagine, aspartic acid, proline and glutamic 
acid), 10% fetal bovine serum (Gibco) 100 units/mL penicillin and 100 µg/mL, streptomycin 
(Gibco Penicillin-Streptomycin). For trypsinization of HeLa cells, a mixture of 0.05% trypsin 
(Gibco) and 0.68 mM ethylenediamine tetraacetic acid (EDTA, titriplex II) in PBS was used. 
PBS consisted of 0.14 M NaCl, 2.7 mM KCl, 1.1 mM K2HPO4 and 10 mM Na2HPO4 in 
MiliQ. FACS buffer consisted of 0.1% albumin from bovine serum (BSA) in PBS. 
Mass spectrometry 
Low resolution mass spectra (LRMS) were recorded on a Thermo Finnigan LCQ 
Advantage Max electrospray (ESI) ion-trap mass spectrometer (organic synthesis). A 
Thermo Finnigan LCQ Fleet ESI ion-trap mass spectrometer (peptide synthesis), which is 
equipped with a Shimadzu HPLC (C18-column, 200 x 3 mm,particle size 3 µm, 
acetonitrile/water gradient 5-100%, 1-31 minutes and a flow of 0.2 mL/min) and a PDA 
detector, was used to record low resolution mass spectra of peptides (LCMS). In addition, 
a Thermo Finnigan Polaris-Q electron ionization (EI) ion-trap mass spectrometer equipped 
with a VF1701MS column, 30 m x 0.25 mm, Df 0.25 µM (GCMS) was used to measure low 
resolution mass spectra of organic compounds. 
High-performance liquid chromatography (HPLC) 
Analytical HPLC spectra of peptides were recorded on a Shimadzu LC-20A Prominence 
system (Shimadzu,’s-Hertogenbosch, The Netherlands) equipped with a Gemini-Nx C18 
column, 150 x 3 mm, particle size 3 µm, pore size 110 Å (Phenomenex, Torrance, 
California, U.S.A.). Peptides were eluted in an aqueous acetonitrile gradient containing 
0.1% TFA (v/v) (5 - 100%, 1 - 40 min., flow 0.4 mL/min). 
Preparative HPLC of peptides was performed on a Shimadzu LC-20A Prominence system 
(Shimadzu, ’s-Hertogenbosch, The Netherlands) equipped with a Gemini-Nx C18 column, 
150 x 10 mm, particle size 3 µm, pore size 110 Å (Phenomenex, Torrance, California, 
U.S.A.), using a linear gradient of acetonitrile/water with0.1% TFA (v/v) (5 - 100%, 1 - 50 
min., unless stated otherwise) and a flow of 6.0 mL/min. 
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Nuclear magnetic resonance (NMR) 
For NMR analysis a Varian Inova400 (400 MHz for 1H), and a Bruker Avance III 500 (125 
MHz for 13C) spectrometer were used. In 1H-NMR spectra chemical shifts (d) are listed as 
parts per million (ppm) relative to CDCl3 (d=7.26). The following abbreviations are used to 
describe multiplicities: s (singlet), bs (broad singlet), d (doublet), t (triplet), dd (double 
doublet), and m (multiplet). Coupling constants are reported in Hertz (Hz) as a J value. 
Chemical shifts (d) of 13C-NMR spectrometry are listed as ppm relative to a residual 
solvent proton peak, d=77.2 for CDCl3. 
Organic Synthesis 
(4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenyl)methanamine hydrochloride, (4-
azidophenyl)methanamine hydrochloride and bicyclo[2.2.1]hept-5-en-2-ylmethyl (2,5-
dioxopyrrolidin-1-yl) carbonate were kindly donated by Suzanne Timmermans. 
Fmoc-(4-azidophenzyl)methanamine 
(4-Azidophenyl)methanamine hydrochloride (102.1 mg, 0.68 
mmol, 1.0 eq.) was dissolved in DCM (5 mL) together with 
DiPEA (235 µL, 1.34 mmol, 2.0 eq.) and Fmoc-Cl (165.3 mg, 
0.64 mmol, 0.94 eq.). The mixture was stirred for 30 minutes, 
after which it was washed with aqueous HCl (1M, 3 x 20 mL). 
The organic layer was dried over Na2SO4 and volatiles were 
removed under reduced pressure, yielding Fmoc-(4-azidophenzyl)methanamine (220.5 mg, 
0.60 mmol, 93%). 
1H-NMR (400 MHz, CDCl3) = δ 7.78 (t, J = 7.9 Hz, 2H), 7.63 - 7.56 (m, 2H), 7.47 - 7.37 (m, 2H), 7.37 - 
7.28 (m, 2H), 7.26 - 7.19 (m, 2H), 6.98 (d, J = 8.0 Hz, 2H), 5.04 (bs, 1H), 4.48 (d, J = 6.7 Hz, 2H), 4.40 
- 4.29 (m, 2H), 4.22 (t, J = 6.7 Hz, 1H). 13 C-NMR (125 MHz, CDCl3) = δ 156.5, 144.0, 144.2, 129.2, 
128.4, 127.9, 127.5, 127.2, 125.1, 120.2, 119.4, 66.8, 47.5, 44.6.  
LRMS (ESI+) m/z calcd. for C22H18N4O2 370.4 [M+H]+, found 370.8, 393.1 [M+Na]+. 
Fmoc-3-(1-(4-(aminomethyl)phenyl)-1H-1,2,3-triazol-4-yl)propanoic acid  
CuSO4 • 5H2O (2.1 mg, 8.41 µmol, 0.03 eq.) and sodium 
ascorbate (9.5 mg, 47.9 µmol, 0.18 eq.) were mixed in 
DMF/degassed H2O (9:1, v/v) for 2 h. Then Fmoc-(4-
azidophenzyl)methanamine (99.6 mg, 0.27 mmol, 1.0 
eq.) and 4-pentynoic acid (27.2 mg, 0.28 mmol, 1.0 eq.) 
were added and the reaction was stirred at r.t. After 3 h, 
CuSO4 • 5H2O (6.5 mg, 26.0 µmol, 0.1 eq.) and sodium 
ascorbate (13.8 mg, 69.7 µmol, 0.26 eq.) were added, 
and after an extra 19 h of stirring again CuSO4 • 5H2O (6.2 mg, 24.8 µmol, 0.1 eq.) and 
sodium ascorbate (10.4 mg, 52.5 µmol, 0.20 eq.) were added. The reaction mixture was 
then heated to 80 ºC and stirred for another 23 h. Then, the reaction mixture was allowed 
to cool down to r.t., after which H2O and aqueous HCl (10%) were added to reach a pH of 
1, followed by extraction with DCM (3 x 10 mL). The combined organic layers were then 
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washed once with brine of pH 1 and dried over Na2SO4, after which volatiles were removed 
under reduced pressure. Heptane was added to co-evaporate DMF. This yielded the 
triazolo amino acid as a crude product, which was directly used in peptide synthesis. 
LRMS (ESI+) m/z calcd. for C27H25N4O4 469.2 [M+H]+, found 469.1, 491.0 [M+Na]+. 
Peptide synthesis 
General peptide synthesis 
All peptides were prepared by Fmoc solid phase peptide synthesis (SPPS) on breipohl 
resin or 2-chlorotrityl chloride resin. Resins were swollen in DMF (breipohl amide resin) or 
DCM (2-chlorotrityl chloride resin) for at least 20 minutes prior to synthesis. Fmoc 
deprotection was achieved by rinsing the resin once with piperidine in DMF (20%, v/v), 
followed by incubation with piperidine in DMF for 20 minutes. Sequence extension of 
peptides was performed by incubation with Fmoc-L-amino acids (3.0 eq.), DIPCDI (3.3 eq.) 
and HOBt (3.6 eq.) in DMF for 45 - 60 minutes unless stated otherwise. Unreacted sites 
were capped using excess of a pyridine/Ac2O mixture (1:1, v/v) in DMF and incubating the 
resin for 5 minutes in this mixture. The progress of peptide couplings and Fmoc 
deprotections was followed by Kaiser tests.	  29 When these showed that couplings were not 
complete, they were repeated using Fmoc-L-amino acids (3.0 eq.), HATU (2.0 eq.) and 
DiPEA (3.0 eq.). When Fmoc-deprotections were suspected to be not fully complete, resin 
was incubated with a mixture of 2% DBU and 2% piperidine in DMF (v/v) for 5 minutes to 
assure full deprotection. After the final Fmoc deprotection the resin was washed with DMF 
(3 x), DCM (3 x), MeOH (3 x) and Et2O (2 x) after which it was air-dried for at least 2 h. 
Cleavage of the peptide from the resin was achieved by suspending the resin in a mixture 
of TFA/water/triisopropyl-silane (95:2.5:2.5, v/v/v) for 4 to 5 h. Then the peptides were 
precipitated in Et2O, redissolved in water or acetic acid and lyophilized to yield crude 
peptides. Purification by reversed-phase HPLC, followed by lyophilization yielded pure 
peptides as powders. 
Peptides with a C-terminal carboxylic acid 
After swelling in DCM, the 2-chlorotrityl chloride resin was loaded with the first amino acid 
using the specific amino acid (2.0 eq.) and DiPEA (3.0 eq.) in dry DCM during 1 h, after 
which unreacted sites on the resin were capped with DiPEA (2.0 eq.) in MeOH. After 
washing the resin with DMF (3 x), MeOH (1 x) and DMF (1 x), the peptide synthesis was 
continued as described above for "General peptide synthesis". 
Peptides with a C-terminal amide 
Peptides with a C-terminal amide were prepared on a Breipohl resin following the 
procedure described above for "General peptide synthesis". 
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Fluorescein-labeled peptides 
Fluorescein-labeled peptides were prepared by coupling FITC (1.5 eq.) after the final Fmoc 
deprotection. This coupling was performed in a mixture of DiPEA/DMF/DCM (12:7:5, v/v/v) 
o/n. When the Kaiser test showed completion of the reaction, the resin was washed with 
DMF (3 x), isopropanol (3 x) and DCM (6 x). Afterwards, the peptide was cleaved from the 
resin and further handled as described in the section "General peptide synthesis". 
FITC-Ahx-Arg-Arg-Arg-Arg-tetrazine (R4-Tz) 
 
FITC-Ahx-Arg-Arg-Arg-Arg-OH was prepared following the procedures as described in the 
sections "General peptide synthesis", "Peptides with a C-terminal amide" and "Fluorescein-
labeled peptides". Next, the peptide was functionalized with tetrazine by adding (4-(6-
Methyl-1,2,4,5-tetrazin-3-yl)phenyl)methanamine hydrochloride (3.0 eq.), BOP (2.0 eq.) 
and DiPEA (4.0 eq.) in DMF. The mixture was stirred at r.t. o/n, followed by precipitation in 
Et2O, redissolving it in acetic acid, lyophilization and subsequent purification by reversed-
phase HPLC (using a gradient of 10 - 70% acetonitrile/water, v/v from 1 - 60 min.). This 
yielded R4-Tz. 
HPLC: rt. 16.121 min. LCMS (ESI+) m/z [M+H]+ 1328.4 (calcd. 1328.6), [M+2H]2+ 664.8 (calcd. 664.8), 
[M+3H]3+ 443.6 (calcd. 443.5), [M+4H]4+ 333.0 (calcd. 332.9). 
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FITC-Ahx-Arg-Arg-Arg-Arg-azide (R4-Az) 
 
 
FITC-Ahx-Arg-Arg-Arg-Arg-OH was prepared following the procedures as described in the 
sections "General peptide synthesis", "Peptides with a C-terminal amide" and  
"Fluorescein-labeled peptides". Next, the peptide was functionalized with an azide by 
adding (4-Azidophenyl)methanamine hydrochloride (3.0 eq.), BOP (2.0 eq.) and DiPEA 
(4.0 eq.) in DMF. The mixture was stirred at r.t. o/n., followed by precipitation in Et2O, 
redissolving it in acetic acid, lyophilization and subsequent purification by reversed-phase 
HPLC (using a gradient of 20 - 70% acetonitrile/water, v/v from 1 - 50 min.). This yielded 
R4-Az. 
HPLC: rt. 16.4 min. LCMS (ESI+) m/z [M+H]+ 1275.5 (calcd. 1275.6), [M+2H]2+ 638.4 (calcd. 638.8), 
[M+3H]3+ 426.0 (calcd. 426.2), [M+4H]4+ 319.7 (calcd. 319.9). 
 
4-Pentynoic acid-Arg-Arg-Arg-Arg-NH2 (pent-R4) 
 
4-pentynoic acid-Arg-Arg-Arg-Arg-NH2 was prepared following 
the procedures in the sections "General peptide synthesis" and 
"Peptides with a C-terminal amide". For purification by 
preparative reversed-phase HPLC a gradient of 3 - 50% 
acetonitrile/water, v/v was used from 1 - 50 minutes. 
 
HPLC: rt. 3.7 min. LCMS (ESI+) m/z [M+H]+ 722.5 (calcd. 722.5). 
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Norbornene-Arg-Arg-Arg-Arg-NH2 (norb-R4) 
H-Arg-Arg-Arg-Arg-Arg-NH2 was prepared following the 
procedures in the sections "General peptide synthesis" and 
"Peptides with a C-terminal amide". Next, the peptide (25.0 
mg, 38.9 µmol, 1.0 eq.) was dissolved in phosphate buffer 
of pH 7.5 (5 mL) and bicyclo[2.2.1]hept-5-en-2-ylmethyl 
(2,5-dioxopyrrolidin-1-yl) carbonate (53.2 mg, 201 µmol, 
5.2 eq.) was added. The mixture was stirred at r.t. o/n., 
followed by purification of the norbornene-functionalized 
peptide by preparative reversed-phase HPLC. After 
evaporation of excess solvents, the peptide was lyophilized yielding norb-R4 (5.50 mg, 
6.94 µmol, 18%). 
HPLC: rt. 13.0 min. LCMS (ESI+) m/z [M+H]+ 792.7 (calcd. 792.5), [M+2H]2+ 396.9 (calcd. 396.8), 
[M+3H]3+ 264.9 (calcd. 264.8). 
BCN-Arg-Arg-Arg-Arg-NH2 (BCN-R4) 
H-Arg-Arg-Arg-Arg-Arg-NH2 was prepared following 
the procedures in the sections "General peptide 
synthesis" and "Peptides with a C-terminal amide". 
Next, the peptide (24.0 mg, 37.4 µmol, 1.0 eq.) was 
dissolved in phosphate buffer of pH 7.5 (5 mL) and 
BCN-NHS (57.6 mg, 198 µmol, 5.3 eq.) was added. 
The mixture was stirred at r.t. o/n, followed by 
purification of the BCN-functionalized peptide by 
preparative reversed-phase HPLC. After evaporation 
of excess solvents, the peptide was lyophilized 
yielding BCN-R4 (6.87 mg, 8.40 µmol, 22%). 
HPLC: rt. 13.2 min. LCMS (ESI+) m/z [M+H]+ 818.7 (calcd. 818.5), [M+2H]2+ 409.8 (calcd. 409.8), 
[M+3H]3+ 273.5 (calcd. 273.5). 
FITC-Ahx-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH2 (R8) 
FITC-Ahx-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH2 was made following the procedures under 
"General peptide synthesis", "Peptides with a C-terminal amide" and "Fluorescein-labeled 
peptides". 
HPLC: rt. 14.420 min. LCMS (ESI+) m/z [M+H]+ 1769.6 (calcd.1770.9), [M+2H]2+ 884.8 (calcd. 885.9), 
[M+3H]3+590.5 (calcd. 590.9), [M+4H]4+ 443.2 (calcd. 443.5), [M+5H]5+ 354.8 (calcd. 354.9), [M+6H]6+ 
295.8 (calcd.295.9). 
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FITC-Ahx-Arg-Arg-Arg-Arg-tetrazine-norbornene-Arg-Arg-Arg-Arg-NH2 (R4-n-R4) 
 
Norb-R4 (1.14 mg, 1.44 µmol, 1.0 eq.) and R4-Tz (1.89 mg, 1.42 µmol, 1.0 eq.) were 
mixed together in MilliQ (1 mL). This mixture was stirred at r.t. o/n, followed by purification 
of the ligated peptide by reversed-phase HPLC. Evaporation of excess solvents under 
reduced pressure, and subsequent lyophilization yielded R4-n-R4 (0.61 mg, 0.29 µmol, 
20%). 
HPLC: rt. 14.3 min. LCMS (ESI+) m/z [M+2H]2+ 1047.1 (calcd. 1046.6), [M+3H]3+ 698.2 (calcd. 
698.09), [M+4H]4+ 524.2 (calcd. 523.8), [M+5H]5+ 419.6 (calcd. 419.2). 
 
FITC-Ahx-Arg-Arg-Arg-Arg-tetrazine-BCN-Arg-Arg-Arg-Arg-NH2 (R4-b-R4) 
 
BCN-R4 (1.18 mg, 1.44 µmol, 1.0 eq.) and R4-Tz (1.87 mg, 1.41 µmol, 1.0 eq.) were mixed 
together in MilliQ (1mL). This mixture was stirred at r.t. o/n, followed by purification of the 
ligated peptide by reversed-phase HPLC. Evaporation of excess solvents under reduced 
pressure, and subsequent lyophilization yielded R4-b-R4 (1.76 mg, 0.83 µmol, 59%). 
HPLC: rt. 14.4 min. LCMS (ESI+) m/z [M+2H]2+ 1060.1 (calcd. 1059.6), [M+3H]3+ 707.0 (calcd. 706.7), 
[M+4H]4+ 530.7 (calcd. 530.3), [M+5H]5+ 424.8 (calcd. 424.4), [M+6H]6+ 354.2 (calcd. 353.9), [M+7H]7+ 
303.6 (calcd. 303.4). 
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FITC-Ahx-Arg-Arg-Arg-Arg-triazolo-Arg-Arg-Arg-Arg-NH2 (R4-t-R4) 
 
FITC-Ahx-Arg-Arg-Arg-Arg-triazolo-Arg-Arg-Arg-Arg-NH2 was made following the 
procedures under "General peptide synthesis", "Peptides with a C-terminal amide" and 
"Fluorescein-labeled peptides". The triazole group was introduced by coupling with Fmoc-
3-(1-(4-(aminomethyl)phenyl)-1H-1,2,3-triazol-4-yl)propanoic acid (1.5 eq.) o/n after 
coupling of the first four arginine residues. 
HPLC: rt. 14.365 min. LCMS (ESI+) m/z [M+H]+ 1998.4 (calcd. 1997.1), [M+2H]2+ 999.4 (calcd. 999.0), 
[M+3H]3+ 666.6 (calcd. 666.4), [M+4H]4+ 500.4 (calcd. 500.0), [M+5H]5+ 400.4 (calcd. 400.2), [M+6H]6+ 
333.8 (calcd. 333.7). 
Cell experiments 
Cell culture 
HeLa cells were grown in a culture flask and incubated in a humidified incubator with 7.5% 
CO2 at 37 ºC in the presence of cell culture medium. The cells were passaged every two to 
three days at 80% confluency, maintaining HeLa cells until their growth reduced. For 
passaging, the culture medium was removed and the cells were rinsed twice with 5 mL 
PBS, followed by incubation with 0.05% trypsin in EDTA during 5 minutes. Fresh culture 
medium was added to inactivate the trypsin and cells were suspended by trituration with a 
pipette. An appropriate number of HeLa cells was then added to a new culture flask. 
Cell viability assay 
HeLa cells were seeded in 96-well plates at a density of 20,000 cells per well one day prior 
to the experiment. Cells were then incubated with 100 µL peptide solution in cell culture 
medium for 30 minutes in a humidified atmosphere with 7.5% CO2 at 37ºC. After 
incubation, cells were washed thrice with HeLa culture medium, followed by incubation with 
CCK-8 (10% in HeLa culture medium, Cell Counting Kit-8, Dojindo Molecular 
Technologies, Rockville, U.S.A.) in a humidified atmosphere with 7.5% CO2 at 37ºC. After 
3.5 h of incubation, a microplate reader (Wallac Victor 1420 multilabel counter, Perkin 
Elmer) was used to measure the absorbance at 450 nm. The experiments were performed 
in triplicates for all peptides. A value of 100% viability was obtained by measuring cells that 
were not incubated with peptides and the viability of cells treated with peptides was 
calculated from this. 
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Flow cytometry 
HeLa cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) at a density of 
60,000 cells per well one day prior to the experiment. Cells were then washed with HeLa 
culture medium, followed by 30 minutes (pre-ligated peptides) or 30, 60 or 90 minutes (in 
situ activation) of incubation with 400 µL of peptide solutions in a humidified atmosphere 
with 7.5% CO2 at 37 °C. Subsequently, the cells were washed twice with PBS, after which 
they were detached from the wells by treatment with trypsin/EDTA for 5 minutes. Cells 
were removed from the wells after trituration in the trypsin/EDTA solution and rinsing with 
culture medium, after which they were spun down at 1000 rpm for 5 minutes. After 
resuspension of the cells in 200 µL of FACS buffer, the fluorescence of fluorescein was 
measured using a Beckman Coulter FC500 flow cytometer (Beckman Coulter, Brea, 
California, U.S.A.) after excitation at 488 nm. Results were based on gating for 1 minute. 
Confocal laser scanning microscopy 
HeLa cells were seeded in 8-well chambered coverslips (Nunc, Wiesbaden, Germany) at a 
density of 40,000 cells per well one day prior to the experiment. Cells were then incubated 
with 200 µL peptide solution in HeLa culture medium for 30 minutes (pre-ligated peptides) 
or 30, 60 or 90 minutes (in situ activation) in a humidified atmosphere with 7.5% CO2 at 
37ºC. After incubation, peptide solutions were removed, cell culture medium was added 
and cells were visualized immediately with confocal microscopy using a Leica TCS SP2 
AOBS Confocal Laser Scanning Microscope (Leica Microsystems, Mannheim, Germany) in 
combination with Leica Confocal Software. A HCX apo Long working distance Ultraviolet 
(VI) 40x water immersion lens was used and fluorescein was excited by an argon laser at 
488 nm. The emission was collected between 500 and 550 nm. 
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4.1 Introduction 
The delivery of intracellular drugs is dependent on their ability to cross the cellular 
membrane that represents an impermeable barrier to most pharmaceutically 
relevant compounds.1 Cell-penetrating peptides (CPPs) possess the ability to 
quickly enter living cells, and are therefore being regarded as suitable candidates 
for the delivery of bioactive constructs into cells.2 Extensive research has been 
carried out to identify efficient, non-toxic CPPs that can facilitate the intracellular 
transport of almost any type of cargo.3 These cargoes can be attached to the CPP 
chemically, or possibly if the cargo is a protein, via genetic fusion. The use of 
chemical coupling reactions often involves harsh conditions that may lead to 
impairment of the cargo and moreover, it may be a challenge to perform selective 
coupling reactions.4 In addition, the toxicity of CPPs can be heavily influenced by 
the coupling strategy used to attach a cargo.5 As an alternative conjugation of the 
cargo to the CPP, non-covalent coupling strategies can be employed. To this aim, 
we have previously reported a modular system in which the CPP and cargo are 
linked non-covalently through heterodimerizing coiled-coil forming peptides. 6 The 
coiled-coil structure is formed by the specific interaction of two complementary 
peptides that contain a leucine zipper motif. The binding specificity between the 
two peptides arises from the amino acid sequence.7 Most of the leucine zippers 
are characterized by a heptad repeat, abcdefg, in which residues a and d are 
hydrophobic, resulting in an amphipathic helix. The nonpolar a and d residues 
pack together with the a’ and d’ residues from the complementary peptide, which 
produces the majority of the binding energy (figure 1).8 Residues e and g are 
responsible for electrostatic interactions, and dictate heterodimerization of the 
peptides, while furthermore ensuring the directionality (parallel or anti-parallel). 9 
 
Figure 1 – Representation of helical wheel (I) parallel dimeric coiled-coil, (II) antiparallel dimeric 
coiled-coil. When an α-helix is viewed from the end of its helical axis, the amino acid scan be 
represented as interconnected dots forming a wheel. For a heterodimerizing coiled-coil, the 
hydrophobic interactions (light grey) between residues a and d as well as the ionic interactions (dark 
grey) occuring between residues e and g can be rationalized. Figure adapted from 7 
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Although these coiled-coil forming peptides can be used for the non-
covalent linkage of a CPP to its cargo, it does not solve one of the main limitations 
of the usage of CPPs in targeted drug delivery, which is their lack of cell-type 
specificity and absence of control over their moment of uptake.2,10 To overcome 
these limitations, several strategies have been developed to gain temporal control 
over the activity of CPPs. In general, inert peptides are converted into CPPs upon 
a specific environmental trigger, such as a pH-change, exposure to UV-light or by 
enzymatic reactions.11-16 By applying such strategies, the peptide and its cargo 
will only be taken up at their target location where the conversion into active CPPs 
can take place. Previously, we have reported an activation strategy of oligo-
arginine CPPs that is independent of the micro-environment and that is based on 
the reconstitution of two short inert oligo-arginines, both functionalized with a 
cysteine residue (chapter 2). 17 Upon disulfide linkage, an active CPP containing 
eight to nine arginine residues was obtained. However, a drawback of this 
approach is that non-specific interactions due to the thiol functionality may occur 
before the target has been reached because of the presence of thiol groups in 
various proteins. Here, we investigate whether two inert tetra-arginines can be 
reconstituted selectively into a functional CPP through a coiled-coil mediated 
activation strategy that relies on the specific interaction between heterodimerizing 
leucine zippers (figure 2A). For such strategy, monomeric leucine zippers that are 
N-terminally elongated with tetra-arginine should not induce cellular uptake, 
whereas upon coiled-coil formation with the complementary leucine zipper, 
cellular uptake is induced. To investigate the efficiency of coiled-coil induced 
uptake, three leucine zipper pairs that all form heterodimeric coiled-coils with 
parallel directionality, but differ in coiled-coil stability and amino acid composition 
(figure 2B) were investigated. These coiled-coil structures could furthermore be 
stabilized via disulfide bond formation between cysteine residues incorporated in 
both peptides. We here show that reconstitution through coiled-coil formation is a 
feasible strategy for the activation of oligo-arginine CPPs, and that the nature of 
the coiled-coil can influence both the need of a disulfide linkage between the two 
tetra-arginines and cellular uptake behavior.  
Chapter 4 
 
84 
	  
 
Figure 2 – A) Schematic representation of the coiled-coil mediated activation strategy presented in 
this chapter. B) Schematic overview of the three leucine zipper pairs used to employ the activation 
strategy.  
 
4.2 Results and Discussion 
4.2.1 Selection and preparation of leucine zipper peptides 
We selected three parallel heterodimerizing leucine zipper pairs that vary in amino 
acid composition and binding efficiency (figure 2B). For each pair, one peptide 
was N-terminally elongated with the sequence Cys(Npys)-(Arg)4 and the 
complementary peptide with FITC-Ahx-(Arg)4-Cys-(Gly)4. The thiol of the peptides 
functionalized with 3-nitro-2-pyridinesulfenyl (Npys), which both protects the thiol 
and activates it for rapid disulfide bridge formation at neutral pH.18 The tetra-
glycine spacer was included in the complementary peptide to allow a linear 
representation of the arginine residues after disulfide bridge formation between 
the two peptides (Fig 1A). In order to be able to employ fluorescence-based 
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techniques to evaluate the cellular uptake of the peptides, the (Gly)4-containing 
peptide was N-terminally labeled using fluorescein isothiocyanate (FITC) 
connected via an ε-aminohexanoic acid (Ahx) spacer. The three leucine zipper 
pairs used were reported previously by the groups of Vinson19, Hodges20 and 
Jerala21 and are referred to in this study by an abbreviation of these names (Vin, 
Hod and Jer). The amino acid sequences of the peptides can be found in table 1. 
We selected these leucine zipper pairs because of their parallel directionality and, 
moreover, for their different coiled-coil stability and affinity, with the Vinson coiled-
coil having the highest binding affinity, and the Jerala coiled-coil the lowest (figure 
1B). The cysteine residues were included to allow for disulfide bridge formation 
between the two N-terminal tetra-arginine parts to seal them in a conformation in 
which the arginine residues are in close proximity, resembling the structure of the 
R4-R4 peptide reported in chapter 2 (table 1) which may facilitate cellular uptake.  
Table 1- leucine zipper sequences and their elongation sequences (in blue). For each pair, one 
peptide is elongated with FITC-XRRRRCGGGG and the complementary peptide with C(Npys)RRRR. 
X represents aminohexanoic acid. All peptides are C-terminal amides. 
  
4.2.2 Determination of secondary structure and binding affinity 
The conformation of the monomeric leucine zipper peptides and the 
heterodimerized complexes was evaluated by circular dichroism (CD) 
spectroscopy. It was observed that the R4-Jer-A and R4-Jer-B peptides exhibited 
no substantial helical content, but that by mixing the peptides a coiled-coil was 
obtained (figure 3A). For the monomeric Hod leucine zippers we observed a slight 
α-helical content for R4-Hod-A peptide, and for the R4-Hod-B leucine zipper the 
α-helical content was further increased. Nevertheless, when the two elongated 
Hod leucine zippers were mixed, a strong increase in α-helical structure was 
observed (figure 3B). The analysis of the R4-Vin-A and R4-Vin-B leucine zippers 
showed some amount of α-helical conformation, but importantly, upon 
heterodimerization, the α-helicity content increased substantially (figure 3C).  
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Figure 3 – Circular dichroism (CD) spectra for the R4-leucine zippers and the coiled-coils formed. A) 
R4-Jerala leucine zippers, B) R4-Hodges leucine zippers, C) R4-Vinson leucine zippers. D) Binding 
constants in KD (KD = KA-1) observed for the coiled-coils using isothermal titration calorimetry (ITC). 
To investigate whether elongation of the sequence influenced the 
biophysical properties of the leucine zipper interactions, the binding constants of 
the leucine zippers were measured by means of isothermal titration calorimetry 
(ITC). The ITC data is summarized in figure 3D and showed that although the 
affinity of the leucine zipper pairs for each other was reduced two to threefold, the 
binding constant of the three zipper pairs remained of the same order of 
magnitude.  
4.2.3 Cellular uptake studies on leucine zipper peptides and coiled-coil complexes 
With the modified leucine zipper peptides in hand, cellular uptake of the FITC-
labeled monomeric leucine zippers was studied in HeLa cells, quantified by flow 
cytometry and visualized using confocal laser scanning microscopy (CLSM). It 
was expected that monomeric peptides would not be taken up by cells, as they 
only contain a single tetra-arginine stretch. To visualize cellular uptake by CLSM, 
cells were incubated with 10 µM peptide for 30 minutes at 37º C, briefly washed 
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and imaged immediately. It was observed that none of the monomeric leucine 
zippers entered cells (figure 4 upper row). However, for the R4-Hod-B leucine 
zipper some membrane binding was observed (appendix figure A1). This was 
thought to be induced by interactions of the thiol with membrane proteins. 
Therefore, the thiol was blocked by reacting it with iodoacetic acid prior to cell 
experiments. Afterwards, no membrane binding was observed (figure 4, upper 
row *R4-Hod-B). This was reassuring because upon coiled-coil formation no free 
thiol groups will be present. Since the monomeric leucine zippers did not show 
cell-penetrating activity, the next step was to study whether coiled-coil formation 
with the complexed leucine zippers would induce cellular uptake. To achieve this, 
the R4-functionalized peptides for each leucine zipper pair were mixed in a 1:1 
ratio each at a concentration of 10 µM in serum-containing cell culture medium, 
and incubated for 30 minutes with HeLa cells at 37 ºC. As a control, leucine zipper 
complexes that only contained one tetra-arginine stretch were formed by 
complexation of FITC-labeled leucine zipper with the complementary R4-leucine 
zipper (e.g. Vin-A with R4-Vin-B). As expected, these controls did not induce 
uptake (appendix figure A2).  
For the R4-Jer-A/R4-Jer-B coiled-coil no cellular uptake was observed at 
the concentration of 10 µM, but when this concentration was increased to 20 µM 
some uptake by endocytosis was observed (figure 4). The control coiled-coil Jer-
a/R4-Jer-b did not show uptake at this increased concentration, indicating that 
both tetra-arginine stretches are required to induce uptake. Interestingly, the more 
stable coiled-coil formed by the R4-Hod-A/R4-Hod-B peptides showed increased 
cell-penetrating activity compared to the R4-Jer-a/R4-Jer-b coiled-coil, with the 
R4-Hod-A/R4-Hod-B complex taken up by endocytosis at 10 µM (figure 4). The 
control coiled-coil Hod-a/R4-Hod-b did not internalize into cells (appendix figure 
A2), which again suggested that both tetra-arginine stretches are needed to 
induce activity. Importantly, when the experiments were performed using the 
Vinson leucine zippers, a striking uptake pattern was observed for the R4-Vin-
A/R4-Vin-B coiled-coil, suggesting localization of the peptides in the cytosol and 
nuclear membrane (figure 4). To test whether the cellular membrane was 
disrupted by the internalization of the R4-Vin-A/R4-Vin-B complex, the cells were 
incubated with ethidium homodimer-1 (EthD-1). As this compound cannot cross 
the cellular membrane, it is used as an indicator of plasma membrane integrity. 
Reassuringly, no internalization of EthD-1 was observed, suggesting the cellular 
membrane remained intact. Moreover, the control coiled-coil Vin-A/R4-Vin-B did 
not show any uptake (appendix figure A2). To investigate whether disulfide bridge 
formation between the two cysteines on each leucine zipper was necessary to 
induce cellular uptake, the R4-Jer-A, R4-Hodges-A and R4-Vinson-A leucine 
zippers were synthesized with a Cys(Npys) à Ala mutation, to preclude disulfide 
bridge formation. Interestingly, it was found that both the CàA-R4-Jer-A/R4-Jer-B 
and the CàA-R4-Hod-A/R4-Hod-B coiled-coils were not taken up by cells at 
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concentrations of 20 and 10 µM respectively (figure 4, bottom row), meaning that 
for these coiled-coils the disulfide bridge is a prerequisite to keep the two tetra-
arginine parts close together and induce cell-penetrating activity. Intriguingly, the 
CàA-R4-Vin-A/R4-Vin-B coiled-coil showed very similar cellular internalization as 
the R4-Vin-A/R4-Vin-B pair (figure 4, bottom row), implying that for these leucine 
zippers that have very strong interaction for each other, the disulfide bridge is not 
needed to induce cellular uptake.  
 
Figure 4 – CLSM micrographs of the FITC-channel for monomeric leucine zippers R4-Jer-B; *R4-Hod-
B and R4-Vin-B (upper row). *R4-Hod-B represents the R4-Hod-B peptide for which the thiol was 
blocked using iodoacetic acid. Middle row: leucine zipper complexes of R4-Jer-A/R4-Jer-B (20 µM), 
R4-Hod-A/R4-Hod-B (10 µM) and R4-Vin-A/R4-Vin-B (10 µM). Lower row: coiled-coils for which 
disulfide bridge formation was inhibited due to CàA mutation of one of the leucine zippers in each 
pair. Scale bar represents 50 µm. 
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To quantify cellular uptake and compare the uptake efficiency of the 
leucine zipper complexes, the above described experiments were repeated for 
analysis by flow cytometry (figure 5). For these experiments, two additional 
control peptides were used, the R4 and R4-R4 peptide (sequence in table 1). 
These peptides and their cellular uptake behavior are described in detail in 
chapter 2. The R4-R4 peptide contains a disulfide bridge to link the two tetra-
arginine together. By including this reference, it could be studied to what extent 
the coiled-coils contributed to the uptake of R4-R4. As can be seen in figure 5, 
none of the monomeric leucine zippers were taken up by cells. At the 
concentration of 10 µM, the R4-Jer-A/R4-Jer-B coiled-coil did not induce any 
uptake, however, at the concentration of 20 µM some uptake was observed. 
Notably, the uptake of this coiled-coil complex was lower than that of the R4-R4 
peptide, and furthermore a Cys à Ala mutation in R4-Jer-A (C->A R4-Jer-A/R4-
Jer-B) yielded a complex incapable of inducing cellular uptake. Interestingly, the 
R4-Hod-A/R4-Hod-B coiled-coil was taken up equally well as the R4-R4 peptide 
at a concentration of 10 µM. Elimination of the disulfide bridge between the two 
R4 parts by the CysàAla mutation in R4-Hod-A led to an almost complete loss of 
cellular uptake. Strikingly, the R4-Vin-A/R4-Vin-B coiled-coil showed enhanced 
uptake efficacy compared to the R4-R4 peptide. This almost six-fold increase may 
be caused by an alternative uptake mechanism of the coiled-coil complex. 
Disruption of the disulfide bridge did not influence the cellular uptake significantly. 
In addition to the Cys à Ala mutation, the formation of a disulfide bridge was also 
inhibited by reacting the thiols of R4-Jer-A; R4-Hod-A and R4-Vin-A with 
iodoacetic acid. The cellular uptake of the coiled-coil complexes formed using 
these peptide was analyzed using flow cytometry (figure A3 in appendix) and it 
was found that this yielded the similar results as for the Cys à Ala mutation.  
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Figure 5 – Flow cytometry results obtained for cellular uptake experiments. As reference peptides, R4 
and R4-R4 were used, for which it was shown in chapter 2 that R4 is not taken up by cells whereas 
R4-R4 induces efficient cellular uptake, comparable to octa-arginine. 
These results corroborate the findings by CLSM (figure 4), and suggest 
the ability of a stable coiled-coil (Vinson) to keep the two tetra-arginine stretches 
in close proximity without the need of an additional linkage between them through 
disulfide bridge formation. This is an important observation because it renders 
activation of oligo-arginines through a specific, but non-covalent, bio-inert 
interaction possible, which may offer an interesting tool for the delivery of large 
cargos for which temporal control over uptake may be necessary.  
4.2.4 Cellular uptake studies on GFP using the Vinson complex 
Because of the remarkable cellular localization of the R4-Vin-A/R4-Vin-B 
complex, which was devoid of the need of disulfide bridge linkage between the 
two tetra-arginine stretches, this coiled-coil was selected for the delivery of a large 
cargo inside cells. For this purpose superfolder GFP (sfGFP)22 was recombinantly 
expressed, elongated with the Vin-A sequence with ARRRR or CRRRR on the N-
terminus (CR4-VinA-sfGFP and AR4-VinA-sfGFP). The complementary leucine 
zipper to form the Vinson coiled-coil was the Ac-RRRRCGGGG-Vin-B peptide 
(Ac-R4-VinB, which is the same peptide as R4-Vin-B only without fluorescent 
label). The protein and peptide sequences are given in table 2. Using this 
approach, it was expected that the R4-VinA-sfGFP complex will only be taken up 
after coiled-coil formation with Ac-R4-VinB.  
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Table 2 – amino acid sequences for XR4-VinA-sfGFP and *R4-VinB. For XR4-VinA-sfGFP X denotes 
either cysteine or alanine. Ac-R4-VinB represents the same peptide as R4-Vin-B only with FITC-Ahx 
on the N-terminus replaced by acetyl, because the FITC label was no longer needed due to the 
intrinsic fluorescence of sfGFP. The protein was his-tagged for purification purposes (grey) and 
contained N- and C-terminal linkers from the recombination sequence used in cloning (black). The 
leucine zipper sequence is denoted in red, and the sfGFP sequence in green. The tetra-arginine 
elongation is shown in blue. 
 
 
For the cellular uptake experiments, HeLa cells were incubated with 5 µM 
protein/peptide. First, AR4-VinA-sfGFP and CR4-VinB-sfGFP were incubated with 
HeLa cells for 90 minutes at 37ºC, to study the behavior of the protein complexes 
with cells. For these samples, as expected, we did not observe any uptake. As 
aimed for, both CR4-VinA-sfGFP and AR4-VinA-SfGFP were internalized into 
cells by simply mixing the protein complexes with Ac-R4-VinB. The uptake was 
analyzed after 90 minutes of incubation at 37ºC (figure 6). These results show 
that even with a large cargo attached, the coiled-coil mediated activation strategy 
based on the Vin-zipper is devoid of the need of a disulfide bridge. The cellular 
localization suggests that both protein complexes were taken up by endocytosis, 
meaning that the uptake pathway of the R4-Vin-A/R4-Vin-B coiled-coil was 
changed by attaching it to a large cargo, which is a frequently occurring 
observation for many CPPs. It may be interesting to investigate whether an 
increase in incubation time or concentration results in cytosolic delivery of this 
complex. Alternatively, endosomal escape peptides or intracellular targeting 
peptides may be included in Ac-R4-VinB structure, to study if cytosolic delivery 
can be accomplished.  
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Figure 6 – CLSM micrographs for uptake experiments with sfGFP cargo. Scale bar represents 50 µm. 
4.3 Conclusion 
We have shown that the activation of a cell-penetrating peptide can be 
established through coiled-coil formation of leucine zipper peptides. Importantly, 
we were able to temporally control the uptake of a large protein by this activation 
strategy. The CPP of choice was based on octa-arginine, for which it was 
previously demonstrated that it could be activated using two tetra-arginine 
peptides that were linked together via disulfide bridge formation (chapter 2).17 We 
have now elongated the N-termini of heterodimerizing leucine zippers with tetra-
arginine motifs, allowing coiled-coil formation to yield a structure similar to octa-
arginine, inducing cellular uptake. Three different sets of coiled-coils with varying 
binding affinities were tested, and each led to different uptake behavior. From 
their analysis, we could conclude that the stability of the coiled-coil that is formed 
by these peptides influences the uptake mechanism. Importantly, using a coiled-
coil with substantial stability (Kd of about 2.3•10-12), the requirement of a covalent 
linkage between the two tetra-arginine parts to keep them in close proximity could 
be let go. The coiled-coils did not only differ in stability, but also in amino-acid 
composition, suggesting that arginine residues in the leucine zippers might 
influence the cellular uptake behavior of the coiled-coil complex. We can conclude 
that our strategy offers a useful tool for a non-covalent reconstitution of inert 
precursors of CPPs into active peptides. Importantly, this approach is devoid of 
the need of a trigger induced by a specific environment and therefore provides an 
interesting method to gain temporal control over arginine-rich CPPs. 
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4.5 Experimental section 
Materials 
All starting materials were used as received. Amino acids were obtained from 
Novabiochem. The Rink amide resin was obtained from Bachem. N,Nʹ′-
Diisopropylcarbodiimide (DIPCDI) was obtained from Biosolve. All other starting materials 
were obtained from commercial suppliers. Fetal bovine serum (FBS) was obtained from 
Integro (Zaandam, The Netherlands), plain Dulbecco’s Modified Eagle Medium (DMEM) 
and trypsin/EDTA were both from PAA Laboratories (Pasching, Austria). Phenol-red free 
Dulbecco’s Modified Eagle Medium (DMEM) and the ethidium homodimer-1 (EthD-1) were 
obtained from Life Technologies (Thermo Fisher Scientific Inc., Waltham, U.S.A.). HeLa 
CCL-2 cells were obtained from American Type Culture Collection (ATCC, Manassas, 
U.S.A.). 
General peptide synthesis 
Peptides were synthesized on polystyrene Rink amide resins using a Labortec640 peptide 
synthesizer (Labortec, Bubendorf, Schwitzerland), employing a standard Fmoc solid-phase 
peptide synthesis (SPPS) protocol. In brief, the resin was swollen in DMF for 30 minutes 
prior to use. The Fmoc protecting groups were removed by mixing the resin with piperidine 
in DMF (20%, v/v; 3 times for 6 minutes). The desired sequence of amino acids was 
coupled to the resin using Fmoc-L-amino acids (3.0 equiv), diisopropylcarbodiimide 
(DIPCDI, 3.3 equiv) and N-hydroxy benzotriazole (HOBt, 3.6 equiv). Peptide couplings 
were monitored using the Kaiser test.23 After the final Fmoc removal the resin was washed 
with DMF, DCM, i-PrOH, DCM, i-PrOH and air-dried for at least 2 h.  
Synthesis of fluorescein-labelled peptides 
The following peptides were synthesized using standard SPPS as described above up to 
the FITC attachment on their N-terminus: Vin-A; R4-Vin-A; Hod-A; R4-Hod-A; Jer-A; R4-
Jer-A. The FITC labelling was performed by reacting fluorescein isothiocyanate (FITC, 2 
equiv.) and N,N-diisopropylethylamine (DIEA, (3 equiv.) in DMF/DCM (1:1 v/v) with the 
Fmoc-deprotected peptides. The reaction was monitored using the Kaiser test. The 
peptides were cleaved from the resin by suspension in a mixture of trifluoroacetic 
acid/water/triisopropyl-silane/thioanisole (90:5:2.5:2.5 v/v/v/v) for 6 h. The free peptides 
were precipitated in Et2O, redissolved in water and lyophilized yielding the crude peptides. 
The crude peptides were purified by reversed phase HPLC and subsequently lyophilized 
yielding a yellow powder. Purity was evaluated by analytical reversed-phase HPLC and 
identity confirmed by mass spectrometry.  
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Synthesis of N-terminal Cys(Npys)-peptides 
The following peptides were synthesized using standard SPPS as described above:  
R4-Vin-B; R4-Hod-B and R4-Jer-B. The last coupling was performed using 3 equiv. Boc-
Cys(Npys), 3.3 equiv DIPCDI and 3.6 equiv HOBt in DMF. The peptides were cleaved from 
the resin by suspension in a mixture of trifluoroacetic acid/water/triisopropyl-
silane(92.5:5:2.5 v/v/v) for 6 h. The free peptides were precipitated in Et2O, redissolved in 
water and lyophilized yielding the crude peptides. The crude peptides were purified by 
reversed phase HPLC yielding a yellow powder after lyophilization. Purity was evaluated by 
analytical reversed phase HPLC and identity confirmed by mass spectrometry. 
Peptide characterization 
Peptides were characterized using mass spectrometry and purity was analyzed using 
analytical reversed phase HPLC on a Shimadzu LC-20A Prominence system (Shimadzu, 
‘s-Hertogenbosch, The Netherlands), equipped with a ReproSil column (Screening 
Devices, Amersfoort, The Netherlands). Semi-preparative RP-HPLC purification of 
peptides was performed using a c18 column (250 x 10 mm, particle size 5 µm, 4 mL/min 
flow or 150 x 20 mm, particle size 10 µm, 8 mL/min flow) and a MeCN/water gradient 
containing 0.1% trifluoroacetic acid (5-100%, 1-50 min). The purity of the fractions was 
assessed by analytical RP-HPLC using a C18 column (150 x 3 mm, particle size 3 µm). 
Peptides were eluted in an aqueous acetonitrile gradient containing 0.1% TFA (v/v) (5 - 
100%, 1 - 40 min., flow 0.4 mL/min). 
Peptide mass characterization was performed by electrospray ionization time-of-flight (ESI-
TOF) on a JEOL AccuTOF. Deconvoluted mass spectra were obtained using MagTran 
1.03b2.  
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Peptide HR ESI-ion TOF m/z HPLC RT (min) 
Vin-A [M+H]+5542.4 (calcd. 5542.1) 15.2 
Vin-B [M+H]+5920.1 (calcd. 5919.9) 17.1 
R4-Vin-A [M+H]+6381.8 (calcd. 6381.6) 16.4 
R4-Vin-B [M+H]+6875.2 (calcd. 6875.4) 19.3 
Hod-A [M+H]+2323.5 (calcd. 2323.3) 15.6 
Hod-B [M+H]+2780.8 (calcd. 2780.5) 17.8 
R4-Hod-A [M+H]+3162.7 (calcd. 3162.9) 16.8 
R4-Hod-B [M+H]+ 3736.3 (calcd. 3736.1) 18.2 
Jer-A [M+H]+ 3234.9 (calcd. 3234.7) 16.3 
Jer-B [M+H]+3693.6 (calcd. 3693.8) 18.8 
R4-Jer-A [M+H]+4074.1 (calcd. 4074.3) 16.8 
R4-Jer-B [M+H]+4650.2 (calcd. 4650.4) 19.1 
C->A-R4-Vin-A [M+H]+6195.2 (calcd. 6195.4)  16.3 
C->A-R4-Hod-A [M+H]+3887.9 (calcd. 3888.1) 16.7 
C->A-R4-Jer-A [M+H]+2976.4 (calcd. 2976.6) 16.6 
 
Determination of secondary structure and binding affinity 
CD spectroscopy  
Monomeric leucine zippers were dissolved at a concentration of 50 µM in 10 mM 
phosphate buffer, pH 7.0. The circular dichroism spectra were obtained at 20 ºC on a 
Jasco-J815 (190-256 nm at 0.5 nm intervals with a scanning speed of 50 nm/ min and 2.0 
seconds integration time). For measurement of the coiled-coils a 1:1 mixture of the two 
leucine zippers (each 50 µM) was made and the spectra were obtained as for the 
monomeric peptides.  
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Isothermal titration calorimetry 
ITC experiments were conducted using an automated Microcal AutoITC200 (GE 
Healthcare). Generally 250 µM of peptide (syringe) was titrated to 10 µM of complementary 
peptide (cell). For the Jer peptides, which displayed low binding affinities, concentrations of 
500 µM peptide were titrated to 20 µM of complementary peptide. The peptides were 
dissolved in 10 mM phosphate buffer pH 7.0, which was also present in the reference cell. 
Heats of dilution were subtracted from the titration binding data curve fitting. Curve fitting 
was performed with Origin 6.0 (Microcal Inc., Northampton, MA) using a one-site 
complexation model. 
Blank measurements, in which the peptides were titrated in phosphate buffer were also 
conducted to determine the heat contribution from dilution of the titrant. However, this 
yielded no significant signal and therefore the ITC experiments were not corrected for this.  
Cell culture, cell viability assays and cellular uptake experiments 
Cell culture 
HeLa-CCL2 cells were maintained in sterile conditions in DMEM or RPMI (Gibco, 
Invitrogen, Eugene, U.S.A.) supplemented with 10 % heat-inactivated fetal bovine serum 
(FBS; PAN Biotech). All cells were incubated at 37 ºC in a humidified atmosphere of 5 % 
CO2. Cells were passaged every 2 to 3 days. 
Cell viability assay 
Cell viability was evaluated using Cell Counting Kit-8 (CCK-8, Dojindo Molecular 
Technologies, U.S.A). HeLa cells were seeded in 96-well plates to obtain 40,000 cells/well 
the day of the experiment. On the day of the experiment, cells were incubated with 100 µL 
peptide solution in DMEM for 30 minutes at 37°C. Cells were washed 3 times with DMEM + 
10% FBS and maintained in this solution after the last washing step. After 4 hours of 
incubation, the supernatant was removed and a solution of CCK-8 (10 % in DMEM + 10% 
FBS) was added. After 3 hours of incubation at 37 °C, the absorbance was measured at 
450 nm using a microplate reader (Wallac Victor 1420 multilabel counter, Perkin Elmer). 
The experiments were performed in triplicates and repeated twice independently. A value 
of 100% survival was obtained by measuring cells that were not incubated with peptides 
and viability of cells treated with the peptides was calculated from this.  
Flow cytometry 
HeLa cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) one (60,000 
cells/well) or two (30,000 cells/well) days prior to the experiment. On the day of the 
experiment, cells were incubated with the peptide solutions (10 µM) for 30 min at 37°C in 
RPMI + 10% FBS. After washing the cells with HBS buffer pH 7.4 (10 mM HEPES, 135 
mM NaCl, 5 mM KCl, 5 mM MgCl2, 1.8 mM CaCl2), cells were detached by trypsinization 
for 5 minutes, spun down and resuspended in 200 µL RPMI + 10% FCS. The cells were 
spun down again and the pellet was resuspended in HBS buffer supplemented with 0.1% 
bovine serum albumin. The fluorescence was measured using a FACSCalibur flow 
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cytometer (BD Biosciences, Erembodegem, Belgium) and subsequently data was analyzed 
with the Summit software (Fort Collins, USA). Results were based on 10,000 gated cells.  
Confocal laser scanning microscopy 
HeLa cells were seeded in chambered coverslips (Nunc, Wiesbaden, Germany) that were 
coated using a 0.1% gelatin solution, at a density of 40,000 cells (one day) or 20,000 cells 
per well (two days prior) to the experiment. Cells were incubated with the peptide (10 µM) 
for 30 min at 37 ºC. Cells were washed twice after incubation with DMEM + 10 % FBS and 
living cells were analyzed immediately by confocal microscopy using a TCS SP2 confocal 
microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 40 
x N.A. 1.2 water immersion lens. To check on possible membrane disruption caused by the 
internalization of the peptides, ethidium homodimer-1 (EthD-1) was used. This compound 
was added to the cells at a concentration of 16 µM. After 15 minutes incubation, it was 
studied whether EthD-1 was internalized. Fluorescein was excited by an argon laser at 488 
nm and emission was collected between 500 and 550 nm. EthD-1 was excited at 561 nm 
and emission was collected between 600 and 650 nm.  
For the analysis of uptake of the protein complex, the same procedure was used, only with 
5 µM protein concentrations and an incubation time of 90 minutes. 
Preparation of the XR4-VinA-SfGFP construct 
Cloning of protein-zipper expression constructs 
Two partially complementary oligonucleotides coding for the leucine zipper, flanked by 
restriction sites (Biolegio) were elongated by overlap-extension PCR. The product was 
inserted into a pCR4-TOPO vector (Invitrogen) using a TA overhang. A restriction site was 
introduced upstream of the recombination site in a pDEST17 destination vector (Invitrogen) 
by site-directed mutagenesis. Subsequently the sequence for the leucine zipper was cut 
from the pCR4 plasmid using xhoI (New England Biolabs) and ligated into the modified 
pDEST17 vector using T4 ligase (New England Biolabs) and used to transform Escherichia 
coli ccdB Survival 2 T1R (Invitrogen). The CRRRR and ARRRR sequences were 
introduced by site-directed mutagenesis with partially overlapping primers. 24 
The superfolder-GFP sequence22 was PCR amplified and inserted into a pENTR/SD/D-
TOPO entry vector (Invitrogen). This plasmid was then recombined with the pDEST17 
plasmid containing CRRRR or ARRRR sequences in a Gateway LR reaction using LR 
clonase II (Invitrogen). 25 Resulting expression constructs were confirmed by sequencing 
(Sequence Facility Radboudumc). 
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Expression and purification of the fusion protein 
Escherichia coli BL21 AI (Invitrogen) was transformed with the pDEST17-based expression 
constructs and single-colonies were used for expression. 1.5 L of 2TY containing 100 
µg/ml ampicillin was inoculated and grown at 37 °C, 200 rpm until an optical density of 0.6 
was reached. At that time, protein expression was induced with 0.1%(w/v) L-arabinose 
(Sigma-Aldrich) and 0.5 mM isopropyl β-D-1-thiogalactopyranoside (MP Biomedicals) and 
expression was carried out overnight at 25 °C. Cells were harvested by centrifugation, 
resuspended in phosphate buffered saline and lysed by sonication. Soluble fractions were 
obtained by 20 min centrifugation at 29.000 g and incubated with Ni-NTA sepharose (IBA) 
to bind the poly-histidine tag present in the pDEST17 vector. After incubation the 
suspension was cast in a column and washed with wash buffer (20 mM TRIS, 500 mM KCl, 
20 mM imidazole, 10 % glycerol, pH 8.0), wash buffer with 1M KCl and wash buffer with 50 
mM imidazole. Bound proteins were eluted (20 mM TRIS, 100 mM KCl, 500 mM imidazole, 
10 % glycerol) and analyzed by SDS-PAGE. The buffer was then exchanged to 50 mM 
TRIS pH 8.0 and samples were concentrated using 10 kDa MWCO centrifugation filters 
(Millipore). Protein concentrations were calculated using the extinction coefficient22 of 8.33 
x 104 M-1 cm-1 and absorption at 485 nm as measured on a Nanodrop 1000 (Thermo Fisher 
Scientific). 
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Appendix 
 
Figure A1 – CLSM micrographs of the FITC channel for uptake experiments with monomeric R4-Hod-
B and *R4-Hod-B. The thiol in the *R4-Hod-B peptide was blocked using iodoacetic acid. Scale bar 
represents 50 µm. 
 
 
Figure A2 – CLSM micrographs of the FITC channel for uptake experiments with coiled-coils 
containing only one tetra-arginine stretch: Jer-A/R4-Jer-B; Hod-A/*R4-Hod-B; Vin-A/R4-Vin-B. The 
thiol in the *R4-Hod-B peptide was blocked using iodoacetic acid. Scale bar represents 50 µm. 
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Figure A3 – flow cytometry results for uptake of the R4 functionalized coiled-coils, to show the 
influence of the disulfide bridge between the two tetra-arginine parts. The formation of the disulfide 
bridge is inhibited either by reacting the thiol of one leucine zipper with iodoacetic acid (e.g. *R4-Jer-A) 
or by mutating the cysteine residue for alanine (e.g. C àA R4-Jer-A). 
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Chapter 5 
 
Enzyme-activatable cell-penetrating peptides through a 
minimal side chain modification 
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M. van Hest and Dennis W. P. M. Löwik, Bioconjug. Chem., 2015, 26, 850-856 
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5.1 Introduction 
The transport of numerous biologically relevant cargoes inside cells has been 
facilitated by a wide range of cell-penetrating peptides (CPPs).1,2 One specifically 
well-studied class of these CPPs comprises the group of highly cationic peptides, 
such as the HIV-derived Tat-peptide and oligo-arginines. These charged CPPs 
have gained interest because their uptake into cells occurs both via endocytosis 
and, especially at higher peptide concentrations, also via direct translocation 
through the plasma membrane.3,4 Despite their promising characteristics and high 
potential for use in drug delivery, their pharmaceutical usage is still limited. This is 
mainly due to the lack of cell-type specificity for most CPPs and because their 
moment of uptake cannot be controlled. For this reason, much research is now 
focused on the development of strategies to add specificity to CPP-based delivery 
systems. Recently, several targeting strategies have been reported that utilize 
inert peptides of which their cell-penetrating ability can be induced by a specific 
change in the environment. This strategy is employed to circumvent non-specific 
uptake before reaching the target. CPPs can now be activated by several triggers, 
such as a pH-change5,6, by exposure to UV-light7, or by enzymatic reactions.4,8-11 
Furthermore, cell-specific targeting peptides have been attached to CPPs to 
obtain fusogenic peptides with dual activity.12-14 The pH-controlled activation of 
CPPs relies on the presence of an acidified microenvironment around the target 
tissue, which is used to protonate a peptide to become a CPP, or to activate 
CPPs immobilized on a delivery vehicle. Although these strategies have shown 
great promise in efficient activation of CPP-based delivery vehicles, it 
necessitates a pH difference between the target and normal tissue, which only 
applies to a limited number of pathological conditions.15 Activation through UV-
light seems independent of the environmental characteristics of the target tissue, 
however, its usage for in vivo applications is limited. Fusogenic peptides that 
possess the ability to enter cells and that can be targeted to specific tissue allow 
delivery to the desired cell-types. However, non-specific uptake at healthy tissue 
still occurs for these peptides. Activatable CPPs based on activation through a 
specific enzymatic reaction offer a particular interesting alternative targeting 
strategy. In this regard, the specificity and efficiency originate from the activation 
process, which is catalyzed by specific cell-surface enzymes potentially leading to 
activation of CPPs in a very short time and in a designated area. As a result, the 
CPPs will be taken up primarily in areas where the specific surface enzymes are 
present. An elegant example of activation by enzymatic cleavage was reported by 
Tsien and co-workers.11 A peptide hairpin was designed in which an oligo-arginine 
CPP was attached to oligoglutamic acid through an enzyme-cleavable sequence. 
The anionic domain functioned to inhibit the activity of the CPP and enzymatic 
cleavage of the peptide linker led to release of the oligo-arginine and thus to 
uptake. 
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Interestingly, in a alanine scan of Tat (RKKRRQRRR), Wender and co-
workers have shown that substitution of either one of the lysine residues by an 
alanine residue leads to a tremendous decrease in cellular uptake of the resulting 
peptide.16 Jin et al. have recently used this finding to develop acid-activatable Tat 
peptides, which were obtained by amidation of the lysine residues to succinyl 
amides.6 The resulting peptides were not able to enter cells, until they were 
exposed to an acidic pH, which led to hydrolysis of the succinyl amides. These 
reports inspired us to investigate if attachment of enzyme-cleavable sequences at 
the lysine side- chains may lead to an enzyme-triggered variant of this approach. 
Interesting model enzymes to validate such an enzyme-activatable strategy are 
two surface-expressed peptidase enzymes, aminopeptidase N (APN)17 and 
dipeptidyl peptidase IV (DPPIV)18. Expression of both enzymes is upregulated in 
multiple types of cancer cells.19-21 Furthermore, APN serves as a receptor for 
several virus infections22,23 and DPPIV is expressed on activated immune cells.24 
Additionally, these two peptidases exhibit interesting substrate selectivities as 
DPPIV preferentially cleaves Xaa-Pro dipeptides from the N-terminus of 
peptides25, whereas APN cleaves almost all unacylated amino acids.26 Therefore, 
Tat peptides inactivated with sequences recognized by these enzymes might 
serve as a way to target these particular pathological conditions. 
 
 
 
Figure 1 - General concept of the enzyme-activatable Tat peptide. The positive charges from the 
lysine residues are shielded by inactivating modifications. These modifications can be cleaved off by 
treatment with the appropriate enzyme, yielding the active Tat peptide. 
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 Here we report a simple yet efficient approach to temporarily inactivate a 
cell-penetrating peptide, Tat, by conjugating a shielding amino acid or dipeptide to 
one or both lysine side chains in its sequence. Subsequently, the blocked Tat 
peptide can be reactivated by cleaving off the inactivating amino acids by 
treatment with the appropriate enzyme (figure 1). This approach offers a 
complementary strategy to previously reported systems based on enzymatic 
activation because it blocks the activity of the CPP as a result of a minimal 
modification of a peptide side chain in contrast to shielding via the peptide main 
chain. Our strategy presents activatable Tat peptides based on minimal 
modifications on the peptide sequence. 
 
5.2 Results and discussion 
5.2.1 Preparation of enzyme-activatable Tat-peptides  
We prepared various enzyme-activatable Tat-peptides by using two different 
shielding approaches on the lysine side chains. One involved coupling a single 
alanine residue to the side chains while the other made use of a glycine-proline 
dipeptide. Since the Tat-peptide contains two lysine residues, this modification 
was performed in three ways: by a single modification on the N-terminal or the C-
terminal lysine or by a modification on both lysine residues. These modifications 
are denoted Tat-X(10) for coupling to the first lysine residue, Tat-X(01) for 
modification on the second lysine residue and Tat-X(11) for a functionalization of 
both lysine residues, with X being an alanine residue or the glycine-proline 
dipeptide (figure 2). Furthermore, all peptides were acetylated at the N-terminus 
to prevent degradation of the Tat peptide by peptidases (peptide structures can 
be found in the appendix A1). The alanine-blocked Tat peptides were selected 
because of their potential as a minimal modification to inhibit the activity of Tat, 
and because they were expected to be suitable substrates for APN, as this 
enzyme represents a broad substrate specificity. The glycine-proline dipeptide 
was selected because Mutter and co-workers previously reported the cleavage of 
arginine-proline from the N-terminus of an unnatural O-acyl isopeptide using 
DPPIV.27 We however observed that introducing the dipeptide arginine-proline to 
the lysine side-chains in Tat did not inhibit the cellular uptake of the obtained 
peptide, which is likely to be caused by the guanidinium groups in the arginine 
side chains, which are known to enhance cellular uptake (data in appendix). 
Therefore, the dipeptide sequence was modified to glycine-proline (GP), which 
was also expected to be a suitable substrate for DPPIV. To prepare the desired 
enzyme-activatable Tat-peptides, we made use of a methyltrityl (Mtt) protection 
group on the lysine residues. In this way, three Tat peptides were synthesized in 
which either one of the lysines or both lysine residues were protected with the Mtt-
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group. After acetylation of the N-terminus, the Mtt groups were selectively 
removed using a mixture of trifluoroacetic acid (TFA), triisopropylsilane (TIS) and 
dichloromethane (DCM) in a ratio of TFA/TIS/DCM 1:2:97 (v:v:v). Subsequently, 
the lysine side chains were functionalized with alanine or the glycine-proline 
dipeptide employing standard solid phase peptide synthesis (SPPS). As both the 
alanine and the GP-dipeptide were Boc-protected at their N-terminus, cleavage of 
the peptide from the resin ensured that the side chain modifications had free N-
termini. After global deprotection and cleavage from the resin, the C-terminal 
cysteine was used to conjugate fluorescein diacetate 5-maleimide to the peptides. 
This label allows for fluorescence-based techniques to analyze the ability of the 
peptides to enter cells.  
 
Figure 2 - Peptide sequences with inactivating modifications on the lysine residues. 
5.2.2 Uptake studies on inactivated Tat-peptides 
The uptake efficiency of the inactivated peptides at a concentration of 5 µΜ in 
Human Embryonic Kidney (HEK 293) cells was quantified by flow cytometry and 
visualized using confocal laser scanning microscopy (CLSM). Unmodified Tat 
peptide was also included and used as a reference. Flow cytometry (figure 3) 
showed that the unmodified Tat was taken up extensively, which is in sharp 
contrast to the inactivated Tat peptides. It is important to note here that only 
internalized peptide is evaluated in this experiment, since the cells are washed 
with trypsin to remove any membrane-bound peptide. The Tat-A peptides almost 
completely lost their cell penetrating ability and interestingly, the Tat-A peptides 
with a single modification (Tat-A(01) and Tat-A(10)) were inactivated slightly, yet 
significantly more efficiently than the Tat-A(11) peptide. Similar results were 
observed for the Tat-GP peptides, although these were taken up slightly more 
than the Tat-A peptides. This clearly shows the potential of (temporarily) blocking 
the activity of Tat by a side chain modification on the lysine residues, and that 
even a single amino acid residue is sufficient. 
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Figure 3 - Flow cytometry results of uptake studies at 5 µM, with an incubation time of 30 minutes at 
37 °C. No difference in uptake efficacy was observed for Tat(A(01) and Tat-A(10), but the uptake of 
Tat-A(11) was significantly higher (p = 0.0029). Similarly, no difference in uptake efficacy was 
observed between Tat-GP(01) and Tat-GP(10), but the uptake of Tat-GP(11) was slightly, but 
significantly higher (p = 0.012). 
The inactivation strategy was furthermore studied by confocal laser 
scanning microscopy (CLSM), which allows for the visualization of the intracellular 
distribution of the peptides. The CLSM images showed a clear uptake by 
endocytosis (localized dots) for the unmodified Tat peptide, but hardly any 
intracellular fluorescence (smeared fluorescence of the cytosol) was observed for 
all of the inactivated Tat variants (figure 4). These results agree with the flow 
cytometry experiments and furthermore suggest that at the concentration of 5 µΜ 
the inactivated peptides are not prone to membrane binding. 
 
Figure 4 – CLSM micrographs for uptake experiments of unmodified Tat peptides. No uptake was 
observed for the modified Tat peptides, Scale bar represents 50 µm. 
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5.2.3 Enzymatic activation of the inactivated Tat-peptides  
To test whether the inactivated Tat peptides could be re-activated enzymatically, 
the peptides were treated with aminopeptidase (APN) and dipeptidyl peptidase 
(DPPIV) and the reaction mixture was analyzed by reversed phase HPLC. To 
study whether Tat itself withstands peptidase activity from APN and DPPIV, the 
acetylated Tat peptide was incubated with both enzymes. As expected, no 
conversion could be observed for either one of the enzymes. At low enzyme 
concentrations, no cross-reactivities were observed, meaning that the Tat-A 
peptides were only converted by APN, and not by DPPIV, and that the Tat-GP 
peptides could only be cleaved by DPPIV. However, at these low concentrations 
of enzyme, only a maximum conversion of 50% was achieved after 90 minutes 
(figure 5A). In order to obtain full conversion within this time frame, the enzyme 
concentration was increased (figure 5B). Under these conditions, we could keep 
the incubation time at 90 minutes, which is the preferred time-span for cellular 
uptake experiments, as longer incubation times could lead to less reliable results 
due to non-specific binding of positively charged peptides to the plasma 
membrane and the possibility of subsequent internalization. Although we 
observed cross-reactivities of the enzymes at these concentrations, the 
unmodified Tat remained stable and therefore we decided to use the higher 
enzyme concentrations for further experiments. 
 
Figure 5 - A) conversion of the Tat-A(11) and Tat-GP(11) peptides by APN and DPPIV, respectively, 
at low enzyme concentrations (0.23U APN and 0.071U DPPIV). B) Enzymatic conversion of the 
peptides at the higher concentration of 0.68U APN and 0.21U DPPIV. 
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5.2.4 Cellular uptake of re-activated Tat-peptides  
The potential toxicity of the Tat variants in presence of the model enzymes was 
analyzed by means of a cell viability assay. For this purpose, HEK cells were 
incubated with the inactivated peptides at 5 µM together with APN or DPPIV. After 
2 hours, the cells were washed thoroughly and incubated with FCS-supplemented 
DMEM. The cells were allowed to rest for 4 hours, after which the cell counting 
dye WST-8 was added and incubated with the cells for three hours. For these 
experiments, a survival value of 100% was defined for untreated HEK cells. Since 
no significant cell death was observed (figure 6), it was assured that at the 
desired incubation conditions for the cellular uptake studies the cells would 
remain viable allowing us to proceed with analysis of the uptake efficiency of the 
re-activated Tat peptides. 
 
Figure 6 – Cell viability assay after treatment of cells with 5 µM peptide in presence or absence of 
enzyme for 2 hours and a resting period of 4 hours. 
The uptake behavior of the blocked Tat peptides in HEK cells after in situ 
re-activation was studied using both flow cytometry (figure 7A) and CLSM (figure 
7B). HEK cells were treated with 5 µΜ peptide in presence of either APN (0.68 U) 
or DPPIV (0.21 U) and were incubated for 90 minutes at 37 °C. For the flow 
cytometry experiments, the cells were briefly washed after the incubation period 
with trypsin/EDTA to remove membrane-bound peptides, as trypsin leads to 
digestion of the membrane-bound peptides.28 As a reference, unmodified Tat was 
included and the average median fluorescence of Tat was defined as 100%. Flow 
cytometry of cells treated with APN re-activated Tat-A peptides revealed an 
uptake efficiency up to 60% compared to unmodified Tat. Similar results were 
observed for the Tat-A peptides that were re-activated by DPPIV. The Tat-GP 
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peptides were found to regain the ability to enter cells after re-activation with 
DPPIV up to an amount of ~75% compared to Tat. Treatment with APN was less 
efficient, yielding uptake efficiencies of ~60%. As expected from the HPLC data 
obtained during the enzymatic conversion of the inactivated Tat peptides (figure 
5), treatment with either APN or DPPIV did not affect the uptake of unmodified Tat 
itself.  
 
Figure 7 - Cellular uptake studies at 5 µM Tat peptide concentrations in the presence of APN or 
DPPIV. All studies were conducted in the presence of serum. A) Flow cytometry results of uptake 
studies conducted in the presence of APN or DPPIV. Unmodified Tat was also treated with the 
enzymes. The average median fluorescence intensity of Tat uptake was defined as 100%. B) Confocal 
laser scanning microscopy images of the Tat-A series (top) which were co-incubated with APN and 
(below) microscopy images of the Tat-GP series which were co-incubated with DPPIV. Unmodified Tat 
was included and treated with APN or DPPIV as a positive control. Scale bar represents 50 µm. 
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The same experiment was also performed with the lower enzyme 
concentration (0.23 U APN and 0.071 U DPPIV), however, this only showed 
uptake efficiencies up to 25 to 30% compared to unmodified Tat itself (figure 8). 
These results again confirm the need to use the higher enzyme concentrations to 
achieve efficient in situ reactivation of the Tat peptides. 
 
 
Figure 8 - Uptake of Tat and the modified Tat-peptides in HEK 293 cells, analyzed by flow cytometry. 
Enzyme concentration of APN was 0.23 U and DPPIV 0.071U. For every series of experiments, the 
uptake of unmodified Tat was set to 100% 
By means of CLSM we were able to study the cellular localization of the 
re-activated peptides after uptake by HEK cells. These experiments were, like the 
flow cytometry studies, performed with a peptide concentration of 5 µΜ and an 
incubation time of 90 minutes at 37 °C, using in situ enzymatic reactions with APN 
or DPPIV. Unmodified Tat was used as a reference and this peptide was also 
incubated in presence of the enzymes. We observed that all Tat variants entered 
HEK cells by endocytosis after re-activation, similarly to what we previously 
observed for the unmodified Tat peptide (figure 7B).  
 
5.3 Conclusion 
We have shown that it is possible to temporarily block the activity of a cell-
penetrating peptide, Tat, by a minimal modification of the lysine side chains and 
restore its cell-uptake potential upon enzymatic cleavage of the lysine 
modification. Importantly, our results show that only one lysine residue needs to 
be modified to obtain an almost complete loss in cellular uptake of Tat. 
Interestingly, we observed that this de-activation strategy works with no more than 
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a single amino acid residue on a single lysine side-chain. The inactivating groups 
on the lysine side chains could be enzymatically removed in situ using the model 
enzymes aminopeptidase N (APN) or dipeptidyl peptidase IV (DPPIV). This 
enzymatic activation of Tat has the potential to become a useful, physiologically 
benign, strategy to control the activity of CPPs.  
 
5.4 Experimental procedures 
General  
NovaPEGRink amide resin was purchased from Novabiochem and Fmoc-L-amino acids 
from Bachem (Bubendorf, Switzerland) or Novabiochem (EEMBD Chemicals, Gibbstown, 
U.S.A.). Diisopropylcarbodiimide (DIPCDI) was obtained from Biosolve. Dipeptidyl 
peptidase IV (porcine kidney, EC 3.4.14.5) was from Sigma Aldrich and aminopeptidase N 
(Rat, EC 3.4.11.2) from Calbiochem (Merck, Darmstadt, Germany). Fetal bovine serum 
(FBS) was obtained from Integro (Zaandam, The Netherlands), plain Dulbecco’s Modified 
Eagle Medium (DMEM) and trypsin/EDTA were both from PAA Laboratories (Pasching, 
Austria). Human Embryonic Kidney cells were obtained from American Type Culture 
Collection (ATCC, Manassas, U.S.A.). All other chemicals were purchased from Baker, 
Fluka or Sigma Aldrich and were used as received. 
RP-HPLC peptide purification and liquid chromatography mass spectrometry  
Semi-preparative HPLC was performed on a Shimadzu LC-20A Prominence system 
(Shimadzu,’s-Hertogenbosch, The Netherlands) equipped with a C18 ReproSil column, 
250x10 mm, particle size 5 µm (Screening Devices, Amersfoort, The Netherlands). Elution 
of the peptides was achieved with a MeCN/water gradient containing 0.1% trifluoroacetic 
acid (5-100%, 1-50 min, flow 4 mL/min). The fractions were analyzed by liquid 
chromatography mass spectrometry using a Thermo Finnigan LCQ-Fleet ESI-ion trap 
(Thermo Fischer, Breda, The Netherlands) equipped with an Alltima C18 column, 2.1x150 
mm, particle size 3 µm or an Alltima C18 column, 2x50 mm (Alltech Applied Sciences BV, 
Breda, Netherlands) using the same gradient as used for HPLC (trifluoroacetic acid was 
replaced with formic acid) or a shorter gradient (3-100%, 3-10 min), respectively. The 
collected fractions containing the desired peptide were pooled, evaporated until the volume 
was halved and lyophilized.  
Peptide synthesis 
Synthesis of Mtt-protected Tat-peptides  
The three Mtt-protected Tat peptides were synthesized on a NovaPEG Rink amide resin 
using a Labortec640 peptide synthesizer (Labortec, Bubendorf, Switzerland) and 
employing a standard Fmoc solid phase peptide synthesis (SPPS) protocol. The peptides 
had the general sequence Ac-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-(ε-Ahx)-Cys-NH2. 
Either the first, the second or both lysine residues were protected with a methyltrityl 
protecting group (Mtt) by incorporating the Fmoc-Lys(Mtt) amino acid instead of Fmoc-
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Lys(Boc). In brief, the resin was swollen in DMF for 20 minutes prior to use. The first and 
subsequent Fmoc protecting groups were removed by washing the resin with piperidine in 
DMF (20%, v/v) and then shaking for 25 minutes with another portion of piperidine in DMF. 
The desired sequence of amino acids was coupled to the resin using Fmoc- Ll-amino acids 
(3.0 eq), diisopropylcarbodiimide (DIPCDI, 3.3 eq) and N-hydroxybenzotriazole (HOBt, 3.6 
eq). Peptide couplings were monitored to completion using the Kaiser test.29 After the final 
Fmoc removal, the N-terminus was acetylated by agitation in a mixture of pyridine (1 mL) 
and acetic anhydride (1 mL) in DMF for 10 minutes. Afterwards, the resin was washed 
thoroughly with DMF, DCM, i-PrOH, DCM and Et2O and dried in vacuo. A small amount of 
the resin was used to verify the quality of the synthesized peptide and was suspended in 
trifluoroacetic acid/water/triisopropylsilane/thioanisole (90:5:2.5:2.5 v/v) and stirred for 8h at 
rt. Then the resin was filtered off and the filtrate was precipitated from Et2O, redissolved in 
water and lyophilized yielding the crude peptide as a white powder. Liquid Chromatography 
Mass Spectrometry was performed to verify the identity of the peptides. 
Tat(Mtt-01) ESI-ion trap m/z: [M+3H]3+ 522.05 (calcd. 522.01) 
Tat(Mtt-10) ESI-ion trap m/z: [M+3H]3+ 522.05 (calcd. 522.01) 
Tat(Mtt-11) ESI-ion trap m/z: [M+3H]3+ 522.07 (calcd. 522.01) 
Synthesis of branched Tat-peptides  
The NovaPEG resin carrying the Mtt-protected Tat peptides was suspended in a mixture of 
TFA/TIS/DCM (1:2:97 v:v:v) for 20 minutes. A small amount of resin was then removed and 
to this 1-2 drops of neat TFA was added. If no bright orange colour emerged, the resin was 
washed with DCM, MeOH, diisopropylethyl amine (DIEA) in DMF (1% v/v) and finally with 
DMF. The resin was then ready for coupling with Boc-Ala to obtain the Tat-A peptides or 
with Fmoc-Pro and subsequently Boc-Gly to obtain the Tat-GP peptides, using standard 
SPPS protocols and resin cleavage procedures as described above. Liquid 
Chromatography Mass Spectrometry was performed to verify the identity of the peptides. 
Tat-A(01) ESI-ion trap m/z: [M+3H]3+ 575.74 (calcd. 575.68) 
Tat-A(10) ESI-ion trap m/z: [M+3H]3+ 575.76 (calcd. 575.68) 
Tat-A(11) ESI-ion trap m/z: [M+3H]3+ 599.40 (calcd. 599.36) 
Tat-GP(01) ESI-ion trap m/z: [M+3H]3+ 603.39 (calcd. 603.36) 
Tat-GP(10) ESI-ion trap m/z: [M+3H]3+ 603.41 (calcd. 603.36) 
Tat-GP(11) ESI-ion trap m/z: [M+3H]3+ 654.78 (calcd. 654.72) 
Solution labeling of the Tat peptides 
The peptides (25 µmol) were dissolved in a mixture of water-DMF (1:1, v/v, 6 mL) and to 
this triscarboxyethylphosphine (12 mg, 48 µmol) and fluorescein diacetate 5-maleimide (17 
mg, 33 µmol) were added. The reaction mixture was stirred at 60 ºC for 18 h. Next, the 
reaction mixture was concentrated in vacuo and redissolved in a water-formic acid (1:1 v/v) 
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mixture and the product was purified using semi-preparative HPLC yielding the fluorescein-
labeled peptides. Identity of the peptides was confirmed by liquid chromatography mass 
spectrometry. 
Tat ESI-ion trap m/z: [M+3H]3+ 722.84 (calcd. 722.7); HPLC RT 14.8 min 
Tat-A(01) ESI-ion trap m/z: [M+3H]3+ 746.61 (calcd. 746.38); HPLC RT 15.2 min 
Tat-A(10) ESI-ion trap m/z: [M+3H]3+ 746.63 (calcd. 746.38); HPLC RT 15.3 min 
Tat-A(11) ESI-ion trap m/z: [M+3H]3+ 771.22 (calcd. 770.05); HPLC RT 15.5 min 
Tat-GP(01) ESI-ion trap m/z: [M+3H]3+ 774.25 (calcd. 774.06); HPLC RT 15.8 min 
Tat-GP(10) ESI-ion trap m/z: [M+3H]3+ 774.23 (calcd. 774.06); HPLC RT 16.0 min 
Tat-GP(11) ESI-ion trap m/z: [M+3H]3+ 825.57 (calcd. 825.42); HPLC RT 17.2 min 
Enzymatic reactions  
For the enzymatic reactions the peptides were dissolved in Tris buffer (200 mM; pH 7.4), in 
case of APN and in Tris buffer (100 mM, pH 7.8) for DPPIV. The enzymes (APN: 3.75 µL 
for 0.23U and 11.25 µL for 0.68; DPPIV (7.5 µL for 0.071 U and 22.5 µL for 0.21 U) were 
added to the peptide aliquots and analyzed by analytical HPLC at 15-20 minutes time 
intervals, with an isocratic gradient of 28 % MeCN for Tat-A(11) and 36% MeCN for Tat-
GP(11). Using the isocratic gradient, the three peaks could be observed corresponding to 
Tat, single-modified Tat and double-modified Tat (figure 9). The final peptide 
concentrations were 75 µΜ.  
 
Figure 9 - Example HPLC trace showing the co-injection of Tat; Tat-GP(01) and Tat-GP(11) at an 
isocratic gradient of 36% MeCN. This experiment was performed to make sure the conversion of Tat-
GP(11) into Tat-GP01/Tat-GP(10) and Tat could be detected using analytical HPLC. Coinjection of 
Tat; Tat-A(01) and Tat-A(11) at an isocratic gradient of 28% MeCN yields a similar separation. 
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Cell culture  
HEK 293 cells were maintained in sterile conditions in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS). Cells were 
maintained on tissue culture plastic and kept at 37 °C in a humidified atmosphere of 7.5% 
CO2. Cells were passaged every 2-3 days. Prior to cell viability assays or cellular uptake 
studies, cells within a confluent layer were detached using trypsin/EDTA. Cells were then 
resuspended in FBS-supplemented DMEM and the number of cells was counted using a 
standard inverted microscope and a cell counting chamber (Fuchs-Rosenthal). 
Flow cytometry  
HEK cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) one (80,000 
cells/well) or two (40,000 cells/well) days prior to the experiment. On the day of the 
experiment, cells were incubated with the peptide solutions (5 µM) for 90 min at 37 °C in 
RPMI + 10% FCS. For the cellular uptake experiments with in situ activation using APN or 
DPPIV, the peptides were co-incubated with APN (3.75 µL, 0.23 U for low enzyme 
concentrations or 11.25 µL, 0.68 U for high enzyme concentrations) or DPPIV (7.5 µL, 
0.071 U for low enzyme concentrations or 22.5 µL, 0.21 U for high enzyme 
concentrations). After washing the cells with HBS buffer pH 7.4 (10 mM HEPES, 135 mM 
NaCl, 5 mM KCl, 5 mM MgCl2, 1.8 mM CaCl2), cells were detached by trypsinisation for 5 
minutes, spun down at 1000 rpm for 5 minutes and resuspended in 200 µL RPMI + 10% 
FCS. The fluorescence was measured using a FACSCalibur flow cytometer (BD 
Biosciences, Erembodegem, Belgium) and subsequently data was analyzed with the 
Summit software (Fort Collins, U.S.A.). Results were based on 10,000 gated cells. 
Confocal laser scanning microscopy  
HEK cells were seeded in chambered coverslips (Nunc, Wiesbaden, Germany that were 
coated with 0.1% gelatin in PBS at a density of 40,000 cells (one day) or 20,000 cells per 
well (two days prior) to the experiment. Cells were incubated with the 5 µM peptide for 90 
min at 37 ºC. For the cellular uptake experiments with in situ activation using APN or 
DPPIV, the peptides were co-incubated with APN (3.75 µL, 0.23 U for low enzyme 
concentrations or 11.25 µL, 0.68 U for high enzyme concentrations) or DPPIV (7.5 µL, 
0.071 U for low enzyme concentrations or 22.5 µL, 0.21 U for high enzyme 
concentrations). Cells were washed twice after incubation with DMEM + 10 % FCS and 
living cells were analyzed immediately by confocal microscopy using a TCS SP2 confocal 
microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63 
x N.A. 1.2 oil immersion lens. Fluorescein was excited by an argon laser at 488 nm and 
emission was collected between 500 and 550 nm. 
Cell viability assay  
Cell viability was evaluated using Cell Counting Kit-8 (CCK-8, Dojindo Molecular 
Technologies). HEK cells were seeded in 96-well plates to obtain 40,000 cells/well the day 
of the experiment. On the day of the experiment, cells were incubated with 100 µL mixture 
of peptide and enzyme in DMEM for 120 minutes at 37 °C. A peptide concentration of 5 µM 
was used and this was co-incubated with APN (3.75 µL, 0.23 U for low enzyme 
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concentrations or 11.25 µL, 0.68 U for high enzyme concentrations) or DPPIV (7,5 µL, 
0.071 U for low enzyme concentrations or 22.5 µL, 0.21 U for high enzyme 
concentrations). Cells were washed 3 times with DMEM + 10% FCS and maintained in this 
solution after the last washing step. After 4 hours of incubation, the supernatant was 
removed and a solution of CCK-8 (10 % in DMEM + 10% FCS) was added. After 3 hours of 
incubation at 37 °C, the absorbance was measured at 490 nm using a microplate reader 
(Wallac Victor 1420 multilabel counter, Perkin Elmer). The experiments were performed in 
triplicate and repeated twice independently.  
 
Appendix 
A1. Peptide structures 
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A2. Additional confocal fluorescence micrographs 
 
Figure A2.1 - Uptake of Tat; Tat-RP(01); Tat-RP(10) and Tat-RP(11) in HEK 293 cells without addition 
of enzyme. Scale bar represents 50 µm. 
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6.1 Introduction 
There is a great need for the development of methods that enable targeted 
delivery and cellular uptake of drugs only by diseased and, in particular, cancer 
cells. The major advantage of such methods is that healthy tissue is not affected 
by the pharmaceutical substance, as only diseased cells take up the drug. Such 
strategies may avoid the many side-effects that arise in standard chemotherapy. 
However, before selectivity can be introduced, first efficient cell uptake has to be 
achieved. Human cells are surrounded by a plasma membrane that with 
exception of specific molecules that are needed for cell function and survival, 
represents an impermeable barrier. For this reason, successful transport of 
chemotherapeutic agents into cells is dependent on the use of delivery vectors. 
Cell-penetrating peptides (CPPs), sometimes known as protein transduction 
domains (PTDs) represent a class of peptides that have the ability to penetrate 
the plasma membrane without induction of cytotoxicity.1 In addition, various types 
of cargoes may be attached to CPPs to transport them inside cells. Because of 
these characteristics, CPPs are frequently included as components in drug 
delivery methods. However, an important drawback of CPPs is that they are 
hardly cell type specific, causing them to be taken up by almost any type of cell.2 
To overcome this limitation, extensive research has been carried out towards the 
development of CPP-based cell-selective delivery systems.3 One way to achieve 
this is by the combination of CPPs with homing devices, such as an antibody or a 
homing peptide, which allows for the accumulation of the drug complex to the 
tumor surface through interactions with receptors or antigens. An example of such 
an active targeting system was reported by Kang et al. in which folate was used 
as homing device for the delivery CPP decorated liposomes.4 Recently, Kondo et 
al., reported novel cell-penetrating homing peptides that were identified by mRNA 
phage display technology.5 These peptides were able to bind to tumor cell lines, 
and were internalized into these cells afterwards. The specificity for tumor cells is 
encoded in the peptide sequence. Although active tumor-targeting approaches 
such as the study described above have yielded successful results, there are still 
limitations. First of all, the specificity and affinity of homing devices should be 
improved, because with current strategies, binding to healthy tissue, either in an 
aspecific manner or via the presence of some tumor antigens, poses a major 
limitation of the methodology.6 Secondly, the intrinsic activity of the CPPs should 
be attenuated, in order to prevent undesired untargeted uptake in healthy cells.7 
Another way to induce selectivity in CPPs is to activate them in the 
presence of the target tissue, by the use of external stimuli, such as a change in 
pH8,9, an enzymatic reaction10,11 or a trigger such as UV-light12. These so-called 
activatable CPPs or ACPPs are blocked and thus inactive, until they reach a 
specific tissue in which the environment triggers the release of the CPP. Because 
most CPPs are positively charged, a useful method to block their activity is by 
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interaction with anions. Furthermore, poly(ethylene glycol) (PEG) chains have 
frequently been used to shield CPPs.13 In these approaches the PEG shield is 
cleaved from the delivery vehicle, exposing the CPP, by an enzyme that is 
upregulated in tumor tissue, such as the matrix metalloproteases (MMPs). Apart 
from PEG chains, different blocking moieties such as anionic peptides have been 
used for similar activation strategies. These approaches have been used for 
several applications such as tumor detection14 and imaging.11. In an alternative 
method for the development of ACPPs, Liu et al. made use of a legumain 
cleavable linker.15 This enzyme is upregulated in various solid tumors. The 
tripeptide linker (Ala-Ala-Asn) was attached to a lysine in the CPP Tat, to create a 
branched moiety, which led to a substantial decrease in cellular uptake. The 
branched peptide was used for the delivery of doxorubicin-loaded liposomes to 
legumain-expressing cells.  
Although the work described above provides elegant examples of ACPP 
systems, their methodology depends on the sub-environment of tumor tissue, and 
either the presence of specific enzymes or a decrease in pH, to function. 
Furthermore, sometimes large alterations or additions in the CPP structure need 
to be included to induce an activatable and specific system, such as the 
incorporation of PEG chains, or enzyme cleavable linkers and shielding groups.  
Similarly, we have recently reported modified Tat-peptides for enzymatic 
activation and uptake in HEK cells (chapter 5).10 We found that by elongating the 
lysine side-chain of Tat as little as a with a single amino acid, the uptake of this 
cell-penetrating peptide was blocked, preventing cellular delivery. By co-
incubation with enzymes that have the ability to cleave off the side-chain 
modification, cellular uptake was recovered. However, the reduction of cellular 
uptake via this minimal perturbation was in fact quite unexpected as only the side 
chain length and not the charge density was affected. The side chain modification 
with one or more amino acids replaced the amine of the lysine side chain with the 
N-terminus of the added amino acid. This prompted us to investigate whether this 
subtle change in distribution of positive charges resulting from minimal 
modifications on the lysine side-chain of Tat leads to preferential uptake by 
specific cell lines.  
In this chapter we demonstrate that via applying minimal changes at 
lysine side chains of Tat we are indeed able to induce differential uptake profiles, 
first between HEK and HeLa cells and then for various leukemic cell lines, 
whereas white blood cells derived from a healthy donor are targeted to a much 
lesser degree. Our strategy therefore offers the opportunity to develop intrinsically 
active and tumor selective cell-penetrating peptides by only a single lysine 
modification step of the Tat peptide without the need for any explicit targeting or 
activation strategy. 
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6.2 Results and discussion 
6.2.1 Peptide design and synthesis 
In order to validate our hypothesis we selected two series of modified Tat 
peptides, in which the side-chain of one or two of the lysine residues was 
modified. In a first series, a single alanine residue was coupled to either one or 
both of the side chains while in a second series the dipeptide glycine-proline was 
used.10  
We designate the modified Tat peptides using the following abbreviation: 
Tat-X(10) is used for coupling of moiety X to the N-terminal lysine residue, Tat-
X(01) for modification on the lysine residue closer to the C-terminus, and Tat-
X(11) for functionalization of both lysine residue side chains. To preclude 
degradation by peptidases, all Tat-derived peptides were N-terminally acetylated. 
To allow studying of uptake by fluorescence-based techniques the peptides were 
labeled with fluorescein diacetate 5-maleimide, which was conjugated to a 
cysteine residue introduced at the C terminal side of the peptide (figure 1). 
Peptide synthesis was performed according to earlier reported procedures in 
chapter 5.10 
 
Figure 1 – Overview of modified Tat peptides and their structure 
6.2.2 Comparison of cellular uptake by HEK and HeLa cell lines 
The uptake of Tat and the modified Tat peptides was studied in HEK and HeLa 
cells. An important difference between these cell lines is that HeLa cells are 
derived from tumorous tissue, while HEK cells are obtained from healthy tissue. 
The uptake of the peptides was visualized using confocal laser scanning 
microscopy (CLSM) and quantified by flow cytometry. For this purpose, adherent 
cells were treated with 5 µM peptide in cell culture medium containing 10% fetal 
bovine serum (FBS) (v/v) and incubated for 30 minutes at 37 ºC. After this 
incubation period, the cells were washed and analyzed by CLSM immediately. As 
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a positive control, unmodified Tat was included in the uptake experiments, and it 
was observed that this peptide was taken up by both HeLa and HEK cells. For all 
modified Tat peptides, no fluorescence was observed in HEK cells (figure 2A, 
upper row), meaning the peptides were unable to enter these cells. However, in 
HeLa cells, bright punctate spots were observed, similar to cells treated with 
unmodified Tat (figure 2A, second row). This demonstrated that the HeLa cells 
were able to take up the modified Tat peptides. The experiment was repeated for 
analysis by flow cytometry. We again observed no uptake by HEK cells, but in 
contrast, the HeLa cells did take up all modified peptides with varying efficacy 
(figure 2B).  
 
Figure 2– A) CLSM micrographs of uptake of Tat and modified Tat peptides in HEK293 and HeLa 
cells. In HEK cells, only Tat is taken up, whereas in HeLa cells, all peptides are taken up by 
endocytosis. Scale bar represents 50 µm B). Summary of flow cytometry data for uptake of Tat and 
the modified Tat peptides by HEK293 (dark grey) and HeLa (light grey) cells. The median fluorescence 
of Tat is set to 100% for both cell lines, to allow for comparison of uptake efficacies of the modified Tat 
peptides. 
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To gain information about the uptake mechanism that took place in HeLa 
cells but not in HEK 293 cells, experiments using several endocytosis inhibitors 
were performed. We selected chlorpromazine (CPZ), genistein (GS), methyl-β-
cyclodextrin (MβCD) and amiloride (AM) as endocytosis inhibitors, because these 
are the most frequently used in combination with CPPs. CPZ is a cationic 
amphiphilic drug which is used as inhibitor of clathrin-coated pit formation by a 
reversible translocation of clathrin and its adapter proteins from the plasma 
membrane to intracellular vesicles.16 MβCD and GS are evaluated as inhibitors of 
clathrin-independent endocytosis. MβCD is a cyclic oligomer of glucopyranoside 
that inhibits cholesterol-dependent endocytotic processes by reversibly extracting 
the steroid out of the plasma membrane.17 MβCD is regularly used to determine 
whether endocytosis is dependent on the integrity of lipid rafts. GS is a tyrosine-
kinase inhibitor and this agent causes local disruption of the actin network at the 
site of endocytosis and inhibits the recruitment of dynamin II, both known to be 
indispensible events in the caveolae-mediated uptake mechanism.18,19 Amiloride, 
a guanidinium-containing pyrazine derivative is known to inhibit macropinocytosis, 
but the mechanism in which this takes place is not yet fully understood. 20 
However, it is suggested that it acts by inhibition of Na+/H+ exchangers, leading to 
lowering of the submembrane pH. We evaluated the uptake of Tat, Tat-A(01), Tat-
A(11), Tat-GP(01) and Tat-GP(11) in the presence of the above mentioned 
endocytosis inhibitors in HeLa cells by flow cytometry. The results of these 
experiments, with the uptake of Tat in the absence of inhibitors normalized to 
100%, are summarized in figure 3. The results of this experiment do not present a 
clear trend, as it was observed that none of the tested endocytosis inhibitors could 
block the uptake of Tat or the modified Tat peptides completely. MβCD seemed to 
have the most pronounced effect on cellular uptake. However, the data obtained 
by this experiment is not sufficient to draw conclusions on the endocytotic 
pathway that HeLa cells employ to internalize the modified Tat peptides.  
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Figure 3 - flow cytometry data for the uptake of Tat, Tat-A(01), Tat-A(11), Tat-GP(01) and Tat-GP(11) 
in HeLa cells, in presence or without chlorpromazine (CPZ), genistein (GS), methyl-β-cyclodextrin 
(MβCD) and amiloride (AM). The average median fluorescence of Tat internalization without addition 
of inhibitors was set to 100%.  
To investigate whether the observed selective uptake by HeLa cells was 
caused by an enzymatic reaction, Tat-a(01) was synthesized, which is the same 
peptide as Tat-A(01), only the Ala residue is replaced by D-Ala to hamper 
enzymatic cleavage of the alanine residue from the lysine side-chain. It was 
observed that Tat-a(01) behaved similarly as Tat-A(01) in both HeLa and HEK 
cells, suggesting that the preferential uptake by HeLa cells may not be caused by 
an enzymatic trigger (data in supporting information). To further investigate the 
possibility that HeLa cells excrete enzymes that may cleave off the side-chain 
modification of the peptides, co-culture experiments with HEK and HeLa cells 
were performed. To be able to easily differentiate between the two cell lines using 
CLSM and flow cytometry we made use of HeLa cells with an mCherry labeled 
nucleus. For the co-culture experiments, HEK and mCherry HeLa cells were 
seeded in a 1:1 ratio one day prior to the experiment. On the day of the 
experiment, the cells were treated in the same way as described above and were 
analyzed by both CLSM and flow cytometry. From the CLSM micrographs it could 
be concluded that uptake by endocytosis took only place for the mCherry HeLa 
cells, while the HEK cells hardy any uptake was observed (figure 4A). Using flow 
cytometry, four cell populations could potentially be observed: unlabeled cells 
which correspond to HEK cells that did not take up any peptide, FITC-labeled 
cells which correspond to HEK cells in which peptide was internalized, mCherry 
labeled cells that correspond to HeLa cells not having taken up any peptide and 
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doubly labeled cells that represent HeLa cells that have taken up peptide. A co-
culture treated with the positive control, Tat, showed uptake by both HEK and 
HeLa cells. For the Tat-A series we observed hardly any uptake by HEK cells, as 
in agreement with the flow cytometry experiments described above for this cell 
line. The HeLa cells were able to take up the three peptides from this series. 
Interestingly, the Tat-GP series showed to be less selective than the Tat-A series, 
as slight uptake by HEK cells was shown. However, uptake by mCherry HeLa 
cells was predominant (figure 4B).  
 
Figure 4 – A) Overlay image of the differential contrast, mCherry and FITC channel obtained by a 
CLSM study of uptake of Tat-A(11) and Tat-GP(11) in a co-culture of HEK293 and mCherry-HeLa 
cells. B). Summary of flow cytometry data for uptake of Tat and the modified Tat peptides by a co-
culture of HEK293 and mCherry HeLa cells. The median counts for each population was calculated as 
relative population fraction, where the FITC+ mCherry+ represents the population of HeLa cells that 
have taken up peptides (red/green), the mCherry+ represents the population of HeLa cells that are not 
FITC-labeled and have not taken up peptide (red), FITC+ represents the population HEK cells that 
have taken up peptide (green) and unlabeled represents the population that was not fluorescently 
labeled, thus representing the HEK cells that have not taken up any peptide (gray).  
Because this observed specificity of HeLa cells for the Tat-A and Tat-GP 
peptides remained present during co-culture experiments, uptake by HeLa cells is 
highly unlikely to be caused by enzymes excreted by these cells. The differential 
uptake behavior of these Tat analogs seems therefore an intrinsic property of 
these modified CPPs.  
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6.2.3 Selective uptake by leukemic cells 
Because of these promising results in HeLa and HEK cells, we next set 
out to investigate whether our modified CPPs also displayed tumor selectivity in a 
model system for leukemia. First it was investigated whether RBCs could take up 
Tat and the modified Tat peptides, or whether the peptides would stick to the RBC 
membrane. For this experiment, peripheral blood from a healthy human donor 
was used. Because RBCs are at least 1000 times more abundant in blood than 
WBCs, there was no need to isolate the RBCs before performing the experiment. 
The samples were incubated with 5 µM peptide in FCS-containing cell culture 
medium for 30 minutes and analyzed afterwards by flow cytometry. It was 
observed that none of the peptides, including Tat, could enter RBCs at these 
conditions. We observed only slight membrane binding for all peptides tested 
(figure 5A) 
Next, it was investigated whether white blood cells (WBCs) obtained from 
peripheral blood of a healthy human donor, could take up Tat and the modified 
Tat peptides. Analysis of this study was performed by flow cytometry. To study 
the WBCs, first the erythrocytes (red blood cells, RBCs) were lysed from the 
population, because these cells are much more abundant in blood, making the 
analysis of WBCs challenging. The remaining WBCs (lymphocytes and 
granulocytes) were incubated with 5 µM peptide in FCS-containing cell culture 
medium for 30 minutes. Afterwards, a short trypsin treatment was performed to 
remove any membrane-bound peptide. Reassuringly, it was observed that only 
the unmodified Tat peptide itself was internalized into WBCs, and that 
lymphocytes took up the Tat peptide most efficiently. The modified Tat peptides 
were not able to efficiently enter any of the WBCs, with their uptake reduced to 
15% or less compared to Tat (figure 5B). The intensity of the FITC signal in the 
fow cytometry results in RBCs and WBCs is shown in the insert in this figure. As 
can be observed, the FITC signal for Tat uptake in WBCs is much higher than 
than in RBCs, leading us to conclude that the RBCs do not take up the peptides, 
whereas WBCs can take up Tat, but none of the modified Tat peptides.  
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Figure 5– A) Flow cytometry results of uptake studies in RBCs. The fluorescence intensity is equally 
low for all peptides observed. B) Flow cytometry results of uptake of Tat and the modified Tat peptides 
by normal WBCs. The average median fluorescence of Tat was set to 100%. Insert: comparison of 
FITC signal for untreated RBCs (red); RBCs incubated with Tat (green) and WBCs incubated with Tat 
(orange).  
With these promising results with blood cells derived from a healthy donor 
in hand, the next step was to evaluate uptake of the modified Tat peptides in a 
variety of leukemic cells. For this purpose, three cell lines derived from patients 
with acute myeloid leukemia (AML) and two cell lines derived from patients with 
B-cell lymphocytic leukemia (B-ALL) were selected. These syndromes are of 
interest because AML is the type of leukemia most prevalent in adults and B-ALL 
is a frequently occurring childhood cancer. The AML cell lines correspond with 
different stages of the disease, with HL60 cells being the most immature cells, 
followed by THP-1 cells and KG1a cells. The experiments were conducted in 
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analogy to the abovementioned experiments, by incubating the selected cells with 
5 µM peptide in FCS-containing cell culture medium for 30 minutes. Membrane-
bound peptides were subsequently removed by a short trypsin treatment. Analysis 
of uptake was performed using flow cytometry. For all cell lines, the uptake of Tat 
was used as positive control and set to 100%. We started the experiments with 
the HL60 cell line, which corresponds to early AML. It was observed that the 
peptides were taken up by these cells with varying uptake efficiency. Typically, 
the Tat-A(11) peptide was taken up almost equally well as Tat itself. Moreover, in 
the Tat-GP series it was found that the doubly modified Tat-GP(11) peptide was 
internalized more efficiently than Tat-GP(10). Notably, Tat-A(10) and Tat-GP(01) 
were hardly taken up by these cells. Next, uptake by THP-1 cells was evaluated. 
These cells are derived from a patient with AML and are known to be more 
phagocytic than the HL60 cells. We observed slightly different results in this cell 
line. In summary, the THP01 cells did not show a difference in uptake efficiency 
for Tat-A(01) and Tat-A(11) (95-105%). Importantly, the Tat-A(10) peptide was 
taken up only slightly less efficiently (80%) than the other two peptides in these 
series, which is striking because it could not induce efficient uptake in HL60 cells. 
For the Tat-GP-series we observed an overall diminished uptake, and only Tat-
GP(11) was able to be taken up by the cells. Moving forward to the KG1a cells, 
which was derived from a patient with erythroleukemia that developed into acute 
myeloid leukemia, we again observed different selectivities for the modified 
peptides. Tat-A(01), Tat-A(11) and Tat-GP(01) showed to be taken up equally or 
even more efficiently than Tat. No significant differences in uptake were observed 
for the other peptides Tat-A(10), Tat-GP(10) and Tat-GP(11), that were all 
internalized with an efficacy of ± 50% compared to Tat. A summary of these data 
can be found in figure 6. 
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Figure 6 – Summary of flow cytometry results of uptake of Tat and modified Tat peptides by AML cell 
lines HL-60 (blue), THP-1 (purple) and KG1a cells (orange). For each cell line, the average median 
fluorescence of Tat was set to 100%.  
 
Next, the uptake of the modified Tat peptides by B-ALL cell lines was 
investigated (figure 7). The first cell line to be studied was BV-173, which consists 
of B cell precursor leukemia cells, obtained from the peripheral blood of a patient 
with chronic myeloid leukemia in a blast crisis. The Tat-A series was taken up 
more efficiently by these cells than the Tat-GP peptides, with the most efficient 
internalization observed for Tat-A(11) (110%). There was no significant difference 
in uptake among the Tat-GP series, with all three peptides taken up around 60% 
compared to Tat. The second B-ALL cell line to be investigated, was the B-cell 
precursor leukemia cell line REH. These cells were established from a peripheral 
blood sample from a patient with acute lymphocytic leukemia at first relapse. For 
these cells, a remarkable effect was observed for the Tat-A series, where Tat-
A(11) was taken up even more efficiently than Tat, while the single modified 
peptides Tat-A(01) and Tat-(A(10) were hardly taken up. For the Tat-GP series a 
similar, but less pronounced uptake preference for the double modified Tat-
GP(11) was observed, but notably, Tat-GP(01) and Tat-GP(10) were still able to 
induce uptake (±35%) in REH cells. A summary of the flow cytometry data for the 
BV-173 and REH cells can be found in figure 7. In this graph, the uptake of the 
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peptides by lymphocytes derived from the peripheral blood of a healthy donor is 
also included, to allow for comparison of internalization of the peptides in 
leukemic lymphocytes and normal lymphocytes. From this, it can be observed that 
the modified peptides were hardly taken up by lymphocytes obtained from the 
healthy donor, but that for the leukemic cell lines at least one of the modified Tat 
peptides induced efficient uptake.  
 
Figure 7– summary of flow cytometry results of uptake of Tat and modified Tat peptides by REH (blue) 
and BV173 cells (purple) and healthy lymphocytes (orange). For each cell line, the average median 
fluorescence of Tat was set to 100%.  
For these results, the uptake of Tat in a cell line is always set to 100% to 
allow for easy comparison of uptake efficiency among cell lines. The fluorescence 
intensity obtained from the internalization of Tat into the cells was similar in these 
three cell lines. A summary of the uptake efficiency of Tat and the various 
modified Tat peptides in the different cell lines tested in this study is given in table 
1. From this, it can be observed that for each cancer cell line at least one modified 
Tat peptide can be identified that shows promising selective uptake 
characteristics.  
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Table 1 – summary of uptake efficiency in different cell lines of Tat and modified Tat peptides 
analyzed by flow cytometry. For uptake <25% the denotation – (red) is used; uptake >25%<50% the 
denotation +/- (light orange) is used, for uptake <80%>50% the denotation + (orange) is used and for 
uptake >80% the denotation ++ (green) is used. 
 HEK HeLa WBCs HL-60 THP-1 KG1a BV-173 REH 
Tat ++ ++ ++ ++ ++ ++ ++ ++ 
Tat-A(01) - + - + ++ ++ ++ - 
Tat-A(10) - + - - + +/- ++ +/- 
Tat-A(11) - ++ - ++ ++ + ++ ++ 
Tat-GP(01) - ++ - - +/- ++ + +/- 
Tat-GP(10) - ++ - + +/- +/- + +/- 
Tat-GP(11) - ++ - + + ++ + + 
 
Notably, we observed large amounts of dead cells during experiments 
with some of the peptides added to BV173 and REH cells. This is depicted in 
figure 8, in which the percentage of living cells is visualized in the forward/side 
scatter gating and the average amount of viable cells in the live gate is 
summarized in figure 8A. In figure 8B, two examples of such ‘live gates’ for BV173 
cells are given; the first one for Tat which induced a tremendous effect on 
cytotoxicity, and the second one for Tat-A(11) which did not have a striking effect 
on viability. The comparison of these two peptides is interesting, because in both 
BV173 and REH cells the peptides are taken up efficiently. There seems to be no 
clear correlation between uptake efficiency and cell death; for example, Tat-A(01) 
is hardly taken up by REH cells, however it induces much cell death. In BV173 
cells this peptide is taken up, and it shows a large effect on cell viability (similar tot 
Tat). 
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Figure 8- A) summary of average percentage of living cells in the live gate. B) example of live gates 
for Tat and Tat-A(11) in BV173 cells, the green scatter represents live cells whereas the black scatter 
represents dead cells. 
6.2.4 Uptake behavior in bone marrow samples derived from patients with 
leukemia 
Because of the observed selective uptake by various cell lines derived from 
patients with either acute myeloid leukemia or B-cell lymphatic leukemia, the next 
step was to investigate whether the modified Tat peptides would be taken up by 
malignant cells in bone marrow derived from patients. Therefore the ability of Tat 
and the modified Tat peptides to internalize in cells present in bone marrow 
derived from patients with AML, B-cell ALL was studied. Due to the fragility of the 
material, all uptake experiments were performed at ambient temperature to 
preserve a maximum amount of living cells while endocytotic uptake mechanisms 
(that are energy-dependent) could still occur. The uptake of the peptides was 
evaluated using flow cytometry and for the identification of the various cell types 
present in the sample several clusters of differentiation (CD) antibodies were 
used. First, bone marrow samples from two patients with AML were evaluated, 
with one patient having an early stage of the disease with minimal maturation 
(stage M1) whereas the second patient had a more matured leukemia, 
corresponding to acute myelomonocytic leukemia (stage M4). For these 
experiments a Cy5-labeled CD45 antibody (leukocyte common antigen) was used 
to identify leukocytes, PE-labeled CD33 was added to stain myeloid blasts, and 
Cy7-labeled CD14 was used to identify monocytes. In the AML M1 sample, no 
monocytes were observed, however in the AML M4 sample some of these cells 
were still present. Furthermore, in the AML M1 material both lymphocytes and 
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CD33+ myeloid blasts were observed and in the AML M4 material lymphocytes, 
CD33+ myeloid blasts and CD33- blasts (which are generally less ripe than 
CD33+ blasts) were observed. The median fluorescence intensity for each 
peptide tested in both bone marrow samples is represented in figure 9A for AML 
M1 and figure 9B for AML M4, in figure 9C the median fluorescence value for 
uptake by lymphocytes derived from blood from a healthy donor is compared for 
the median fluorescence observed for lymphocytes and monocytes derived from 
the AML M4 bone marrow. Surprisingly, we observed hardly any uptake of the Tat 
peptide or the modified Tat peptides in both the lymphocytes and myeloid blasts 
present in the M1 bone marrow sample. Generally, the blasts show increased 
uptake compared to the lymphocytes, but this pattern does not differ among the 
various peptides tested. The results for the M4 sample are very similar; none of 
the peptides was able to effect efficient uptake in the lymphocytes, CD33+ blasts 
and CD33- blasts. The monocytes present in the sample showed some uptake 
capacity, which is not a complete surprise because these cells are known to be 
able to induce efficient phagocytosis. 21 Unfortunately, based on these results it 
was not possible to conclude whether the observed selectivity in cultured cell lines 
is still present in cells in bone marrow derived from a patient with AML M1 or M4. 
The gating strategies to obtain this data for the M1 and M4 samples are shown in 
figures A1 and A2 in the appendix, for which the Tat peptide is shown as an 
example.  
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Figure 9 – A) Summary of flow cytometry results for CPP uptake in cells present in bone marrow 
derived from a patient with AML stage M1. The median fluorescence for uptake of each peptide is 
depicted for a population of lymphocytes and CD33+ blasts. B) Summary of flow cytometry results for 
CPP uptake in cells present in bone marrow derived from a patient with AML stage M4. The median 
fluorescence for uptake of each peptide is depicted for a population of lymphocytes, monocytes, 
CD33+ blasts and CD- blasts. C) Comparison of median fluorescence values observed for uptake of 
Tat in lymphocytes derived from te blood of a healthy donor (blue), in lymphocytes present in the bone 
marrow from a patient with AML M4 (red) and in monocytes present in the bone marrow from a patient 
with AML M4 (green). 
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Next, the uptake of Tat and the modified Tat peptides in bone marrow 
derived from a patient with B-cell acute lymphocytic leukemia was studied. Cy5-
labeled CD45 antibody was used to identify leukocytes and PE-labeled CD19 was 
used to identify B-cells). Both lymphoblasts and lymphocytes could be observed 
in the sample and the median FITC fluorescence in both of these cell types is 
depicted in figure 10. The differentiation between lymphocytes and lymphoblasts 
was made by their CD45 expression, which is lower in lymphoblasts than in 
lymphocytes. The gating strategy used to obtain the data that is represented in 
figure 10 is shown in the appendix (figure A3). Similarly as for the AML M1 
material, a largely reduced fluorescent signal (compared to the results in WBCs 
from blood), indicating low uptake efficiency, was observed in lymphocytes as well 
as in lymphoblasts for all peptides tested. Remarkably, the Tat-A11 peptide 
showed no increased FITC fluorescence compared to the negative control, 
whereas this peptide induced the most efficient uptake in BV173 and REH cell 
lines (figure 7; table 1).  
Because in none of the bone marrow samples evaluated Tat or any other 
peptide was able to efficiently internalize into cells other than monocytes, we 
cannot draw conclusions on specific uptake by malignant cells in bone marrow. It 
might be possible that the cells need to be incubated at 37 ºC to induce efficient 
endocytosis pathways, however we observed that monocytes were still able to 
effect phagocytosis, suggesting that at room temperature energy-dependent 
uptake mechanisms can occur. Another explanation is that the cells might first 
need to undergo proliferation before they are able to induce uptake of the 
peptides. In that case, growth factors might be added to the cells to induce 
proliferation, after which it can be studied if the cells acquire the ability to take up 
the peptides and if selective uptake by malignant cell populations in bone marrow 
can be observed. Furthermore, the experiments should be repeated using 
peripheral blood of patients with leukemia, to study whether the cells present in 
blood can take up Tat and the modified Tat peptides. This would especially be 
interesting because we observed efficient uptake of Tat by lymphocytes and 
granulocytes (figure 5B), suggesting that there is no need for the use of growth 
factors for cells derived from peripheral blood. However, it should be noted that 
the blood sample was used directly after it was obtained, whereas the bone 
marrow was frozen. This means that possible effects from freezing and thawing of 
the cells cannot be eliminated. All in all, at this moment there is no sufficient data 
to draw conclusions on the ability of the modified Tat peptides to induce specific 
cellular uptake by leukemic cells present in bone marrow.  
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Figure 10 – A) Summary of flow cytometry results for CPP uptake in cells present in bone marrow 
derived from a patient with B-ALL. The median FITC fluorescence for uptake of each peptide is 
depicted for a population of lymphocytes and lymphoblasts.  
 
6.3 Conclusion 
Herein, we have shown that a minimal modification of the lysine side-chains of Tat 
peptides modulates the uptake behavior of these peptides in various cell lines. As 
reported in chapter 5, in HEK cells these modified peptides are not able to induce 
cellular uptake. Strikingly, we observed uptake of these peptides in HeLa cells, 
with several of the modified Tat peptides being taken up equally well as Tat itself. 
This specific uptake by HeLa cells remained present when the internalization of 
the peptides was studied in a co-culture of HEK and mCherry-labeled HeLa cells. 
This shows that the preferential uptake by HeLa cells is not due to enzymatic 
conversion of the modified Tat peptides by enzymes that might be expressed by 
HeLa cells. Another clue that observed specificity is enzyme-independent was 
obtained when the proteolytically more stable Tat-a(01), with a D-amino acid side 
chain modification, showed similar uptake behavior as Tat-A(01). To gain more 
information about the endocytotic pathway employed by HeLa cells, uptake 
studies using various endocytosis inhibitors were employed, however, this yielded 
no conclusive results. This might indicate that the difference in uptake behavior 
between HEK and HeLa cells is caused by proteoglycans present on the cell 
surface. Because no uptake in HeLa cells was observed using a modified Tat 
peptide in which the lysine side chain was acetylated (Tat-Ac(10)) we feel that the 
positioning of the positive charges on the lysine side-chain is responsible for 
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inducing the preferential uptake by tumor cell lines. However, more experiments 
are required to substantiate this theory.  
The uptake of Tat and the modified tat peptides was also studied in white 
blood cells obtained from a healthy donor, showing that only Tat could be 
efficiently internalized in these cells. This prompted us to study the internalization 
efficiency of the modified Tat peptides in various leukemic cell lines. We observed 
that the modified Tat peptides could be efficiently internalized in these cell lines, 
with intriguingly a strong variation in efficiency of uptake between the modified 
peptides in each cell line tested (table 1). These findings indicate that it might be 
possible to identify a suitable side chain modification to induce specific uptake in a 
distinct cell line, which offers an interesting diagnostic opportunity for various 
types of leukemia. Furthermore, it is highly interesting to attach anticancer drugs 
to the modified peptides, to study their therapeutic potential in leukemic cell lines. 
However, there is still much research required to both elucidate the uptake 
mechanism of the modified peptides, and to extend the uptake experiments to 
cells that are directly derived from patients (peripheral blood, bone marrow).  
6.4 Experimental section 
General  
Fetal bovine serum (FBS) was obtained from Integro (Zaandam, The Netherlands), plain 
Dulbecco’s Modified Eagle Medium (DMEM), Iscove's Modified Dulbecco's Medium 
(IMDM), Roswell Park Memorial Institute culture medium (RPMI-1640) and trypsin/EDTA 
were from PAA Laboratories (Pasching, Austria). HeLa-CLL2 and Human Embryonic 
Kidney cells were obtained from American Type Culture Collection (ATCC, Manassas, 
U.S.A.). mCherry labeled HeLa cells were kindly donated by the group of Matthieu Piel 
(Institut Curie, Paris, France). DNase was obtained from Roche applied Science. 
Antibodies used for flow cytometry were obtained from Beckman Coulter. All other 
chemicals were purchased from Baker, Fluka or Sigma Aldrich and were used as received. 
Peptide synthesis and purification 
The synthesis and purification of the peptides used in this study was described in our 
earlier work in chapter 5 (Bode, Bioconj Chem, 2015), with the exception of Tat-a(01) and 
Tat-Ac(01). Tat-a(01) was synthesized using the same procedure as for Tat-A(01). For Tat-
Ac(01), after Mtt-removal, the free amine groups of the lysine side chain were capped 
using an excess of a pyridine/Ac2O mixture (1:1, v/v) in DMF and incubating the resin for 5 
minutes in this mixture.  
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Cell culture  
HEK 293, HeLa-CCL-2 and mCherry HeLa cells were maintained in sterile conditions in 
Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS). Cells were maintained on tissue culture plastic and kept at 37 °C 
in a humidified atmosphere of 7.5% CO2. Cells were passaged every 2-3 days. Prior to 
cellular uptake studies, cells within a confluent layer were detached using trypsin/EDTA. 
Cells were then resuspended in FBS-supplemented DMEM and the number of cells was 
counted using a standard inverted microscope and a cell counting chamber (Fuchs-
Rosenthal).  
HL-60, THP-1, KG1a, BV-173 and REH cells were maintained in sterile conditions in IMDM 
medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS). Cells 
were maintained on tissue culture plastic and kept at 37 °C in a humidified atmosphere of 
5% CO2. Cells were passaged every 2-3 days. Prior to cellular uptake experiments, cells 
were spun down for 5 minutes at 1500 rpm, thoroughly washed with cell culture medium 
and the number of cells was counted using a standard inverted microscope and a cell 
counting chamber (Fuchs-Rosenthal). 
CLSM analysis of uptake in HEK and HeLa cells 
HEK or HeLa-CCL-2 cells were seeded in 8-well chambered coverslips that were coated 
with a 0.1% solution of gelatin in PBS (Nunc, Wiesbaden, Germany) at a density of 40,000 
cells (one day prior) or 20,000 cells per well (two days prior) to the experiment. Cells were 
incubated with the 5 µM peptide for 30 min at 37 ºC. Cells were washed twice after 
incubation with DMEM + 10 % FCS and living cells were analyzed immediately by confocal 
microscopy using a TCS SP2 confocal microscope (Leica Microsystems, Mannheim, 
Germany) equipped with an HCX PL APO 63 x N.A. 1.2 oil immersion lens. Fluorescein 
was excited at 488 nm and emission was collected between 500 and 550 nm. 
For the HEK/mCherry HeLa co-culture experiments, a mixture of 20,000 HEK and 20,000 
mCherry HeLa cells were seeded one day prior to the experiment in each well of the above 
mentioned chambered coverslips. The same protocol for cellular uptake was then 
performed as described above. Fluorescein was excited at 488 nm and emission was 
collected between 500 and 550 nm, mCherry was excited by a 561 nm laser and emission 
was collected between 600 and 650 nm.  
Flow cytometry experiments with HEK and HeLa cells  
HEK or HeLa cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) one 
(60,000 cells/well) or two (30,000 cells/well) days prior to the experiment. On the day of the 
experiment, cells were incubated with the peptide solutions (5 µM) for 30 min at 37 °C in 
RPMI + 10% FBS. After washing the cells with HBS buffer pH 7.4 (10 mM HEPES, 135 
mM NaCl, 5 mM KCl, 5 mM MgCl2, 1.8 mM CaCl2), cells were detached by trypsinization 
for 5 minutes, spun down and resuspended in 200 µL RPMI + 10% FCS. Afterwards, the 
cells were spun down again and resuspended in HBS buffer supplemented with 0.1% 
bovine serum albumin (BSA). The fluorescence was measured using a FACSCalibur flow 
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cytometer (BD Biosciences, Erembodegem, Belgium) and subsequently data was analyzed 
with the Summit software (Fort Collins, U.S.A.). Results were based on 10,000 gated cells. 
For analysis of the HEK/mCherry HeLa co-culture, a mixture of 30,000 HEK cells and 
30,000 mCherry HeLa cells was seeded in each well of a 24-well plate (Sarstedt, 
Numbrecht, Germany) one day prior to the uptake experiments. The experimental 
procedure was the same as described above for HEK or HeLa cells. The fluorescence was 
measured using a Cyan flow cytometer (Beckman Coulter Inc.) and the data was analyzed 
using the Summit Software. Results were based on 10,000 gated cells. 
Inhibition of endocytotic pathways in HeLa cells 
HeLa cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) one day 
(60,000 cells/well) prior to the experiment. On the day of the experiment, cells were 
incubated with the peptide solutions (5 µM) for 30 min at 37 °C in RPMI + 10% FBS. 
Incubation was in presence of various endocytosis inhibitors. For genistein a concentration 
of 500 µmol/l was used, for MβCD a concentration of 10 µmol/l was used, for CPZ a 
concentration of 15 µg/ml was used and amiloride was added in a concentration of 4 mM. 
Solutions were made in RPMI. After washing the cells with HBS buffer pH 7.4 (10 mM 
HEPES, 135 mM NaCl, 5 mM KCl, 5 mM MgCl2, 1.8 mM CaCl2), cells were detached by 
trypsinization for 5 minutes, spun down and resuspended in 200 µL RPMI + 10% FCS. 
Afterwards, the cells were spun down again and resuspended in HBS buffer supplemented 
with 0.1% BSA. The fluorescence was measured using a FACSCalibur flow cytometer (BD 
Biosciences, Erembodegem, Belgium) and subsequently data was analyzed with the 
Summit software (Fort Collins, U.S.A.). Results were based on 10,000 gated cells 
Flow cytometry experiments with WBCs and RBCs 
For uptake experiments in WBCs, peripheral blood was drawn from a healthy individual on 
the day of the experiment. Subsequently, the RBCs were lysed from the blood using 
erythrocyte lysis buffer pH 7.4 (75 mM NH4Cl; 5 mM KHCO3; 0.05 mM EDTA-4Na) and 
incubation for 10 minutes at RT. Subsequently, the samples were spun down for 10 
minutes at 1500 rpm and afterwards the supernatant was discarded. The pellet was 
washed with PBS twice, and afterwards the amount of WBCs was counted. The cells were 
resuspended in 10% FBS-containing IMDM so that there were 150,000 cells per sample. 
Subsequently, the cells were incubated with the peptide solutions (5 µM) for 30 min at 37 
°C in RPMI + 10% FBS. After washing the cells with PBS buffer, the cells were treated with 
trypsin/EDTA for 5 minutes to remove membrane-bound peptide, spun down and 
resuspended in 200 µL IMDM + 10% FCS. Afterwards, the cells were spun down again and 
resuspended in PBS buffer supplemented with 0.1% BSA. The fluorescence was 
measured using an FC500 flow cytometer (Beckman Coulter Inc. Miami) and the data was 
analyzed using the Kaluza software (Beckman Coulter). Results were based on 10,000 
gated cells. 
For uptake experiments in RBCs, peripheral blood was drawn from a healthy individual on 
the day of the experiment. The cells were spun down at 1500 rpm for 10 minutes and the 
pellet was resuspended in PBS. The amount of RBCs was counted and dilutions were 
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made so that there were 150,000 RBCs per sample. Subsequently, the cells were treated 
as described above, only the trypsin/EDTA was excluded from the procedure.  
Flow cytometry experiments with leukemic cells 
On the day of the experiment, HL-60, THP-1, KG1a, BV-173 or REH cells were washed 
twice in 10% FCS-containing RPMI, counted and distributed in 24-well plates (Sarstedt, 
Numbrecht, Germany) so that there were 150,000 cells per well. The cells were incubated 
with the peptide solutions (5 µM) for 30 min at 37 °C in RPMI + 10% FBS. After washing 
the cells with PBS buffer, the cells were treated with trypsin/EDTA for 5 minutes to remove 
membrane-bound peptide, spun down at 1500 rpm in 5 minutes and resuspended in 200 
µL IMDM + 10% FCS. Afterwards, the cells were spun down again and resuspended in 
PBS buffer supplemented with 0.1% bovine serum albumin (BSA). The fluorescence was 
measured using an FC500 flow cytometer (Beckman Coulter Inc. Miami) and the data was 
analyzed using the Kaluza software (Beckmam Coulter). Results were based on 10,000 
gated cells. 
Flow cytometry experiments with bone marrow cells 
On the day of the experiment, frozen bone marrow (liquid nitrogen) was thawed 
(approximately 1 mL), to this 1.5 mL of FCS, 150 µL of a 25 mM solution of MgCl2 and 100 
µL of an 2 mg/mL solution of DNAse were added. Then, 4 mL of IMDM culture medium 
was added and the mixture was incubated at room temperature for 10 minutes. Afterwards, 
the cells were spun down at 1000 rpm for 5 minutes and resuspended in 4 mL FACS 
buffer. The cells were counted and diluted so that the cells could be distributed at a density 
of 200.000 cells/sample in a volume of 100 µL. Next the cells were incubated with 5 µM 
peptide in FACS buffer (containing 0.1% BSA) for 30 minutes at room temperature. For the 
AML samples, 5 µL CD33 and 5 µL CD45 were added to each tube. For the AML M4 
samples, CD14 was used as additional antibody, of which 2 µL was added to each sample. 
For the ALL samples 5 µL CD19 and 5 µL CD45 were added to each sample. Hereafter, 
the cells were spun down again and resuspended in PBS buffer supplemented with 0.1% 
BSA. The fluorescence was measured using an FC500 flow cytometer (Beckman Coulter 
Inc. Miami) and the data was analyzed using the Kaluza software (Beckman Coulter). 
Results were based on one minute of gating cells. 
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Appendix 
 
 
Figure A1 – gating strategy used to obtain the data (median FITC fluorescence for lymphocytes and 
CD33+ blasts) presented in figure 9A. No CD14 positive cells were observed, which corresponds to an 
absence of monocytes in this sample. The plots shown in this figure were obtained for the uptake of 
Tat. The same gating strategy was used to obtain the median FITC fluorescence in lymphocytes and 
blasts for the modified Tat peptides.  
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Figure A2 – gating strategy used to obtain the data (median FITC fluorescence for lymphocytes, 
monocytes, CD33- blasts and CD33+ blasts) presented in figure 9B. The plots shown in this figure 
were obtained for the uptake of Tat. The same gating strategy was used to obtain the median FITC 
fluorescence in lymphocytes, monocytes, CD33- blasts and CD33+ blasts for the modified Tat 
peptides.  
 
Figure A3 – gating strategy used to obtain the data (median FITC fluorescence for lymphoblasts and 
lymphocytes) presented in figure 9B. The plots shown in this figure were obtained for the uptake of 
Tat. The same gating strategy was used to obtain the median FITC fluorescence in lymphoblasts and 
lymphocytes for the modified Tat peptides.  
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Chapter 7 
 
Sensing cell adhesion using polydiacetylene-containing 
peptide amphiphile fibers 
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7.1 Introduction 
Polydiacetylenes are an interesting class of conjugated polymers with intrinsic 
optical properties. In addition to absorbing light in the visible region they can 
undergo a color change in response to external stimuli, which makes them 
promising molecular probes for sensing their environment.1-3 Polydiacetylenes 
can be easily prepared through topochemical polymerisation of the diacetylene 
monomers using ultraviolet (UV) irradiation.4 However, their formation is subject to 
the distance between the monomers and the angle between the moieties, which 
must be ~4.9Å and ~45° respectively.5 Systems in which these requirements are 
met include fibers,6-8 monolayers,9-11 and vesicles 12,13 Charych et al. were first to 
utilize the sensing properties of polydiacetylenes by decorating polydiacetylene-
based liposomes with sialic acid and monitoring the color change of the 
polydiacetylene backbone upon addition of the influenza virus.14 They found that 
the ultraviolet-visible (UV-Vis) spectrum of the liposomes shifted from ~630nm to 
~490nm, which coincides with a color change from blue to red upon binding of the 
virus. Since then various polydiacetylene-based sensors have been designed to 
detect a wide variety of analytes such as microorganisms,15,16 various proteins,17-
19 and even membrane perturbing events in cells.20,21 In these sensor systems the 
polydiacetylene was incorporated in coatings, vesicles or liposomes. 
Polydiacetylene formation has also been realized in well-organized peptide 
amphiphile fibers, as a means of creating disassembly-resistant architectures, but 
not to exploit their colorimetric properties. In one example, Stupp and co-workers 
functionalized the peptide Lys-Lys-Leu-Leu-Ala-Lys with a diacetylene-containing 
alkyl tail and found that these amphiphilic molecules could self-assemble into 
fibers.6 Furthermore, the diacetylenes could then be cross-linked using UV-light to 
yield fibers with an intense blue color which is indicative of polydiacetylene 
formation. In similar work, polymerized fibers were prepared from a diacetylene-
containing alkyl tail coupled to a peptide segment based on the circumsporozoite 
(CS) protein of a malaria parasite.8,22,23  
Peptide-based materials can be efficiently tailored to induce biological 
function, for example to facilitate cell adhesion. The RGD domain is probably the 
most applied cell adhesion motif, and as such has been introduced onto 
numerous materials.24-33 An example includes the peptide amphiphile fibers used 
by Webber et al. to culture bone-marrow mononuclear cells.34 However, the alkyl 
tail in these fibers did not contain a diacetylene functionality. A two-dimensional 
polydiacetylene-based material was used for cell culture by Biesalski and co-
workers. They synthesized amphiphiles composed of a 10,12-tricosadiynoic acid 
tail and a GRGDSP head group.9 They were able to use diacetylenes to cross-link 
monolayers comprised of these peptide amphiphiles. In this example the 
polydiacetylene functionality was again only used to stabilise the monolayers. 
Until now, the sensory properties of polydiacetylenes have not been employed in 
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conjunction with any type of cell binding scaffold to detect the interaction with 
mammalian cells. This would be a valuable feature as it would allow a direct 
visualization of the adhesion process and also could be used to study cell 
migration in materials by visual inspection.  
 In this study we report to the best of our knowledge, for the first time, 
polydiacetylene-containing peptide amphiphile fibers that have the right level of 
stability to be used as a sensitive colorimetric sensor for cell adhesion (Figure 1). 
To achieve this we functionalized diacetylene-containing peptide amphiphiles with 
the cell adhesion motif RGDS and mixed these with spacer (non-RGDS) 
diacetylene-containing amphiphiles to form nanofibers. We found that the 
propensity of the RGDS fibers to change color in response to cell adhesion could 
be tuned by varying the C-terminal amino acid of the spacer amphiphiles. It was 
found that the degree of the color change was related to the amount of RGDS 
amphiphile present in the fiber. 
 
Figure 1 - schematic representation of the project concept. 
 
7.2 Results and discussion 
The amphiphiles were designed to contain two structural components, the 
hydrophilic peptide sequence found in silk-worm silk, containing repeating glycine 
and alanine residues, and a 10,12-pentacosadiynoic acid alkyl tail.36-38 In this way 
the formation of stable fibers was enabled as a result of both the hydrophobic 
interactions of the alkyl tails and the β-sheet-forming character of the peptides. By 
manipulating the C- terminal amino acid of the spacer amphiphile (C25Gly-Ala-Gly-
Ala-Xaa), we aimed to tune the stability of the fibers and thus the susceptibility of 
the polydiacetylene backbone to color change (figure 2). Previous studies have 
shown that the amino acid sequence of the peptide segment in these fibers can 
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have a marked effect on the sensitivity of the diacetylene backbone to 
environmental changes.11,37 In order to allow for cell adhesion on the surface of 
the fibers we synthesized an amphiphile with the sequence 10,12C25-Gly-Ala-Gly-
Ala-Lys-Arg-Gly-Asp-Ser (RGDS amphiphile) and as a control an amphiphile with 
the scrambled cell adhesion sequence 10,12C25-Gly-Ala-Gly-Ala-Lys-Asp-Gly-Ser-
Arg (scrambled amphiphile) (figure 2). In order to obtain tunable nanofibers with 
respect to composition, a spacer amphiphile was mixed with the RGDS 
amphiphile or scrambled amphiphile, the structures are shown in figure 2. The 
first letter of the fiber name indicated the amino acid at the C-terminal position of 
the spacer amphiphile. In this way we aimed to create an RGDS-containing fiber 
that was stable enough to resist changing color at the temperature required for 
cell growth but sensitive enough to change color due to cell adhesion on the 
surface of the fibers. 
Figure 2 - The structures of the amphiphiles used in this study.  
For the fiber solutions to be compatible with cell growth, fiber formation 
should be possible in phosphate buffered saline (PBS). All of the spacer 
amphiphiles were able to form fibers in PBS with the exception of the E-spacer 
and D-spacer amphiphiles which were first formed in water and diluted with 
concentrated PBS. Both of the E- and D-spacer fiber solutions became dark 
purple and slightly aggregated upon the addition of PBS. The structure of the 
various fibers was investigated using transmission electron microscopy (TEM) 
(figure 3). All the fibers had a similar ribbon-like morphology, with the exception of 
fibers consisting of the K-spacer amphiphile in which small aggregates comprized 
of short fibers were observed in addition to extended fibers. 
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Figure 3 – Transmission electron micrographs of the different fibers. The letter denotes the C-terminal 
amino acid of the spacer amphiphile, for example the E-fibers have the amino acid sequence Gly-Ala-
Gly-Ala-Glu. A) E-fibers, scale bars represent 500 nm and 200 nm (magnification). B) K-fibers, scale 
bars represent 2 µm and 500 nm (magnification). C) A-fibers, scale bars represent 1 µm and 200 nm 
(magnification). D) S-fibers, scale bars represent 500 nm and 100 nm (magnification). E) V-fibers, 
scale bars represent 5 µm and 200 nm (magnification). F) D-fibers, scale bars represent 2 µm and 500 
nm (magnification). G) Q-fibers, scale bars represent 1 µm and 200 nm (magnification). H) N-fibers, 
scale bars represent 1 µm and 500 nm (magnification).  
Inspired by the results obtained by Stupp and co-workers we initially 
chose to mix the spacer amphiphile and RGDS amphiphile or scrambled 
amphiphile in a ratio of 6:1 respectively (Figure 4A).34 Subsequently, we 
investigated the susceptibility to color change of the polydiacetylene backbone in 
the RGDS-containing fibers with respect to increasing temperature. We found that 
merely varying the C-terminal amino acid of the spacer amphiphile had a marked 
effect on the temperature at which a color change occurred in the fibers. The E-
RGDS fibers were most sensitive to a temperature induced color change, 
changing color at 37 °C, whereas the A-RGDS fibers were most temperature 
stable, only exhibiting a color change at 53 °C (Figure 4B). The RGDS fibers 
based on the remaining spacer amphiphiles exhibited a temperature induced 
color change at temperatures spanning this range (Figure 4B). The temperature 
at which the fibers exhibit a color change does not correlate directly with the β-
sheet forming propensity of the C-terminal amino acid, which indicates it occurs 
as a result of more subtle effects.40 The fact that the different RGDS-containing 
fibers changed color at different temperatures also suggests that the color change 
due to cell adhesion will be more pronounced in some fibers than in others, and 
thus that the choice of spacer amphiphile is a crucial element in the overall design 
of the sensor. 
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Figure 4 – A) Schematic representation of the assembly of RGDS-fibers in water and the 
polymerization using UV light to cross-link the amphiphiles. The spacer amphiphiles are shown in blue 
and the RGDS amphiphiles are shown in green. B) Table showing the transition temperatures of the 
various RGDS-fibers composed of a 6:1 ratio of spacer amphiphile to RGDS amphiphile. The first 
letter of the fiber name indicates the amino acid at the C-terminal position of the spacer amphiphile. 
With this library of peptide fibers in hand, we were able to test the ability 
of HeLa cells to adhere to their surface and investigate the effect of cell adhesion 
on the color of the polydiacetylene backbone of the fibers. We performed 
brightfield microscopy on living cells, which not only allowed the analysis of the 
color of the sample, but also provided information about the cell morphology 
(Figure 5A). The samples were prepared by mixing detached HeLa cells (40,000 
per sample) in phenol-red free culture medium with the fiber solutions so that a 
concentration of 0.5 mg/mL of the fibers was obtained. Phenol-red free culture 
medium was used so that a potential color change could be clearly visualized. 
The mixture of HeLa cells and fibers was then seeded in 8-well chambered 
microscopy slides. The cells were incubated for 18 hours at 37 °C. For each 
experiment, a positive control was carried out by seeding 40,000 HeLa cells onto 
a gelatin-coated chamber of the microscopy slides. Furthermore, negative 
controls were performed using fibers that were not functionalized with RGDS 
(spacer fibers) as well as fibers that contained the amphiphiles with the scrambled 
cell adhesion sequence DGSR. In order to be able to determine the extent of the 
color change more accurately, control samples without cells were prepared for 
every experiment. These samples were treated in the same manner as the 
samples with cells. To ensure that the buffer, fiber and serum concentrations in 
these samples were the same as in the samples containing cells, the sample 
preparation was performed by mixing the fiber solution with an equal amount of 
phenol-red free medium supplemented with 10% FBS. After the incubation period, 
all samples were immediately studied using brightfield widefield microscopy.  
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Figure 5 - A) Brightfield widefield microscopy images of cell adhesion experiments and the 
corresponding UV-vis absorption spectra. The color captured by the brightfield camera is compared 
between the scrambled-fibers and the RGDS-fibers. Shown here are the results for the E-, K- and A-
fibers. Because the E-fibers have the tendency to form large aggregates in the presence of cell culture 
medium, some of these superstructures can be observed in the E-scrambled sample. We did not 
observe similar aggregates for the K- and A-fibers. Scale bar represents 150 µm. B) UV-vis spectra 
recorded after the RGD-fibers and scrambled-fibers were incubated for 18h in the presence of 
detached HeLa cells; a color-shift from 630 nm to 550 nm is only observed for the K-RGDS fibers. 
The gelatin control was used to verify the quality of the samples and to 
set the white-balance for the brightfield camera. These experiments showed that 
in general RGDS-fibers promoted cell adhesion, giving rise to nicely spread cells, 
and this observation was independent of the type of spacer amphiphile in the 
fibers. There were three exceptions; in both the Q-RGDS and the N-RGDS 
samples the cell count was severely reduced and a similar effect was seen for the 
D-RGDS fibers, although in this case the effect was less pronounced (figure 6)  
With respect to the colorimetric properties, only the K-RGDS-fibers 
showed a color change from blue to pink upon cell adhesion and importantly, both 
the spacer and scrambled fiber samples retained their original blue color. As was 
expected from the temperature UV-Vis data, the E-fibers already changed color to 
pink upon incubation at 37 °C. RGDS-fibers based on the A-, V- and S-spacer 
amphiphiles remained blue upon cell adhesion, which suggests that the packing 
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in these fibers is too stable (figure 6). The D-, N- and Q-fiber samples also 
remained blue, but this could be attributed to the diminished cell viability observed 
in these samples. The negative controls showed that HeLa cells were not able to 
adhere to any of the non-functionalized spacer-fibers, nor to the fibers with the 
scrambled domain. In these samples, only detached cells with a round 
morphology were observed.  
 
Figure 6 – A) Brightfield widefield microscopy images of cell adhesion experiments. The color 
captured by the brightfield camera is compared between the spacer-fibers, RGDS-fibers and 
scrambled-fibers. Shown here are the results for the S-, V- and D-fibers. Scale bar represents 150 µm. 
B) UV-vis spectra recorded after the RGD-fibers were incubated for 18h in the presence of detached 
HeLa cells; no color shift is observed for any of these samples. 
 
To study the color change caused by cell adherence to the fibers in more 
detail, UV-vis spectra of the RGDS-fibers and scrambled fibers were recorded 
after incubation with detached HeLa cells for 18h at 37 °C (Figure 5B). The extent 
of the color change was quantified by means of the chromatic ratio. The results 
are summarized in Figure 7A and clearly show that the K-RGDS fibers displayed 
the largest color change upon cell adhesion. These experiments were in full 
agreement with the brightfield microscopy experiments. 
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Figure 7 – A) Chromatic ratios calculated for all the fibers that were suitable substrates for cell 
adhesion. B) Chromatic ratios calculated for the K-RGDS fibers with a varying RGDS content. 
To investigate if the density of the RGDS motif present in the fibers had 
an effect on cell adhesion and thus the color change, a collection of fibers was 
made in which the ratio of spacer amphiphile to RGDS amphiphile was varied 
from 3:1 to 24:1. Since only the K-fibers showed distinct color-changing behavior 
upon cell adhesion, we performed the RGDS-ratio studies only with the K-fibers. 
For this fiber series, both brightfield microscopy and UV-vis spectroscopy 
experiments were performed as described above. These studies showed that a 
ratio of 6:1 spacer amphiphile to RGDS amphiphile gave the largest color change, 
which was also reflected in the chromatic ratio calculated for this sample (figure 
7B). Interestingly, increasing the RGDS content by making the 3:1 fibers, led to a 
less pronounced color shift and importantly, only cells that were not spread were 
observed in this sample. The intensity of the color change of the fibers decreased 
as the RGDS-content in the fibers was decreased from 6:1 to 24:1. For the 9:1 
and 12:1 samples the brightfield microscopy showed that some cells were still 
able to adhere to the fibers, although the amount of spread cells seemed to have 
decreased significantly with the reduced RGDS-content (figure 8). Consequently 
the chromatic ratio was found to be much lower in these samples. Hardly any cell 
adhesion was observed for the sample with the lowest RGDS content, 24:1, and 
correspondingly no color change was observed.  
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Figure 8 - Brightfield micrographs of the K-fibers at various RGDS-contents. 
To investigate the cytotoxicity of the RGDS-containing fibers, live/dead 
assays based on calcein AM/ethidium homodimer-1 (EthD-1) were performed. 
The samples were prepared similarly to the procedure described above for the 
brightfield microscopy experiments. After the incubation period, the cells were 
treated with calcein AM and EthD-1 and were analyzed immediately by confocal 
laser scanning microscopy (CLSM). This experiment showed that cells adhering 
to the RGDS-fibers were viable and nicely spread. No significant differences in 
viability and cell count were observed among the various RGDS-fibers, with the 
exception of the previously mentioned N-, Q- and D-RGDS fibers. Furthermore, 
for all spacer- and scrambled-fibers, only cells with a round morphology were 
observed, however the viability of these cells varied with the incorporated spacer 
amphiphile. For example, for the E-fibers all observed cells in the negative 
controls were dead, whereas for the K-fibers the cells were still viable, albeit not 
spread. The series of K-RGDS-fibers with a gradual decreasing amount of RGDS 
were also studied using the live/dead assay (9).  
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Figure 9 - Cell viability images for the K-RGDS fibers and K-scrambled fibers. Images are composed 
from overlays of the calcein (green) and EthD-1 (red) signals. Scale bar represents 150 µm. 
Microscopy images for all other fibers can be found in figure 10. Our 
previous experiments using brightfield microscopy and UV-vis spectrometry 
already suggested that HeLa cells could best adhere to the K-fibers made out of a 
6:1 spacer-amphiphile to RGDS-amphiphile ratio, and the cell viability assay 
again confirmed that the 6:1 fibers are the best substrate for cell adhesion. 
 
Figure 10 - Cell viability images for the E-, A-, D-, V- and S-RGDS fibers. Images are composed from 
overlays of the calcein (green) and EthD-1 (red) signals. Scale bar represents 150 µm. 
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The microscopy data from the cell viability experiments were used to 
quantify both the total amount of cells in each sample, and the amount of spread 
cells in each sample. It was found, as expected, that a ratio of 6:1 spacer 
amphiphile to RGDS amphiphile yielded the most optimal material for cell 
adhesion (figure 12A). Interestingly, increasing the RGDS content by making the 
3:1 fibers, led to a large decrease in the total amount of cells, and importantly, 
only cells with a round morphology were observed in this sample. Furthermore, a 
gradual decrease in cell count and spread cells to total cells ratio was found when 
the RGD content was systematically lowered (figure 11A). This decrease 
correlates with the decrease in the chromatic ratio (figure 7B). 
 
Figure 11 – A) Total amount of cells and spread cells:total cells ratio acquired from the live/dead 
assay. Data is composed out of 4 to 6 confocal microscopy images. Total amounts of cells are counted 
for each sample and depicted in blue numbers above the bars. The bars indicate the ratio between the 
amount of spread cells and total cell count. B) UV-vis absorption spectra of the K-RGDS-fibers 
recorded after 0 and 10 minutes of incubation with the isolated human integrin protein. This shows a 
slight color shift to pink after an incubation of 10 minutes 
To investigate the influence of the fiber concentration on the cell adhesion 
properties and color change upon cell binding, the K-fiber solutions were also 
prepared at concentrations of 0.5 mg/ml and 0.75 mg/ml and were used to 
prepare samples for microscopy analysis as described above. We did not observe 
significant color changes in the RGDS-containing samples and investigation by 
phase contrast microscopy revealed that for the 0.75 mg/ml fiber solutions about 
half of the observed cells remained detached while the rest of the population did 
adhere to the fibers. However, this was not sufficient to induce a similar color 
change as observed for the sample prepared from 1 mg/ml fiber solution. The 
amount of adherent cells was further diminished when a concentration of 0.5 
mg/ml was used. Microscopy images for this experiment are shown in figure 12. 
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Figure 12 – Phase contrast micrographs of the K-fibers at concentrations. A) Experiment performed 
with fiber solutions at a concentration of 0.75 mg/mL. B) results with fiber solutions at 0.5 mg/mL (B). 
Integrin-mediated cell adhesion is induced by recognition of the RGD 
domain in the fibers by integrin receptors and this process is comprised of 
multiple events that can partially take place at the same time. Initially, cell 
attachment is induced by cell contact with the ECM that leads to ligand binding, 
allowing the cell to stick to a surface. Then, the cell starts to flatten and the 
cytoplasm will spread out over the substrate. This induces the organization of the 
actin cytoskeleton, after which focal adhesions will be formed that link the 
cytoskeleton to the ECM. Most probably, the color change of the K-RGDS-fibers 
is induced during the first two steps of the cell adhesion process. To investigate 
whether cell attachment or cell spreading is most crucial for the color-changing 
behavior of the K-RGDS-fibers, UV-vis experiments were performed in which the 
fibers were incubated with the isolated human αVß3 integrin protein and followed 
in time for 10 minutes (Figure 11B). During this experiment, a slight increase for 
the absorbance maximum at 550 nm and a small decrease in the absorbance at 
630 nm were observed. This suggests that the initial cell binding to the fibers 
induces a small color change, but that structural changes imposed on the 
diacetylene backbone by cell spreading are likely to be the most important step to 
set off the color change. Interestingly, this mirrors the slight color change 
observed for the 3:1 K-spacer:K-RGDS fibers for which it was found that cells 
could adhere to the surface, but were not able to spread (Figure 7B and Figure 
11A). When the integrin binding experiment was performed using the stable A-
RGDS-fibers, it was found that these fibers again remained blue. 
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7.3 Conclusion 
In conclusion, polydiacetylene-containing peptide amphiphile fibers functionalized 
with the cell-binding moiety RGDS were designed to be able to detect the effect of 
cell adhesion on the chromatic properties of the polydiacetylene backbone. It was 
found that the K-RGDS fibers were most susceptible to a color change, from blue 
to pink, induced by cell adhesion. RGDS containing fibers based on the spacer 
amphiphiles V, A, S allowed the adhesion of viable cells, however, without 
undergoing a color change. This may be due to the fact that the peptide 
components in these fibers have a more stable packing. The E-RGDS fibers were 
also a suitable substrate for cell adhesion, however these fibers were sensitive to 
the incubation temperature required for the cell studies, and thus turned pink upon 
incubation irrespective of cell adhesion. A broad conclusion appears to be that 
uncharged residues have the propensity to result in overly stable fibers that have 
no switching behavior at physiologically relevant conditions. Anionic residues, on 
the other hand, result in fibers that are insufficiently stable, so that only the 
cationic lysine apparently yields functional fibers. The exact mechanism of the 
blue to red color change in polydiacetylenes is still not clearly understood. 
However, it has been established that the moieties attached to the 
polydiacetylene, in our case the peptide plays a central role in the color transition 
as it influences the conformation of the polydiacetylene backbone, more 
specifically the side chain affects the rotation around the C-C bonds and thus the 
overlap between adjacent π-orbitals.41,42 As the color transition is governed by 
such subtle factors, it is difficult to analyze the contribution of the C-terminal 
amino acid to the color change caused by cell adhesion. 
In addition, the N-RGDS and Q-RGDS fibers were found to be cytotoxic 
to cells and the cell count was notably reduced in these samples. The D-RGDS 
fibers were also suboptimal for cell adhesion and a reduced cell count was 
observed in these samples. Furthermore, we were able to determine that a ratio 
of 6:1 K-spacer:RGDS was optimal for cell adhesion and consequently the 
biggest change in color was observed for the K-RGDS fibers with this ratio. This 
suggests that the RGDS spacing in the fibers is an important factor in the degree 
of cell adhesion and spreading. Intriguingly, it was ascertained that the addition of 
human αVß3 integrin could already trigger a slight color change in the 
polydiacetylene backbone of the 6:1 K-RGDS fibers. Nonetheless, the steric 
crowding induced by cell spreading on the surface of the fibers is required to 
achieve a maximum color change in the polydiacetylene backbone. In the future 
we would like to use this system to track cell migration both in 2D and 3D 
environments by incorporating our material in a suitable hydrogel. Furthermore, 
the sensing system presented here offers interesting possibilities as a screening 
method for cell culturing.  
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7.4 Experimental procedures 
Materials 
All starting materials were used as received. Amino acids were obtained from 
Novabiochem. The 2-chlorotrityl resin (200-400 mesh) was obtained from Bachem. N,Nʹ′-
Diisopropylcarbodiimide (DIPCDI) was obtained from Biosolve. All other starting materials 
were obtained from commercial suppliers. Fetal bovine serum (FBS) was obtained from 
Integro (Zaandam, The Netherlands), plain Dulbecco’s Modified Eagle Medium (DMEM) 
and trypsin/EDTA were both from PAA Laboratories (Pasching, Austria). Phenol-red free 
Dulbecco’s Modified Eagle Medium (DMEM) and the Live/Dead® viability kit were obtained 
from Life Technologies (Thermo Fisher Scientific Inc., Waltham, U.S.A.). HeLa CCL-2 cells 
were obtained from American Type Culture Collection (ATCC, Manassas, U.S.A.). Human 
integrin αVβ3 protein in Triton X-100 formulation was obtained from Merck Millipore 
(Billerica, U. S. A.). Confocal laser scanning microscopy (CLSM) studies were performed 
on a Leica-microsystems (Mannheim, Germany) TCS SP2 AOBS system, installed on an 
inverted motorized DM IRE2 microscope and equipped with a dry HC PL apo CS 20x/0.70 
D lens. Brightfield images were obtained using the same microscope and objective. The 
images were acquired with a Leica DFC 420C color- camera operated by the LAS 
software. 
Synthesis of Peptide Amphiphiles.  
The peptide amphiphiles were synthesized from 1 g of 2-chlorotrityl resin (1 mmol/g). The 
resin was swollen in dry dichloromethane (DCM). 2 equivalents of the relevant amino acid 
and 3 equivalents of diisopropylethylamine (DiPEA) were dissolved in dry DCM and added 
to the resin. Subsequent couplings were carried out with 3.0 equivalents of the required 
amino acid, 3.3 equivalents of DIPCDI and 3.6 equivalents of 1-hydroxybenzotriazole 
hydrate (HOBt) in dimethylformamide (DMF), and all deprotections where achieved with 
20% piperidine in DMF. After each coupling and deprotection a Kaiser test was used to 
ensure the reaction had gone to completion.35 Finally 10,12-pentacosadiynoic acid was 
coupled to the peptide using 3 equivalents of the acid, 3.3 equivalents of DIPCDI and 3.6 
equivalents of HOBt. The peptide was cleaved from the resin by treatment of the resin with 
a mixture of trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/H2O (95:2.5:2.5) for 3 hours, 
followed by precipitation in ether or by removal of the solvents under reduced pressure. 
The peptides were lyophilized from acetic acid and purified using preparative HPLC. The 
peptides were characterized using analytical HPLC and LCMS. 
Reversed phase HPLC 
Semi-preparative HPLC was performed on a Shimadzu LC-20A Prominence system 
(Shimadzu, ’s Hertogenbosch, The Netherlands) equipped with a Gemini-NX C18 column, 
110A, 150x21.2 mm, particle size 10 µm (Phenomenex). Elution of the peptides was 
achieved with a water/acetonitrile gradient containing 0.1% trifluoroacetic acid (5-100% in 
40 mins, then 20 mins at 100%, flow 6 mL/min). Samples were dissolved in acetic acid. 
Analytical HPLC was performed on a Shimadzu LC-20A Prominence system 
(Shimadzu, ’s Hertogenbosch, The Netherlands) equipped with a Gemini-NX C18 column, 
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110A, 150x3 mm, particle size 3 µm (Phenomenex). Elution of the peptides was achieved 
with a water/acetonitrile gradient containing 0.1% trifluoroacetic acid (5-100% in 50 mins, 
flow 0.4 mL/min). Samples were dissolved in acetic acid at 1 mg/ml. 
Liquid Chromatography Mass Spectrometry (LC-MS) 
Mass spectra were recorded on a Thermo Finnigan LCQ-Fleet ESI-ion trap equipped with 
a C18 ReproSil column, 50x2 mm, particle size 3 µm (Screening Devices, Amersfoort, The 
Netherlands), elution with a water/acetonitrile gradient containing 0.1% formic acid, 
gradient 5-100% in 20 mins. Samples were dissolved in methanol at 0.2 µM. 
10,12C25-Gly-Ala-Gly-Ala-Glu-OH 
ESI-ion trap m/z: [M+H]+ 760.12 (calcd. 759.48)  
10,12C25-Gly-Ala-Gly-Ala-Lys-OH 
ESI-ion trap m/z: [M+H]+ 760.56 (calcd. 758.53) 
10,12C25-Gly-Ala-Gly-Ala-Ala-OH 
ESI-ion trap m/z: [M+H]+ 702.08 (calcd. 701.47) 
10,12C25-Gly-Ala-Gly-Ala-Ser-OH 
ESI-ion trap m/z: [M+H]+ 718.08 (calcd. 717.47) 
10,12C25-Gly-Ala-Gly-Ala-Val-OH 
ESI-ion trap m/z: [M+H]+ 730.12 (calcd. 729.50) 
10,12C25-Gly-Ala-Gly-Ala-Gln-OH 
ESI-ion trap m/z: [M+H]+ 759.12 (calcd. 758.49) 
10,12C25-Gly-Ala-Gly-Ala-Asp-OH 
ESI-ion trap m/z: [M+H]+ 746.10 (calcd. 745.46) 
10,12C25-Gly-Ala-Gly-Ala-Asn-OH 
 ESI-ion trap m/z: [M+H]+ 745.12 (calcd. 744.48) 
10,12C25-Gly-Ala-Gly-Ala-Lys-Arg-Gly-Asp-Ser-NH2 
 ESI-ion trap m/z: [M+H]+ 1174.3 (calcd. 1172.73) [M+H]2+ 588.00 (calcd. 587.37) 
10,12C25-Gly-Ala-Gly-Ala-Lys-Asp-Gly-Ser-Arg-NH2 
 ESI-ion trap m/z: [M+H]+ 1174.3 (calcd. 1172.73) [M+H]2+ 588.00 (calcd. 587.37) 
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Fiber preparation  
The peptide amphiphiles were dissolved in PBS (140 mM NaCl, 2.6 mM KCl, 1.5 mM 
KH2PO4, 10 mM Na2HPO4, pH 7.2) at concentrations of 1.0 mg/mL. The samples were 
sonicated for 15 minutes at 25 °C, subsequently heated to 90 °C and allowed to cool to 
room temperature in the water bath overnight. For the fibers with a C-terminal Asp and Glu, 
the samples were prepared at 2.0 mg/mL as described above and diluted with 2x PBS to 
give a final fiber concentration of 1.0 mg/mL. 
Polymerization  
Polymerizations were carried out on 1.0 mg/mL samples in a 4 mL glass vial (containing 
approximately 1.5 mL fiber solution), which was open and illuminated from above using a 
Bluepoint 2 UV lamp with a lamp-sample distance of 3 cm for 999 s. 
Temperature dependent UV-vis spectroscopy 
UV-Vis absorption spectra of the fiber samples during heating were recorded on a Jasco V-
360 spectrometer, with a temperature gradient of 5 °C/min, using a 1 cm quartz cuvette (a 
0.1 mm quartz cuvette was used to measure the K-RGDS fibers). The transition 
temperature was determined by fitting the decrease in absorption at 647 nm with 
temperature using a Hill 1 function in Origin.  
𝑦 = 𝐴! + 𝐴! − 𝐴! ( !!!!!!! )            (equation 1) 
From this equation the melting point of the structural elements can be determined as when 
k = x, then y = (Af +Ai)/2 where Ai is the starting value of the sigmoid and Af is the final 
value of the sigmoid. K is the midpoint of the sigmoid which is equal to the midpoint of the 
transition, thus k represents the melting point. The site cooperativity of the system is 
indicated by the fitting parameter, n.  
Transmission electron microscopy 
Transmission electron microscopy (TEM) samples were prepared by floating a carbon-
coated copper grid on a peptide amphiphile solution of 0.2 mg/mL for 5 min, followed by 
staining by floating the grid on a 1% solution of uranyl acetate in Milli-Q water for 30 
seconds. Finally, the grid was floated on Milli-Q water and the excess water was removed 
by blotting with paper filter. The TEM samples were visualized using a JEOL 1010 
transmission electron microscope set on an accelerating voltage of 60 kV. 
Cell culture 
HeLa cells were maintained in sterile conditions in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS). Cells were 
maintained on tissue culture plastic and kept at 37°C in a humidified atmosphere of 7.5% 
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CO2. Cells were passaged every 2-3 days. Prior to cell viability assays or cell adhesion 
studies, cells within a confluent layer were detached using trypsin/EDTA.  
Cells were then resuspended in phenol-red free DMEM supplemented with 10% FBS and 
the number of cells was counted using a standard inverted microscope and a cell counting 
chamber (Fuchs-Rosenthal). 
Brightfield Microscopy 
Fiber solutions (1 mg/mL in PBS) were prepared as previously mentioned. To each well of 
an 8-chambered coverslip (Nunc, Wiesbaden, Germany) 150 µL of the fiber solution was 
added. Then, 40,000 HeLa cells in 150 µL phenol-red free Dulbecco Modified Eagle 
Medium (DMEM) + 10% Fetal Bovine Serum (FBS) were seeded in each well. Wells 
coated with gelatin were used as a control sample and these were prepared by incubating 
the wells with a 0.1 % gelatin solution for 15 minutes, after which the excess gelatin was 
removed. In these control wells, 40.000 HeLa cells were seeded in 300 µL phenol-red free 
DMEM + 10% FBS. The cells were then incubated for 18 hours at 37 °C/7.5% CO2. After 
the incubation period, the color of the samples and the cell adhesion to the fibers was 
analyzed by brightfield microscopy. For these experiments, the white balance of the 
brightfield camera was set using the transparent gelatin controls. These controls were 
furthermore used to verify the quality of the samples. All images in one experiment were 
recorded using the same camera settings. 
UV-Vis Spectroscopy after Incubation with Cells 
Fiber solutions (1 mg/mL in PBS) were prepared as previously mentioned. For this 
experiment, 48-well plates were used. In each well, 175 µL of the fiber solution was added. 
Then, 60,000 HeLa cells in 175 µL phenol-red free DMEM + 10% FBS were mixed in with 
the fiber solutions in each well. As a control to verify the quality of the sample, wells were 
coated with a 0.1 % gelatin solution for 15 minutes, after which the excess gelatin was 
removed. In these control wells, 60.000 HeLa cells were seeded in 350 µL phenol-red free 
DMEM + 10% FBS. The cells were then incubated for 18 hours at 37 °C/7.5% CO2. After 
the incubation period, the samples were transferred to a cuvette and measured by UV-vis 
absorption spectroscopy. UV-Vis spectra of the fiber samples with/without cells were 
recorded on a Varian Cary-50 spectrometer using a 1 mm quartz cuvette. For each sample 
the chromatic ratio was calculated using the absorptions at 634 nm (Ablue) and 558 nm 
(Ared).  
Chromatic ratio calculations 
Chromatic ratios (CR) were calculated using the following equation. 14 
CR = [PB0-PB1/PB0].100      (equation 2)  
where PB0 = pre-exposure to analyte and PB1 = post-exposure to analyte.  
PB = Ablue/(Ablue + Ared)     (equation 3) 
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Cell Viability 
For the cell viability experiments, the samples were prepared similarly to the brightfield 
microscopy samples. Only after the incubation period of 18 hours at 37 °C/7.5% CO2 the 
cells were treated with the live/dead staining, which was prepared by diluting calcein AM 
and ethidium homodimer-1 (EthD-1) in PBS to obtain a concentration of 8 µM calcein AM 
and 16 µM EthD-1. To each well, 100 µL of the staining solution was added, yielding a final 
concentration of 2 µM calcein AM and 4 µM EthD-1. The samples were then allowed to rest 
for 10 minutes, after which they were immediately analyzed by confocal laser scanning 
microscopy. Calcein was excited with the 488 nm line of an argon ion laser, and emission 
was collected between 494 and 515 nm. EthD-1 was excited with the 561 nm line of a 
yellow diode laser and emission was collected between 600 and 625 nm. Using the ImageJ 
software, overlay images of the calcein and EthD-1 signals were produced. For the series 
of K-fibers (3:1, 6:1, 12:1, 24:1, scrambled and spacer K-fibers) the total amount of cells 
(living and dead) was counted for each sample (composed of at least 4 images for each 
sample) and from this the average total amount of cells was calculated (figure 12A). Next, 
the average total amount of living, spread cells was counted for each sample (data 
obtained from the same images as used to calculated the average total amount of cells). 
This was then used to calculate the ratio between spread cells and the total amount of cells 
(figure 12A). The optimal concentrations for the live/dead dyes were determined by staining 
dead HeLa cells with a varying concentration of EthD-1 (between 1 and 10 µM). From this, 
it was found that at a concentration of 4 µM EthD-1 the nuclei were brightly fluorescing, 
whereas the cytoplasm was not stained. Similarly, the optimal concentration of calcein AM 
was determined by treating dead HeLa cells with a ranging concentration of 1 to 10 µM 
calcein AM to avoid aspecific staining of the cytoplasm. The best results were obtained 
using concentrations lower than 2 µM. We then verified that this concentration gave 
sufficient fluorescence in living HeLa cells. 
Integrin binding 
Isolated human αVβ3 integrin protein (100 nM, in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 
mM MgCl2, 0.2% Triton X-100) and the 6:1 K-RGDS fiber solution (100 nM (based on the 
RGDS content), in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM MgCl2, 0.2% Triton X-
100) were mixed 1:1 and incubated at 30 °C for 10 mins. The UV-Vis spectrum of the 
resulting sample was measured using a 1 mm quartz cuvette on a Varian Cary 50 
spectrometer. The 50 nM fiber solution in the Triton X-100 buffer mentioned above was 
also measured using a Varian Cary 50. The chromatic ratio was calculated using the 
absorptions Ablue = 646 nm and Ared = 540 nm. 
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8.1 Brief summary on activation strategies for CPPs used in this 
thesis 
In this thesis two strategies are described to induce cell-penetrating activity in 
peptides upon a specific trigger. In the first approach, which is reported and 
applied in chapters 2, 3 and 4, short, inert oligo-arginines are used, which can be 
activated upon extension of their sequence by a specific conjugation event. In 
chapter 2, the basic concept of this activation strategy is detailed. It is shown that 
fluorescently labeled truncated oligo-arginines containing 3-5 arginine residues 
and a C-terminal cysteine are unable to induce cellular uptake, but when their 
sequence is extended through disulfide linkage with complementary oligo-
arginines, cellular uptake is attained. Because of the reduced utility of disulfide 
bridges in a biological context, such a link is not employed to connect the two 
tetra-arginine stretches together in chapter 3. Instead, a tetrazine-based bio-
orthogonal ligation reaction is used, allowing the in situ activation of oligo-
arginines in in vitro cell studies. In chapter 4, the reconstitution of two tetra-
arginines to form an active CPP is achieved by heterodimerizing leucine zippers. 
Three different leucine zipper pairs were used in this study, and it was found that 
for two of them the tetra-arginines needed an additional disulfide linkage, whereas 
for the most stable coiled-coil this was not necessary. The characteristics of the 
coiled-coils furthermore greatly influenced the uptake mechanism. 
The second approach for inducing activity relies on temporarily 
inactivating the CPP Tat. In chapter 5, the lysine side-chains of the Tat peptide 
(RKKRRQRRR) were modified with alanine or the glycine-proline dipeptide, to 
impede its cell-penetrating activity. When the Ala or GlyPro groups were 
enzymatically cleaved off, cellular uptake in HEK cells was induced. In this 
strategy the modified Tat peptides have the same net positive charge as Tat – the 
positive charge is just located further away from the peptide backbone. However, 
as small changes in the CPP structure already can have significant effects on 
their properties, we investigated in chapter 6 if besides HEK cells also tumor cells 
are susceptible to this subtle structural change in Tat. Much to our delight, we 
found that these modified Tat peptides are effectively taken up by HeLa cells, 
thereby equipping them with intrinsic tumor-specific uptake ability.  
8.2 Perspectives 
Cell-penetrating peptides are being extensively studied since the past few 
decades, and this is not without reason. With their ability to enter cells without 
inducing cytotoxicity and with their capacity to facilitate cellular delivery of a large 
range of cargos, these molecules present a high therapeutic relevance. However, 
there are still major limitations hampering the pharmaceutical use of CPPs. The 
mechanism of uptake of CPPs remains mysterious, and their uptake behavior can 
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be greatly influenced by numerous factors, as was described in chapter 1. Next 
to unraveling the uptake mechanism for a specific CPP, also the influence of for 
example the cargo and relative peptide concentration and cell type to which it is 
applied should be investigated in order to get a clearer picture about the way of 
action of these peptides. Importantly, delivery of cargos to the cytosol remains 
problematic at this moment. Cargo molecules, which have entered the cell via an 
endocytotic pathway must be released from the endosome before degradation by 
enzymatic processes. Furthermore, no intracellular response can be evoked by 
sole endosomal uptake, since for practical purposes the inside of an endosome is 
similar to the extracellular environment. As most CPPs enter via endocytotic 
routes, understanding the mechanisms of endosomal escape is almost as 
important as understanding cellular uptake. To date, these mechanisms remain 
also poorly defined. Part of the challenge associated with understanding how 
CPP-cargos escape from the endocytotic pathway is that efficiency of endosomal 
escape is often poor, making it difficult to detect.1 Plasma membrane translocation 
is a cellular uptake mechanism for which many mechanisms have been 
proposed.2 Fewer explanations have been offered to explain endosomal escape, 
yet it is often suggested that both mechanisms may rely on similar types of 
interactions between CPPs and lipid membranes. This underlines the importance 
of unraveling the mechanism of action of CPPs, as it could well lead to a better 
understanding of both pathways. At this moment, strategies to induce endosomal 
escape include, but are not limited to, the use of multivalent CPPs3, pH-
dependent membrane active peptides4,5 and photosensitizers.6  
Circumventing endosomal entrapment of CPPs and its cargos is not the 
only challenge to overcome in increasing the pharmaceutical relevance of these 
transporters. CPPs possess a high intrinsic activity, making it difficult to control 
their moment of uptake. But possibly most importantly, CPPs are hardly cell-type 
specific, meaning that when applied in targeted drug delivery, aspecific uptake by 
non-targeted cells is expected, inducing adverse effects in these cells.  
The study of structural variants of known CPPs is one of the most 
thoroughly pursued approaches to both obtain a better understanding of CPP 
uptake and to develop highly efficient CPPs. Structural variants of Tat and oligo-
arginines and their properties were discussed in detail in chapter 1 of this thesis. 
This still remains an interesting topic of research, as small alterations in the CPP 
structure and peptide backbone can induce large differences in uptake behavior, 
which is described throughout this thesis. A better understanding of the key 
structural elements of CPPs that can induce cytosolic delivery might offer 
interesting strategies to circumvent entrapment of CPPs and their cargo in 
endosomes. Although their uptake mechanism is in general largely influenced by 
the cargo attached, for some analogues of Tat cytosolic delivery of GFP has been 
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reported,7,8 demonstrating the importance of identifying highly efficient CPPs that 
can induce direct cytosolic delivery. 
In this thesis, gaining control over the intrinsic activity of CPPs to increase 
their specificity, has been the central research theme. In the following sections, 
possible implications of the activatable systems described in this thesis will be 
discussed. 
8.2.1 Influence of the peptide backbone on uptake behavior 
Relating to the research described in this thesis, we observed in chapter 2 that 
the cellular uptake of analogues of octa- and nona-arginine, which consist of a 
stretch of 3, 4 or 5 arginine residues that were linked via a disulfide bridge to 
another stretch of 5, 4 or 3 arginine residues, heavily depended on the position of 
the disulfide bridge. While a minimum of 8 arginine residues appeared to be 
required for efficient cellular uptake, the minor structural distinctions between the 
various analogues exerted an influence belying their apparently trivial nature. For 
example, the octa-arginine-peptides R3-R5 and R5-R3 were taken up less 
efficiently than R4-R4, while the only difference in the structure of these peptides 
is the position of the disulfide bridge. At a high concentration of 20 µM, R4-R4 and 
R8 were the only octa-arginine peptides that could induce uptake through 
nucleation zones. Regarding analogues of R9, namely R4-R5 and R5-R4, an 
even more striking influence of the position of the disulfide bridge was observed. 
This prompted us to synthesize non-reducible analogues of these peptides, in 
which the two arginine-stretches were linked together via the flexible amino-
octanoic acid spacer. We observed that peptides for which the two arginine 
stretches were connected via this linker, efficient cytosolic uptake could be 
induced, whereas their disulfide analogues could not. This is similar to the finding 
of Wender et al. that an increase in flexibility of the oligo-arginine backbone 
increases it cellular uptake.9 However, cyclization of oligo-arginines has also been 
reported to increase transduction, which was ascribed to the increased 
conformational rigidity and expanded spacing of the guanidino groups.10 These 
different results clearly highlight the complexity in determining the structural 
requirements for efficient cytosolic delivery of oligo-arginine CPPs.  
When we continued to research oligo-arginine peptides to develop 
activatable CPPs, we again observed that a subtle structural difference in the 
peptide backbone can greatly influence its cellular uptake behavior. When 
peptides were studied in which the two tetra-arginine stretches were not linked 
together via a disulfide bridge, but through tetrazine-based bio-orthogonal ligation 
reactions (chapter 3), we clearly observed a linkage-dependent uptake. Notably, 
the peptide that was linked via norbornene-tetrazine ligation could only induce 
endocytotic uptake, while the peptide linked through a BCN-tetrazine ligation 
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showed rapid cytotosolic delivery, already starting at a concentration of 10 µM. 
The only structural difference in the peptides is the nature of the linkage between 
the two tetra-arginine stretches. These findings suggest that structure-activity 
studies of these peptides and their analogues, in which various linkages can be 
inserted between arginine residues, have a high potential because efficient 
cytosolic delivery may be induced. Our findings strongly suggest that the uptake 
pathway may be influenced by the type of linkage in the oligo-arginine peptides, 
while on the other hand it also clearly shows that despite their deceptively simple 
sequence this class of CPPs have complicated interaction profiles. To gain a 
better understanding of the influence of the subtle backbone changes of oligo-
arginine CPPs, a systematically varied library of these peptides should be 
prepared and their cellular uptake behavior studied. When designing such a 
library, hydrophobicity and flexibility of the linkers should be assessed. Another 
factor that might influence the uptake behavior is the stability of the peptides in 
serum. Therefore, it might be interesting to prepare analogues in which the 
linkage is obtained using only natural amino acids, such as glycine and alanine, 
because it is likely that these peptides have reduced stability in serum when 
compared to non-peptide linkers. In addition, the uptake of the peptides should be 
studied in various cell lines, as it has been reported that these respond differently 
to structural changes in CPPs.11,12 With the knowledge obtained from such 
studies, linkers for activation strategies might be designed that may induce 
efficient cytosolic uptake while having low cytotoxicity. 
8.2.2 Directing cytosolic delivery using peptide cargos 
In addition to subtle changes in the backbone of oligo-arginines, we furthermore 
observed that the nature of a peptide cargo markedly influences the uptake 
pathway of these CPPs. When activation through coiled-coil formation was 
investigated in chapter 4, we observed that both the coiled-coil stability and its 
amino-acid composition considerably impacted the cellular uptake mechanism of 
the oligo-arginines. In this system, hetero-dimerizing coiled-coils were used, in 
which both leucine zippers were N-terminally functionalized with cysteine-
containing tetra-arginines, so that upon coiled-coil formation a similar R4-R4 
peptide would be obtained as in chapter 2 but with increased specificity due to 
the leucine zippers attached to it. We observed that when coiled-coils enriched in 
arginine/glutamic acid residues with substantial stability were used, cytosolic 
delivery and uptake by the nuclear membrane could be induced, whereas the two 
other coiled-coils (that did not contain arginine residues and had a lower stability) 
could only induce uptake by endocytosis. This is interesting, because the ‘CPP’ 
part in these systems remains the same, namely R4-R4 and in this respect, the 
coiled-coils can be regarded as cargo. Because it is often observed that 
attachment of a cargo to arginine-rich CPPs increases uptake via endocytosis, 
this striking finding that the combination of an inert cargo with a CPP increases 
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the cytosolic uptake of that CPP is highly interesting and may be of value for 
development of cytosolic delivery vehicles. It should be noted that when GFP was 
attached to his system, only uptake via endocytosis was observed. However, it 
would be worthwhile to study the uptake behavior of this system when a small 
(peptide) cargo is attached to the leucine zippers, to investigate whether delivery 
to the cytosol is then still possible. Furthermore, these findings suggest that 
attaching a seemingly biological inert peptide to a CPP may change the uptake 
pathway of that CPP. Identification of the structural and biophysical requirements 
for such peptide-cargo that can influence uptake behavior of the CPP-cargo 
complex might offer strategies to obtain CPPs that can induce uptake in the 
cytosol or nucleus.  
8.2.3 Inducing cell-specific uptake by side-chain modifications 
While studying an enzyme-based approach as strategy for the activation of 
modified Tat (RKKRRQRRR) peptides (chapters 5 and 6) we observed that by a 
minimal modification of the lysine side-chains of Tat, uptake in cell lines derived 
from non-tumorous tissue was lost. Strikingly, HeLa cells seemed to be less 
sensitive to the ‘blocking misalignment’ of positive charges, as we observed 
cellular uptake of the modified Tat peptides in this tumorous cell line with varying 
efficiency (chapter 6). This was an important observation, as by the side-chain 
modification, the positive charges were not removed, but only moved further away 
from the peptide backbone, disrupting the original alignment of the eight positive 
charges in the Tat peptide. Proceeding with a study of the uptake of the modified 
Tat peptides in healthy white blood cells and various leukemic cell lines, it was 
observed the modified Tat peptides were hardly internalized in WBCs 
(lymphocytes and granulocytes) whereas in leukemic cell lines, the peptides could 
efficiently be taken up. Interestingly, the efficiency of uptake of a specific modified 
Tat peptide varied greatly among the different leukemic cell lines, but importantly, 
in every cell line tested at least one peptide could induce efficient uptake. These 
findings suggest that by a slight modification in the distribution of positive charges 
of Tat, CPPs with an intrinsic specificity for tumor cells could be obtained. There is 
not yet a clear explanation for this phenomenon, although we suspect that 
interactions of these peptides with glycans on the cell membrane (for which their 
exact composition is different for tumor cells than for healthy cells)13 might greatly 
influence their uptake. To support this theory, the interaction of these peptides 
with syndecans, HSPGs and GAGs should be investigated. Furthermore, to 
investigate the influence of the position of the positive charge, various analogues 
of the peptides reported in chapter 6 should be studied. For example, analogues 
can be synthesized in which the atomic distance between the peptide backbone 
and positive charge remains the same, while the exact linking moiety between the 
charge and the backbone is varied. In table 1, such analogues and their relative 
distance to the peptide backbone are summarized. For example, in Tat-G(10), 
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Tat-A(10) and TatO-βA(10) the atomic distance between the positive charge and 
the peptide backbone is the same, but the exact linker between charge and 
backbone is different. Because of the observed intrinsic specificity of these 
modified Tat peptides, it would be interesting to couple them to anti-cancer drugs, 
such as daunorubicin and doxorubicin or to a pro-apoptotic peptide, such as the 
KLAK peptide (KLAKLAKKLAKLAK).14 To increase the therapeutic potential of 
these peptides, research efforts should furthermore focus on investigation 
whether the observed specificity in cultured cell lines can also be demonstrated in 
blood or bone marrow derived from patients with leukemia. In addition, selectivity 
towards other types of cancers should be investigated, and if successful this 
strategy might be extended to in vivo studies to targeting the corresponding tumor 
cells. 
Table 1 – analogues of the modified Tat peptides described in chapter 6. The peptides mentioned in 
this table can be studied to investigate the relevance of the position of the positive charge (blue) 
relative to the peptide backbone, and the exact type of linker, which can vary in the number of amide 
groups (dark grey) or methylations (*) it comprises. Tat-A(10) represents the alanine-modified Tat 
peptide studied in chapter 6, other modifications are denoted in the same fashion, with G representing 
glycine, βA representing beta-alanine and AA representing an alanine-alanine dipeptide. The TatOrn 
series represent peptides in which the N-terminal lysine residue is substituted by ornithine, and the 
TatDab series represent peptides for which the lysine is substituted by diaminobutyric acid. For these 
analogue peptides, the side-chain can be modified in a similar fashion, yielding shorter side chains. 
 
8.2.4 Using activatable CPPs in targeted delivery 
The activation strategies described in chapters 3 and 4 rely on either a bio-
orthogonal ligation reaction or on the specific interaction between two coiled-coil 
forming peptides to link two inert peptides together to form an active CPP. 
Because both of these interactions are unlikely to interact with biomolecules in 
cells and tissue, these strategies are promising to apply in targeted drug delivery. 
Homing peptides (described in chapter 1) may easily be attached to or included 
in the sequence of one of the tetra-arginines (one of the inert peptides), allowing 
targeting to a specific tissue and accumulation of the inert CPP at that site. 
Because uptake of the oligo-arginines can only occur when the linkage to the 
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complementary peptide is successful, aspecific uptake by non-targeted tissue 
may be circumvented. This is beneficial, because in current cell-penetrating 
homing peptide approaches, off-target side-effects occur frequently because 
aspecific uptake due to the intrinsic activity of CPPs. Next to homing peptides, 
targeting ligands such as nanobodies might also be introduced to our tetra-
arginine based activation strategies. While bulkier than most homing peptides, 
nanobodies offer custom homing potential that can well exceed the arsenal of 
presently known homing peptides.15 A schematic representation of a targeting 
strategy based on the coiled-coil mediated activation of tetra-arginines is depicted 
in figure 1. 
 
Figure 1 – schematic representation of a targeting strategy based on the activation approach 
described in chapter 4, where the specific interaction of heterodimerizing leucine zippers leads to 
activation of an oligo-arginine CPP. In this targeting strategy, a homing peptide or nanobody (orange) 
is attached to the N-terminus of one tetra-arginine/leucine zipper pair, while a cargo (green) is 
attached to the other pair. Because the monomeric tetra-arginine/leucine zippers can only induce 
uptake after coiled-coil formation at the target site, efficient uptake may occur.  
To circumvent endocytotic uptake induced by a large targeting ligand, a 
cleavable linker may be placed between the CPP and the targeting moiety. A nice 
candidate for this would be an MMP-2 cleavable linker, because MMP-2 is 
upregulated at many desired target sites.16 
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8.2.5 Tracking cell migration  
Cell-targeting ligands are almost always moieties that have a certain affinity for 
elements that are present on the exterior of a cell, such as GAGs or receptors. It 
is therefore no surprise that the tripeptide RGD has also been used as a targeting 
ligand,17 because this tripeptide motif is a ligand for many of the integrin receptors 
that are present on many cells.18,19. The ability of RGD to target a conjugated 
cargo to cells works both ways: an immobilized RGD recruits cells with equal 
affinity, acting as a cell adhesion motif. Relating to this application, we analyzed 
the ability of RGD comprising polydiacetylene-containing peptide amphiphile 
fibers to recruit cells. These fibers underwent a detectable chromatic shift when 
the linked RGD moiety interacted with a cell, as described in chapter 7. A useful 
future application of this would be to develop this material to allow its chromatic 
shift even when the fibers are encapsulated in a hydrogel, e.g. based on 
polyisocyanides.20 In such a setup, the trajectory of a single cell could be 
recorded when it moves over a surface, because the cell would leave behind a 
trail of color change. In addition, by combining this strategy with biocompatible 
hydrogels, 3D cell growth would be possible. In this work, the conjugated ligand 
(the RGD) has made the larger peptide (the fiber) more specific, because without 
the RGD, the cell would at best non-specifically interact with the peptide material. 
Owing to the combination of an affinity element with an otherwise non-specific 
element, a harnessed interaction is established, unlocking new functionality. 
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Summary 
 
In the past decades, peptides emerged as relevant pharmaceutical alternatives to 
small molecules. However, unlike small molecules, peptides on the market today 
are limited to extracellular targets. In contrast, cell-penetrating peptides (CPPs) 
are able to cross the plasma membrane and carry other cargoes (e.g. other 
peptides, small molecules, proteins or nanoparticles) with them into the cell, thus 
offering great potential as future therapeutics. Despite their promising 
characteristics, no CPPs or CPP conjugates have passed the regulatory threshold 
into the clinics, meaning no CPP-based therapeutics are currently on the market 
as such. There are several challenges hampering the pharmaceutical use of 
CPPs. The mechanism of uptake of CPPs is greatly influenced by the type of 
cargo attached, often resulting in endosomal entrapment of the cargo. From 
endosomes, it is generally not possible to evoke a biologically relevant response. 
More importantly, the intrinsic activity of CPPs causes them to enter almost any 
type of cell, and as a consequence, efficient targeting to diseased tissue is difficult 
to achieve. The research described in this thesis focuses on the development of 
cell-penetrating peptides with tunable activity. By gaining control over the moment 
of CPP uptake, a handle for specific targeting can be obtained. Several strategies 
to obtain activatable CPPs are investigated in this work. In addition, CPPs with 
intrinsic tumor selectivity were studied. 
In chapter 2, the structural requirements of oligo-arginine CPPs are used 
to obtain inert peptides that can be activated to become CPPs. Oligo-arginines 
can only enter cells when comprised of 6 or more arginine residues. To obtain 
inert peptides, a series of short oligo-arginines, containing 3 to 5 residues was 
synthesized. The first series was N-terminally functionalized with fluorescein 
isothiocyanate (FITC) to allow for fluorescence-based techniques to study their 
cellular uptake behavior. These peptides contained a C-terminal cysteine residue, 
offering the possibility to form disulfide bridges with a second series of short oligo-
arginines. The peptides in the second series had a complementary structure, 
containing 3-5 arginine residues but with an N-terminal cysteine residue. This N-
terminal cysteine residue was functionalized with N-pyridinylsulfonyl (Npys) to 
allow for rapid heterodimerization of the peptides at neutral pH.  First, it was 
confirmed that the short cysteine-containing oligo-arginines were not taken up by 
cells. Next, the sequence of the peptides was extended through disulfide bridge 
formation with the complementary peptides, yielding oligo-arginines containing 8 
or 9 arginine residues in total. These extended peptides efficiently internalized 
into cells. However, the position of the disulfide bridge, the total amount of 
arginine residues and the peptide concentration greatly influenced the uptake 
mechanism of the extended peptides. Interestingly, it was found that that the 
extended peptide obtained from the disulfide linkage between two tetra-arginine 
peptides (designated R4-R4) showed equal cellular uptake efficiency as octa-
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arginine. Because many naturally occurring proteins contain thiol-groups, the 
disulfide-bridge linkage in the extended peptide might not be suitable for an in 
vivo application. Therefore, alternative biocompatible linkages were investigated 
to obtain similar activatable oligo-arginine CPPs in chapter 3 and 4. 
In chapter 3, an in situ activation strategy for oligo-arginine CPPs based 
on tetrazine-dependent bio-orthogonal ligations is reported. A FITC-labeled tetra-
arginine peptide that contained a C-terminal tetrazine functionality (R4-Tz) was 
used. It could react with R4 functionalized with BCN or norbornene on its N-
terminus (BCN-R4 and norb-R4). Using these tetra-arginines, pre-ligated CPPs 
could be prepared. Both pre-ligated peptides could induce cellular uptake, but the 
uptake efficiency and mechanism of entry greatly differed, suggesting that the 
nature of the linkage between the two tetra-arginines may influence the 
internalization pathway. The peptide resulting from the ligation between R4-Tz 
and Norb-R4 was taken up by endocytosis at concentrations ranging from 5 to 20 
µM, whereas the peptide resulting from the ligation between R4-Tz and BCN-R4 
could induce rapid cellular uptake by nucleation zones starting from a 
concentration of 10 µM. Because the aim was to develop in situ activatable CPPs, 
the relative reaction rates of the ligations were determined. It was found that the 
ligation of R4-Tz with norb-R4 was too slow for in situ activation. However, the 
ligation of R4-Tz with BCN-R4 was fast, proceeding to almost full conversion 
within 20 minutes, and was therefore expected to be feasible for in situ activation. 
Indeed, in situ ligation of R4-Tz and BCN-R4 already yielded efficient cellular 
uptake with an incubation time of 60 minutes. Using this strategy, a new, bio-
orthogonal approach to induce in situ activation of oligo-arginine CPPs was 
demonstrated. 
In chapter 4, a non-covalent linkage strategy to link two tetra-arginine 
peptides to induce cell-penetrating activity is described. Heterodimerizing coiled-
coil forming peptides were used as a linker. The coiled-coil structure is induced by 
the specific interaction of two complementary peptides that contain a leucine 
zipper motif. The specificity of the binding between the leucine zippers arises from 
their amino-acid sequence. To use these peptides in our activation strategy, the 
N-termini of heterodimerizing leucine zippers were elongated with tetra-arginine 
motifs, allowing coiled-coil formation to yield a structure similar to octa-arginine. 
As intended, the monomeric leucine zippers could not induce cellular uptake, but 
upon coiled-coil formation cellular uptake was induced. Three different sets of 
leucine zippers were used, displaying varying binding affinities. Interestingly, the 
stability of the coiled-coil that is formed by these peptides influences the uptake 
mechanism. Importantly, the most stable coiled-coil (Kd of about 2.3•10-12) no 
longer required a disulfide bridge between the two tetra-arginine parts to keep 
them in close proximity. In addition, temporal control over the uptake of a whole 
protein was demonstrated, using this activation strategy. 
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Importantly, the research described in chapters 3 and 4 is devoid of the 
need of a trigger induced by a specific environment. It therefore provides 
interesting methods to gain temporal control over arginine-rich CPPs. 
In chapter 5, an activation methodology is developed that offers targeting 
along with temporal control over the moment of uptake of the peptide. Here, 
activation was through a specific enzymatic reaction. This offers a particularly 
interesting alternative targeting strategy, because the specificity and efficiency 
both originate from the activation process. The activation reaction is catalyzed by 
specific cell-surface enzymes, which may include activation of CPPs in a very 
short time and in a known area. As a result, the CPPs will be taken up primarily in 
those areas. The research carried out in this chapter is based on the CPP Tat 
(RKKRRQRRR). Literature reports that all positive charges, including the lysine 
residues, are essential to cellular uptake. Therefore, it was anticipated that 
modifying the lysine side chains by an enzyme-cleavable sequence could 
(reversibly) hamper the activity of Tat. A minimal modification of the lysine side 
chains indeed blocked the activity of Tat, and enzymatic cleavage of the lysine 
modification restored the original cell-uptake potential. Interestingly, it was 
observed that this de-activation strategy already functions with no more than a 
single amino acid residue on a single lysine side-chain. The inactivating groups 
on the lysine side chains could be enzymatically removed in situ using the model 
enzymes aminopeptidase N (APN) or dipeptidyl peptidase IV (DPPIV). This 
activation strategy is a physiologically benign approach to not only control the 
activity of CPPs, but to also increase their specificity. 
However, the reduction of cellular uptake via this minimal perturbation 
was surprising as only the side chain’s length and not its charge density was 
affected. The side chain modification of one or more amino acids to the lysine’s 
side chain amine merely displaced the charge to the N-terminus of the conjugated 
amino acid. In chapter 6, it is investigated whether this change in distribution of 
positive charges could lead to preferential uptake by specific cell lines. As 
reported in chapter 5, these modified peptides are not able to induce cellular 
uptake in HEK cells. Strikingly, these peptides were taken up in HeLa cells, with 
several of the modified Tat peptides being taken up equally well as unmodified 
Tat. Specific uptake by HeLa cells prevailed when the internalization of the 
peptides was studied in a co-culture of HEK and mCherry-labeled HeLa cells. In 
addition, the observed specificity remained when a proteolytically more stable Tat-
analogue was studied in which the side chain was modified with a d-amino acid. 
This all indicated that the observed specificity was independent of potential 
deprotecting enzymes. The preferential uptake by tumor cell lines might be 
dependent on the positioning of the positive charges on the lysine side-chain, 
however, more experiments are required to substantiate this theory. The uptake 
of the modified Tat peptides was also studied in white blood cells derived from a 
healthy donor. In these experiments, it was observed that only the unmodified Tat 
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peptide was able to enter these cells. The next logical step was to investigate 
whether the modified Tat peptides were able to induce cellular uptake in leukemic 
cell lines. It was observed that the modified Tat peptides could be efficiently 
internalized in these cell lines, with an intriguingly strong variation in efficiency of 
uptake between the modified peptides in each tested cell line. These findings 
indicate that it might be possible to identify a suitable side chain modification to 
induce specific uptake in a distinct cell line, which offers an interesting diagnostic 
opportunity for various types of leukemia. 
In chapter 7, the research is focused on cell adhesion using the RGDS-
peptide. In this work, polydiacetylene-containing peptide amphiphile fibers were 
functionalized with the integrin ligand RGDS. Polydiacetylenes are an interesting 
class of conjugated polymers with intrinsic optical properties. In addition to 
absorbing light in the visible region, they can undergo a color change in response 
to external stimuli, which makes them promising molecular probes for sensing 
their environment. The polydiacetylene-containing peptide amphiphile fibers were 
designed to be able to detect the effect of cell adhesion on the chromatic 
properties of the polydiacetylene. To achieve this, diacetylene-containing peptide 
amphiphiles were functionalized with the integrin ligand RGDS and mixed with 
spacer (non-RGDS) amphiphiles to form nanofibers. It was found that the 
propensity of the RGDS fibers to change color in response to cell adhesion could 
be tuned by varying the C-terminal amino acid of the spacer amphiphiles. It was 
found that the RGDS fibers with K-spacers were most susceptible to a color 
change, from blue to pink, induced by cell adhesion. RGDS-containing fibers with 
V, A or S spacer amphiphiles allowed cell adhesion, however without undergoing 
a color change. This may be due to the fact that the peptide components in these 
fibers have a more stable packing. The RGDS fibers with E-spacers were also a 
suitable substrate for cell adhesion, however these fibers were sensitive to the 
incubation temperature required for the cell studies, and thus turned pink upon 
incubation irrespective of cell adhesion. Interestingly, it was found that the degree 
of the color change in the K-fibers was related to the amount of RGDS amphiphile 
present in the fiber. This system might be used to track cell migration both in 2D 
and 3D environments by incorporating our material in a suitable hydrogel. 
Furthermore, the sensing system presented here offers interesting possibilities as 
a screening method for cell culturing. 
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Samenvatting 
 
In de afgelopen decennia hebben peptiden zich laten kennen als belangrijke 
moleculen voor de farmaceutische industrie. Zij worden vooral als alternatief 
gebruikt voor kleine moleculen. Maar in tegenstelling tot deze kleine moleculen, 
kunnen peptiden vaak alleen worden ingezet voor extracellulaire doelen. Een 
bepaalde klasse peptiden, zogenaamde “Cell-penetrating-peptides” (CPPs), is 
echter instaat om cellen op een niet-toxische wijze binnen te dringen. Aan deze 
CPPs kunnen farmaceutisch relevante moleculen (cargo’s) vastgemaakt worden, 
zodat ook deze in de cellen terecht komen. Daarom zijn CPPs interessante 
kandidaat-moleculen voor de farmaceutische industrie. Desalniettemin zijn er op 
dit moment nog geen op CPP-gebaseerde medicijnen op de markt. Dit komt 
doordat er verschillende hindernissen zijn die het klinisch gebruik van deze 
peptiden in de weg zitten. Zo is het precieze mechanisme waarmee CPPs cellen 
binnendringen nog niet bekend, en wordt de (sub)cellulaire lokalisatie van het 
cargo dat zij mee kunnen nemen sterk beïnvloed door de eigenschappen van dat 
cargo. Veelal leidt dit tot opname via endocytsose, waardoor het cargo ‘blijft 
steken’ in de endosomen, vanwaar over het algemeen geen biologische respons 
bewerkstelligd kan worden. De grootste limitatie van CPPs is misschien wel dat 
hun intrinsieke activiteit ertoe leidt dat ze door bijna elk celtype worden 
opgenomen.  Hierdoor is specifieke behandeling van enkel bepaalde weefsels of 
tumoren moeilijk te bereiken. Het ontwikkelen van CPPs met beheersbare 
activiteit staat centraal in dit proefschrift. Door controle te hebben over het 
moment van opname van CPPs kan een handvat voor het introduceren van 
specificiteit voor celtypes worden verkregen. Hiernaast zijn ook CPPs met 
intrinsieke tumorselectiviteit onderzocht.  
In hoofstuk 2 wordt gebruik gemaakt van de structurele vereisten van 
oligo-arginine CPPs om activeerbare CPPs te maken. Van deze klasse CPPs is 
bekend dat ze uit 6 of meer arginine residuen moeten bestaan om celopname te 
kunnen initiëren. Daarom is gebruik gemaakt van korte, inactieve oligo-arginines 
die uit 3 tot 5 arginigine residuen bestonden. Hiervan zijn twee series peptiden 
gemaakt; in de eerste serie bevatten de peptiden een fluorescent label op de N-
terminus, en een cysteine residu op de C-terminus. Door de fluorescente groep 
kon cellulaire opname van de peptiden met op fluorescentie gebaseerde 
technieken bestudeerd worden. Via de cysteine konden deze peptiden door 
middel van disulfide-brug vorming verbonden worden met een tweede serie korte 
oligo-arginines. De peptiden in deze serie bevatten weer 3 tot 5 arginine residuen, 
dit maal met en een N-terminaal cysteine residu, voorzien van een N-
pyridinylsulfonyl-groep. Deze groep zorgt ervoor dat de peptiden uit serie 1 
heterodimerizeren met de peptiden uit serie 2. In het eerste deel van het 
onderzoek is laten zien dat de korte cysteine-bevattende oligo-arginines niet door 
cellen werden opgenomen. Wanneer de sequentie van deze peptiden werd 
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verlengd door disulfide-brug vorming met peptiden uit de tweede serie (zodat het 
resulterende peptide 8 of 9 arginine residuen bevat) werd echter efficiënte 
opname door cellen waargenomen. Dit onthulde een interessant fenomeen, 
namelijk dat de oriëntatie van de arginine residuen en de positie van de disulfide 
brug van grote invloed op zowel de opname efficiëntie als het opname 
mechanisme van de peptiden waren. Tevens is het belangrijk aan te merken dat 
het geactiveerde peptide bestaande uit de twee tetra-arginines verbonden via een 
disulfide-brug (R4-R4) even efficiënt cellen kon binnen dringen als de klassieke 
CPP octa-arginine. Omdat veel eiwitten die in het lichaam voorkomen thiolen 
bevatten, kan deze activatie strategie mogelijk niet gebruikt worden voor een in 
vivo applicatie. Daarom zijn alternatieve reacties om twee tetra-arginines te 
verbinden onderzocht in hoofdstukken 3 en 4. 
In hoofdstuk 3 wordt een activatie strategie voor oligo-arginine CPPs 
beschreven die in situ gebruikt kan worden. Deze strategie maakt gebruik van 
bio-orthogonale ligatiereacties die gebaseerd zijn op tetrazine. De sequentie van 
de twee tetra-arginines uit hoofdstuk 2 is daarop aangepast: een van de twee 
tetra-arginines is voorzien van het fluorescente label op de N-terminus, en van 
een tetrazine op de C-terminus (R4-Tz). Dit peptide kan dan via een ringvorming 
reageren met zowel een tetra-arginine met een BCN-groep op de N-terminus 
(BCN-R4) als een tetra-arginine met een norbornene-functionaliteit (Norb-R4). 
Het R4-Tz peptide vertoonde geen opname door cellen, maar nadat dit peptide 
werd verbonden aan Norb-R4 of BCN-R4 werd efficiënte opname door cellen 
waargenomen. Echter, de hoeveelheid opname en het mechanisme verschilden 
sterk. Het peptide dat werd gevormd uit de reactie van R4-Tz met Norb-R4 
vertoonde enkel opname door endocytose bij een concentratiebereik van 5 tot 
20 µM, terwijl het peptide dat werd gevormd uit de reactie van R4-Tz en BCN-R4 
opname via nucleatiezones vertoonde vanaf een concentratie van 10 µM. Het 
doel van deze studie was de in situ activatie van CPPs, en daarom werden de 
relatieve ligatiesnelheden onderzocht tussen de peptiden onderzocht.  Hierbij 
werd gevonden dat de reactie tussen R4-Tz en norb-R4 te langzaam was voor 
een in situ activatie. Echter, de reactie tussen R4-Tz en BCN-R4 was erg snel, 
met een conversiehalfwaardetijd van 20 minuten. De in situ ligatie tussen R4-Tz 
en BCN-R4 leidde al in 60 minuten tot efficiënte opname door cellen. Deze op 
bio-orthogonale ligatie gebaseerde strategie kan gebruikt worden als een nieuwe 
methode voor de in situ activatie van oligo-arginine CPPs.  
In hoofdstuk 4 wordt een strategie voor een niet-covalente koppeling van 
twee tetra-arginines beschreven. Hiervoor zijn sets gebruikt van zogenaamde 
heterodimerizerende spiraalvormende peptiden. Deze vormen gezamenlijk een 
dubbele helix, en de vorming daarvan wordt geïnitieerd door specifieke interacties 
tussen de twee complementaire peptiden middels een zogenaamd ‘leucine rits’ 
motief. Deze peptiden worden daarom ook wel ‘leucine zippers’ genoemd. De 
specifieke interactie tussen leucine zippers heeft zijn oorsprong in de aminozuur 
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sequentie van de peptiden. Om ze  te gebruiken in de beoogde strategie werden 
de N-termini van de leucine zippers verlengd met een tetra-arginine motief. 
Wanneer de leucine zippers heterodimerizeren en de dubbele helix structuur 
wordt gevormd, ontstaat er op hun N-terminuus een structuur die lijkt op octa-
arginine. De opname-efficiëntie van de monomere leucine zippers werd eerst 
onderzocht. Zoals verwacht, konden deze peptiden geen cellen binnendringen. 
Na heterodimerizatie werd echter opname door cellen vastgesteld. Voor dit 
onderzoek werden drie verschillende sets leucine zipper peptiden gebruikt. De 
stabiliteit van de dubbele helix die deze peptiden kunnen vormen verschilde sterk 
per set. De cellulaire opname werd beïnvloed door de stabiliteit van elke dubbele 
helix. Ook werd ontdekt dat bij gebruik van een zeer stabiele dubbele helix, de 
twee tetra-arginines niet extra gestabiliseerd hoefden te worden met een disulifde 
brug om toch opname te kunnen bewerkstelligen. Tot slot werd deze strategie 
gebruikt om een geheel eiwit in cellen te brengen. 
In hoofdstuk 5 wordt een CPP activatie methode beschreven die naast 
een beheersbare activiteit ook de mogelijk geeft om op specifieke weefsels te 
richten. In deze strategie wordt gebruik gemaakt van een specifieke enzymatische 
reactie. Dit is een interessante techniek, omdat de specificiteit en efficiëntie van 
opname beide voortkomen uit de activatie, die wordt gekatalyseerd door 
specifieke enzymen die op bepaalde celoppervlakken voorkomen.  De activatie 
vindt plaats in een korte tijd én bij een vooraf bepaald type weefsel.  Dit hoofdstuk 
is gebaseerd op de CPP ‘Tat’ (RKKRRQRRR), waarvan bekend is dat alle 
positieve ladingen, ook die van de lysine residuen, noodzakelijk zijn voor 
efficiëntie celopname. De beoogde activatie speelt hierop in door de zijketen van 
de lysine te modificeren met groepen die door enzymen geknipt kunnen worden. 
De modificatie blokkeert dan (tijdelijk) de opname van Tat. De activiteit van Tat 
kon inderdaad geblokkeerd worden door een minimale verandering van de lysine 
zijketen, en de opname activatie kon hersteld worden door enzymatische 
verwijdering van de modificatie. Deze strategie was al succesvol bij modificatie 
met één enkel aminozuur op slechts één lysine residu. Deze milde activatie 
strategie kan niet alleen gebuikt worden om de activiteit van CPPs aan banden te 
leggen maar ook om hun specificiteit te verhogen. 
Echter, de afname van cellulaire activiteit via deze minimale aanpassing 
was eigenlijk een verrassing. Door deze aanpassing werd namelijk alleen de 
zijketenlengte aangepast, en niet de ladingsdichtheid. De aanpassing met een of 
meer aminozuren verplaatst namelijk enkel de lading van de amine van de lysine 
zijketen naar de N-terminus van het aangeknoopte aminozuur. In hoofdstuk 6 
werd onderzocht of deze subtiele verandering in ladingsverdeling leidt tot 
selectieve opname van de gemodificeerde Tat peptiden door specifieke cellijnen 
zoals tumor cellijnen. Voor hoofdstuk 5 waren HEK cellen gebruikt. Dat zijn geen 
tumorcellen, en ze namen de gemodificeerde peptiden niet op. HeLa cellen 
namen de Tat analogen wel op, en HeLa is een tumorcellijn. Deze specifieke 
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opname door HeLa cellen werd zelfs nog waargenomen wanneer een cocultuur 
van HEK en HeLa cellen werd onderzocht. Omdat ook een proteolytisch stabiele 
variant van een van de peptiden specifiek door HeLa cellen werd opgenomen, is 
het onwaarschijnlijk dat de getoonde preferentiële opname wordt veroorzaakt 
door enzymatische reacties. De getoonde selectiviteit voor tumorcellijnen zou 
kunnen worden veroorzaakt door de ladingsverdeling in de gemodificeerde Tat 
peptide, echter is er nog niet voldoende bewijs om deze theorie te onderbouwen. 
De opname van de gemodificeerde Tat peptiden werd ook onderzocht in witte 
bloedcellen verkregen van een gezonde donor. Enkel het niet-gemodificeerde Tat 
peptide liet opname zien in deze experimenten. Daarom was onderzoek naar de 
opname efficiënte van de gemodificeerde peptiden in leukemie cellijnen een 
logische vervolgstap. Hierbij werd efficiënte celopname van de Tat-analogen in de 
leukemie cellijnen vastgesteld. Er werd een groot verschil gezien in de efficiëntie 
van opname tussen de gemodificeerde peptiden in elke cellijn die werd 
bestudeerd. Deze bevindingen suggereren dat het mogelijk is om voor een 
specifieke cellijn een geschikte zijketen modificatie te identificeren die lijdt tot 
specifieke opname door enkel die cellijn. Dit zou een mooie opening zijn voor 
diagnostiek van verschillende vormen van leukemie. 
In hoofdstuk 7 staat onderzoek naar celadhesie centraal en hiervoor 
werd het RGDS-peptide gebruikt. Er werd gebruik gemaakt van polydiacetyleen 
bevattende peptide amfifiele vezels waarin de integrine-ligand RGDS was 
ingebouwd. Polydiacetylenen zijn een interessante klasse van geconjugeerde 
polymeren met intrinsieke optische eigenschappen. Ze kunnen namelijk een 
kleurverandering ondergaan als reactie op een externe stimulus, wat ze 
interessante signaalmoleculen maakt om verandering in de omgeving zichtbaar 
mee te maken. In dit hoofdstuk werden polydiacetyleen bevattende peptide 
amfifiele vezels ontwikkeld voor het vaststellen van het effect van celadhesie op 
de chromatische eigenschappen van de polydiacetyleen ketens. Hiertoe werden 
diacetyleen bevattende amfifielen gemodificeerd met het celadhesie motief 
RGDS, en werden zijn gemengd met amfifelen zonder dit motief zodat zij 
gezamenlijk nanovezels konden vormen. In dit onderzoek werd gevonden dat het 
C-terminale aminozuur van de amfifielen de kleurverandering in de vezels 
beïnvloedt. Zo werd gevonden dat K-RGDS vezels het meest geschikt waren om 
een kleurverandering ten gevolge van celadhesie vast te stellen. De vezels 
veranderen hierbij van blauw naar roze. Vezels gevormd uit amfifielen met als C-
terminaal aminozuur V, A of S waren geschikt om cellen op te laten groeien, maar 
lieten geen kleurverandering zien. De peptide componenten in deze vezels 
hebben een stabielere structuur, waardoor celadhesie allicht niet invloedrijk 
genoeg is om kleurverandering op te laten treden. Het in dit hoofdstuk 
beschreven systeem kan mogelijk gebruikt worden om migratie van cellen vast te 
stellen door de vezels te incorporeren in een hydrogel. Hiernaast kan dit systeem 
misschien gebruikt worden als screening methode voor celgroei.  
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opnamemechanismen van CPPs ging werken. Ook tijdens mijn promotie hebben 
wij een fijne samenwerking op kunnen zetten samen met Rike, waarvan het werk 
beschreven staat in hoofdstuk 2. 
Kim, snel nadat jij begon in Nijmegen bedachten we dat het een goed idee was 
een samenwerkingsproject op te zetten. Ik ben blij dat we dat uiteindelijk ook 
gedaan hebben. De resultaten hiervan staan in hoofdstuk 3. Suzanne, dit 
hoofdstuk is voornamelijk voortgekomen uit jouw stageproject, waar je met grote 
toewijding aan hebt gewerkt. Selma, jouw kennis over bio-orthogonale ligaties en 
ervaring met synthese waren onmisbaar voor dit project. Heel erg bedankt voor al 
je hulp en input. 
Ilmar, Ger en Wilbert wil ik graag bedanken voor hun bijdrage aan het project over 
leucine-zipper activeerbare CPPs (hoofdstuk 4). Voor dit onderwerp hadden we 
nog grotere plannen met nanobodies; helaas is dit niet van de grond gekomen. 
Sander van Duinhoven en William Leenders, bedankt voor jullie interesse in het 
project en voor de nanobodies. Ik hoop dat de activeerbare CPPs en nanobodies 
in de toekomst nog een mooie combinatie zullen opleveren.   
Morten, thank you for teaching me how to work with spinach, it is a pity that our 
efforts did not lead to anything useful for our theses. Also thanks for your 
contribution to chapter 5, and for providing the graphics for the leucine zippers. 
Voor het laatste project waar ik aan werkte (hoofdstuk 6) was de samenwerking 
met de afdeling hematologie van het Radboudumc onmisbaar. Harry, bedankt dat 
je me de mogelijkheid hebt gegeven mijn experimenten op jouw lab uit te voeren. 
De overleggen met jou waren voor mij erg leerzaam, en ik wil je dan ook 
bedanken voor al je input in dit project. Rob en Marij, jullie hebben mij allebei veel 
geholpen bij de experimenten. Hartelijk dank voor jullie inzet en geduld! 
Een speciaal woord van dank aan mijn paranimfen, Britta en Anika (of wel: 
peptide angels!). Jullie maakten mij wegwijs op het peptidelab, en we hebben 
samen (ook buiten het werk om) veel leuke dingen gedaan, zoals de congressen 
(Manchester, Sofia) waar we samen zijn geweest, maar ook de shoptripjes & 
etentjes! Ik ben erg blij dat mijn promotie me ook zulke hechte vriendschappen 
heeft opgeleverd en daarom is het voor mij ook zo belangrijk dat jullie mijn 
paranimfen zijn. Bedankt dat jullie altijd voor mij klaar staan. Britta, ik zal onze 
sportieve prestatie samen nooit vergeten, en vooral de gezelligheid die ermee 
gepaard ging! Ook op het lab hebben we veel samen gedaan, waar hoofdstuk 7 
het resultaat van is. De samenwerking met jou was heel gemakkelijk, vooral 
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omdat we erg dezelfde insteek hadden. Ik denk zeker dat dit veel heeft 
bijgedragen aan het succes van dit project. Anika, voor jouw enthousiasme en 
toewijding, eigenlijk met alles wat je doet, heb ik grote bewondering. Samen 
hebben we aan een project gewerkt waar veel tegenslagen in voorkwamen. Ik 
denk dat we hierin veel van elkaar hebben kunnen leren en ben blij dat het toch 
een mooie publicatie heeft opgeleverd!  
Ruud, bedankt voor de samenwerkingsprojecten en de chocola-momentjes! Joep, 
succes met het afronden van je promotie en bedankt voor alle steun. Lise en 
Selma, bedankt voor de gezelligheid en het ‘stoom afblazen’ tijdens de lunch en 
de koffiepauzes. Marcel, jij maakte elk feestje súperleuk! Annika, bedankt voor de 
etentjes en uitjes samen met Britta en Anika. Ook al mijn andere oud-collega’s wil 
ik graag bedanken voor hun bijdrage aan een fijne tijd.   
Ook wil ik Britta, Anika, Stéphanie, Lieveke, TuHa & Victor (Roos & Max) en 
Nearchos bedanken, voor jullie luisterend oor, gezellige etentjes en andere 
activiteiten. Ook een dankjewel voor de ‘Flierenbergers’, voor de ontspannende 
bosritjes, kopjes cappuccino, en het lachen. Ook bedankt aan een ieder die Frap, 
Pluk en Bella verzorgd hebben tijdens de reizen die ik heb gemaakt (mijn andere 
grote bron van ontspanning!).  Niki, I am very happy that the ‘scary’ ENS building 
and french bakeries led to the start of our friendship!  
Frank, mijn ‘grote’ broer, ik ben gelukkig met de band die wij hebben. Intussen 
heb je zelf ook een gezin en is dit stukje niet compleet zonder jullie, Arja, Thijs & 
Ruben. Ik geniet altijd van het contact met jullie, zeker ook in de dierentuin! Elise, 
dankjewel voor de etentjes in Utrecht en Nijmegen.  
Maarten, ondanks dat onze werelden heel verschillend zijn, toon je altijd veel 
interesse in mijn werk en leven. Op mijn beurt heb ik ook veel bewondering voor 
jouw wereld! Ik ben trots op je, en blij met jou als mijn broer. Alexandra, with your 
kind personality, it is always nice to have you around.  
Het laatste stukje houd ik kort, wat zeker geen maat is voor de hoeveelheid 
waardering en dank. Gelukkig is dat makkelijker om naar elkaar uit te spreken 
dan dat het is om hier op te schrijven.   
Papa en mama, dit boekje is niet voor niets aan jullie opgedragen. Bedankt voor 
jullie onvoorwaardelijke steun, tijdens mijn studie en promotie maar vooral ook 
daarbuiten. Ik ben ontzettend trots dat jullie mijn ouders zijn.  
Lieve Stijn, jij had jouw promotie al afgerond voordat ik aan de mijne begon. Je 
wilde me altijd zo graag advies geven, uit interesse, maar vooral ook wanneer ik 
me (onnodig) druk maakte. Jij geeft me zoveel rust en vertrouwen, dat ik kan zijn 
wie ik ben. Ik kijk uit naar onze toekomst! 
	  193 
	  
 
 
 
 
 
 
We know that we'll never find 
anyone like you under the sun, 
'cause you're the one and only one. 
If everybody were like everybody else, 
how boring it would be. 
The things that make me different 
are the things that make me, me! 
 
From: “The One And Only One”, A.A. Milne, Winnie the Pooh 
 
